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Summary 
 
Alzheimer’s disease (AD) is one of the most severe neurodegenerative disorders 
defined by deposition of amyloid plaques and neurofibrillary tangles. An important 
role in AD is also exerted by neuroinflammation and microglial activation is one of 
the hallmarks of the disease pathology. Although microglia are known to be recruited 
and to cluster around amyloid plaques in the AD brain, their involvement in amyloid 
plaque clearance over the course of AD is still controversial.  Impaired microglial 
function resulting in decreased Aβ clearance  was reported in sporadic AD cases as 
well as in mouse models of AD. Moreover, several recently identified genetic risk 
alleles for AD have been linked to microglial function and phagocytosis. To study the 
contribution of microglial phagocytosis in amyloid plaque clearance , I established a 
novel ex vivo co-culture model where I combined organotypic brain slices from aged, 
amyloid plaque-bearing mice (APPPS1) together with slices from young, neonatal 
wild-type (WT) mice. In the ex vivo co-culture model, I observed changes in amyloid 
plaque morphology over 14 days in vitro manifested by clearance of the plaque halo 
bearing diffuse Aβ and increased number of core-only plaques. Additionally, I found a 
strong increase in immunoreactivity of CD68, a lysosomal marker of activated 
microglia/macrophages in the old APPPS1 tissue. Specific recruitment and clustering 
of CD68 positive cells around amyloid plaques  was paralleled by a decrease in plaque 
size upon co-culturing of old and young brain slices. Pharmacological inhibition of 
phagocytosis by cytochalasin D prevented clearance of the plaque halo, suggesting 
that CD68 positive microglial cells detected at amyloid plaques are phagocytosing Aβ.  
Furthermore, specific removal of either old or young microglial cells by clodronate 
hindered amyloid plaque clearance, suggesting a synergistic contribution of both 
microglial populations in plaque phagocytosis. To discriminate between young and 
old microglial cells, I co-cultured either young slices from CX 3CR1+/GFP reporter mice 
with old APPPS1 brain slices or old APPPS1/CX 3CR1+/GFP brain slices together with 
young WT slices. Surprisingly, only the old APPPS1 microglial cells were found in the 
vicinity of amyloid plaques and thus identified as cells responsible for Aβ uptake in 
our ex vivo co-culture model. Intriguingly, culturing old APPPS1 brain slices in 
conditioned media collected from young WT brain slices or from cultured young 
primary microglia was sufficient to increase amyloid plaque clearance, in contrast to 
media obtained from microglia-depleted young slices. These data suggested that 
soluble factors released by young microglia promote Aβ uptake by the old APPPS1 
microglial cells. Hence, I tested action of several pro- and anti-inflammatory 
cytokines on amyloid plaque clearance and found enhanced plaque phagocytosis upon 
direct addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) to old 
APPPS1 brain slices, mimicking the co-culture condition. Moreover, the GM-CSF 
treatment increased numbers of CD68 positive cells confirming its mitogenic 
potential on myeloid cells. Increased numbers of proliferating microglial were also 
detected upon co-culturing of old and young brain slices. Nevertheless, co-culturing 
of young slices from GM-CSF-/- mice with old APPPS1 brain slices still resulted in 
increased numbers of core-only plaques and, accordingly, increased CD68 coverage. 
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Therefore, GM-CSF is not the sole factor triggering microglial proliferation and Aβ 
uptake in the ex vivo co-culture model. However, proliferation of old microglial cells 
was necessary for amyloid plaque clearance, as exposure of the old APPPS1 tissue to 
the young WT conditioned media obtained after treatment with the proliferative 
inhibitor AraC prevented amyloid plaque clearance. This study suggests that impaired 
amyloid plaque clearance of aged microglia in AD may be reversed and microglial 
phagocytic capacity may be restored upon a proper stimulus. The novel ex vivo  model 
system can be used as a platform to screen, test and identify factors or compounds 
directed to therapeutically modulate phagocytic competence of microglia.   
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Zusammenfassung 
 
Die Alzheimer’sche Krankheit (Alzheimer’s disease, AD) oder kurz Alzheimer ist eine der 
schwerwiegendsten neurodegenerativen Erkrankungen und zeichnet sich durch die 
Ablagerungen von amyloiden Plaques und neurofibrillären Bündeln aus. Eine wichtige Rolle in 
Alzheimer spielt zudem die Neuroinflammation, die sich pathologisch unter anderem durch die 
Aktivierung von Mikroglia-Zellen kennzeichnet. Obwohl bereits bekannt ist, dass Mikroglia im 
Alzheimer-Gehirn rekrutiert werden und sich an den amyloiden Plaques sammeln, bleibt ihre 
genaue Beteiligung an der Entfernung der Plaques im Zusammenhang mit Alzheimer kontrovers. 
In Fällen der sporadischen Form von Alzheimer sowie in Mausmodellen konnten mikrogliale  
Defekte gezeigt werden, die zu einem geringeren Aβ Abbau führen. Darüber hinaus wurden 
mehrere kürzlich identifizierte genetische Risiko-Allele für Alzheimer mit der mikroglialen 
Funktion und Phagozytose in Verbindung gebracht.  
Um die Beteiligung der mikroglialen Phagozytose an der Beseitigung der amyloiden Plaques zu 
untersuchen, habe ich ein neues ex vivo Ko-Kulturenmodell etabliert, bei dem ich organotypische 
Gehirnschnitte von gealterten, amyloid Plaque positiven Mäusen (APPPS1) mit Hirnschnitten 
von jungen, neonatalen Wildtyp-Mäusen (WT) kombiniert habe. In diesem ex vivo Ko-
Kulturenmodell konnte ich innerhalb von 14 Tagen Veränderungen in der Morphologie der 
amyloiden Plaques beobachten, nämlich die Höfe diffuser Aβ Plaques wurden  zu  einem Kern 
tragendem (core-only) Plaque abgebaut. Weiterhin konnte ich einen starken Anstieg in der 
Immunreaktivität von CD68, einem lysosomalen Marker aktivierter Mikroglia und Makrophagen, 
im Gewebe der alten APPPS1 Mäuse beobachten. Die spezifische Rekrutierung und Ansammlung 
von CD68-positiven Zellen um amyloide Plaques verlief parallel zur Reduktion der Plaque-Größe 
während der Ko-Kultivierung von alten und jungen Gehirnschnitten. Die pharmakologische 
Inhibition der Phagozytose mit Cytochalasin D verhinderte den Abbau des Plaque-Hofs und 
liefert somit den Hinweis, dass CD68-positive Mikroglia, welche an den amyloiden Plaques 
detektiert wurden, Aβ phagozytieren. Überdies konnte der Abbau von amyloiden Plaques 
spezifisch durch die Entfernung der alten oder jungen Mikroglia mittels Clodronat verhindert 
werden, was auf eine synergetische Beteiligung beider Mikroglia-Populationen an der 
Phagozytose weist.  
Um die jungen und alten Mikroglia-Zellen voneinander unterscheiden zu können, wurden 
entweder junge Schnitte aus CX3CR1+/GFP –Reportermäusen mit alten APPPS1 Hirnschnitten oder 
alte APPPS1/CX3CR1+/GFP –Gehirnschnitte mit jungen Wildtyp-Schnitten kultiviert. 
Überraschenderweise wurden nur die Mikroglia-Zellen der alten APPPS1-Mäuse in der direkten 
Umgebung der amyloiden Plaques gefunden und somit als die für die Aβ-Aufnahme 
verantwortlichen Zellen in unserem ex vivo Ko-Kulturenmodell identifiziert. Interessanterweise 
war die Kultivierung alter APPPS1 Hirnschnitte in Medium, das von jungen WT Hirnschnitten 
oder von jungen, primären Mikroglia gesammelt wurde, ausreichend, um den Abbau der 
amyloiden Plaques zu erhöhen. Dies war nicht der Fall für Medium von jungen Hirnschnitten, bei 
dem die Mikroglia zuvor entfernt wurden. Diese Daten zeigen, dass die jungen Mikroglia lösliche 
Faktoren abgeben und die Aβ Aufnahme der alten APPPS1 Mikroglia begünstigen. Infolgedessen 
habe ich verschiedene pro- und anti-inflammatorische Cytokine auf den Abbau der amyloiden 
Plaques getestet und konnte zeigen, dass die Phagozytose der Plaques nach direkter Zugabe des 
Granulozyten-Monozyten-Kolonie-stimulierende Faktor (GM-CSF) zu den alten APPPS1 
Zusammenfassung 
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Hirnschnitten erhöht war und so die Bedingungen der Ko-Kultur nachgeahmt werden konnten. 
Ferner erhöhte die GM-CSF Behandlung die Anzahl CD68-positiver Zellen und bestätigt so sein 
mitogenes Potential auf myeloide Zellen. Überdies konnte in den Ko-Kulturen alter und junger 
Hirnschnitte eine ansteigende Anzahl proliferierender Mikroglia detektiert werden. Dennoch 
resultierte die Ko-Kultivierung junger Hirnschnitte von GM-CSF-/- Mäusen mit alten APPPS1 
Hirnschnitten in einer erhöhten Anzahl reiner Kern-Plaques (core-only) und dementsprechend 
einer höheren Menge von CD68. Folglich ist GM-CSF nicht der einzige Faktor in dem ex vivo Ko-
Kulturen Modell, der die Mikroglia Proliferation und die Aβ Aufnahme auslöst. Die Proliferation 
alter Mikroglia-Zellen war für die Entfernung der amyloiden Plaques jedoch nötig, da die 
Exposition des alten APPPS1 Gewebes mit Medium von jungen WT Schnitten nach Behandlung 
durch den Proliferations-Inhibitor AraC verhindert wurde. 
Diese Studie konnte zeigen, dass der verminderte Abbau von amyloiden Plaques durch gealterte 
Mikroglia in der Alzheimer Krankheit rückgängig gemacht werden und die mikrogliale 
Phagozytosekapazität durch einen geeigneten Stimulus wiederhergestellt werden kann. Das 
neue ex vivo Modellsystem kann hierbei als Plattform dienen, Faktoren oder Präparate zu 
identifizieren, zu selektieren und zu testen, um therapeutisch die Phagozytosekompetenz der 
Mikroglia zu modulieren. 
 
 
 
 
 
 
 
 
 
 
 
      Table of Contents 
 
 
11 
 
Table of Contents 
 
Eidesstattliche Versicherung/Affidavit  ................................................................................................................... 3 
Summary ............................................................................................................................................................................... 7 
Zusammenfassung  ............................................................................................................................................................ 9 
Table of Contents  ........................................................................................................................................................... 11 
List of Figures  .................................................................................................................................................................. 14 
List of Abbreviations  ..................................................................................................................................................... 16 
1. Introduction ................................................................................................................................................................. 19 
1.1 Alzheimer’s Disease  .......................................................................................................................................... 19 
1.1.1 Pathological hallmarks of Alzheimer’s Disease  ............................................................................ 19 
1.1.2 Origin of Aβ peptide – APP processing  ............................................................................................. 22 
1.1.3 Genetic and sporadic AD  ........................................................................................................................ 23 
1.1.4 The amyloid cascade hypothesis  ........................................................................................................ 24 
1.2 Mouse models of Alzheimer’s disease  ....................................................................................................... 27 
1.2.1 The APPPS1 mouse model  ..................................................................................................................... 29 
1.3 Neuroinflammation and AD  ........................................................................................................................... 30 
1.3.1 Astrocytes  ..................................................................................................................................................... 30 
1.3.2 Microglia  ....................................................................................................................................................... 31 
 1.3.2.1 Microglia in the aging brain  ......................................................................................................... 33 
 1.3.2.2 Microglia in the AD brain  .............................................................................................................. 34 
 1.3.2.3 Aβ-induced microglial activation  .............................................................................................. 34 
1.3.3 AD risk genes cluster in innate immune response pathway  ................................................... 36 
1.3.4 Aβ clearance by microglia ...................................................................................................................... 37 
 1.3.4.1 Other mechanisms of Aβ clearance  .......................................................................................... 38 
1.4 In vitro and in vivo models of Aβ phagocytosis by microglia  ........................................................... 39 
2. Aim of the study  ......................................................................................................................................................... 41 
3. Materials and Methods  ............................................................................................................................................ 43 
3.1 Materials  ................................................................................................................................................................ 43 
3.1.1 Equipment and tools  ................................................................................................................................ 43 
 3.1.1.1 General equipment and consumables  ..................................................................................... 43 
 3.1.1.2 Microscope and immunofluorescence equipment  ............................................................. 43 
 3.1.1.3 Microsurgical instruments  ........................................................................................................... 44 
 3.1.1.4 Cell culture equipment and consumables .............................................................................. 44 
 3.1.1.5 Biochemistry equipment and consumables .......................................................................... 45 
 3.1.1.6 Molecular biology equipment and consumables  ................................................................ 45 
Table of Contents 
 
 
12 
 
3.1.2 Chemicals, reagents, enzymes, antibodies   ..................................................................................... 45 
 3.1.2.1 General chemicals  ............................................................................................................................ 45 
 3.1.2.2 Cell culture reagents  ....................................................................................................................... 46 
 3.1.2.3 Reagents, enzymes, DNA/protein markers and dyes  ....................................................... 47 
 3.1.2.4 Antibodies ............................................................................................................................................ 47 
3.1.3 Drugs and cytokines  ................................................................................................................................. 48 
3.1.4 Buffers and media  ..................................................................................................................................... 48 
 3.1.4.1 Cell culture  .......................................................................................................................................... 48 
 3.1.4.2 Immunofluorescence  ...................................................................................................................... 49 
 3.1.4.3 Biochemistry  ...................................................................................................................................... 49 
 3.1.4.4 Molecular biology  ............................................................................................................................ 50 
3.1.5 DNA oligonucleotides  .............................................................................................................................. 50 
 3.1.5.1 Primers for genotyping  ................................................................................................................. 50 
3.1.6 Services  ......................................................................................................................................................... 51 
3.1.7 Software and online tools  ...................................................................................................................... 51 
3.2 Methods  ................................................................................................................................................................. 51 
3.2.1 Animals  .......................................................................................................................................................... 51 
3.2.2 Genotyping  ................................................................................................................................................... 52 
3.2.3 Organotypic slice cultures  ..................................................................................................................... 53 
3.2.4 Drug and cytokine treatments of slice cultures  ............................................................................ 54 
3.2.5 Slice culture conditioned media: collection and incubation  ................................................... 54 
3.2.6 Primary microglial cultures, conditioned media: collection and incubation  ................... 55 
3.2.7 Immunoblotting  ......................................................................................................................................... 56 
3.2.8 Immunohistochemistry  .......................................................................................................................... 57 
3.2.9 Image acquisition, analysis and quantification  ............................................................................. 57 
3.2.10 Cell viability assay  .................................................................................................................................. 58 
3.2.11 Morphological analysis of microglia  ............................................................................................... 58 
3.2.12 Statistical analysis  .................................................................................................................................. 59 
4. Results  ............................................................................................................................................................................ 61 
4.1 Development of the ex vivo model of AD  .................................................................................................. 61 
4.1.1 Organotypic brain slice culture model (ex vivo model)  ............................................................. 61 
4.1.2 Characterization of the ex vivo co-culture model: cell viability  ............................................. 63 
4.1.3 Characterization of the ex vivo co-culture model: cellular markers  ..................................... 63 
4.2 Clearance of amyloid plaque halo is enhanced in the ex vivo co-culture model  ...................... 66 
4.3 Age-dependent reduction of amyloid clearance in old APPPS1 brain slices in the ex vivo 
model  .............................................................................................................................................................................. 69 
4.4 Microglial recruitment and clustering at plaques in the co-culture model  ............................... 70 
4.5 Young microglia do not infiltrate into the old APPPS1 slice  ............................................................ 72 
      Table of Contents 
 
 
13 
 
4.6 Old microglia engulf Aβ  ................................................................................................................................... 73 
4.7 Amyloid plaque clearance depends on both young and old microglia  ........................................ 74 
4.7.1 Clodronate efficiently depletes microglial cells  ............................................................................ 75 
4.7.2 Both young and old microglia contribute to amyloid plaque clearance  ............................. 77 
4.8 Morphological characterization of microglia in the ex vivo model  ................................................ 79 
4.9 Soluble factors released by young microglia promote Aβ uptake of old microglia  ................ 80 
4.10 GM-CSF stimulates Aβ uptake of old microglia  ................................................................................... 83 
4.11 Amyloid clearance can be achieved upon co-culturing of young GM-CSF-/- and old APPPS1 
brain slices  ................................................................................................................................................................... 86 
4.12 Aggregated Aβ is reduced upon co-culturing and not upon GM-CSF application  ................ 87 
4.13 GM-CSF as well as co-culturing induces proliferation of old microglial cells  ........................ 88 
4.14 Proliferation of old microglial cells is required for amyloid clearance  .................................... 90 
5. Discussion ..................................................................................................................................................................... 93 
5.1 Studying amyloid plaque clearance of microglia  .................................................................................. 93 
5.1.1 Organotypic brain slice culture as a model to study microglial phagocytosis of amyloid 
plaques (ex vivo model)  ..................................................................................................................................... 93 
5.2 Role of microglia in Aβ clearance  ................................................................................................................ 94 
5.3 Modulation of microglial activity as a tool to reduce Aβ load  ......................................................... 96 
5.3.1 Pro- and anti-inflammatory modulation of microglia through cytokines  ......................... 98 
5.3.2 The pro-inflammatory factor GM-CSF induces amyloid clearance and proliferation of 
microglia in the ex vivo model  ......................................................................................................................... 98 
5.4 Link between microglial proliferation and amyloid clearance  ....................................................... 99 
5.4.1 Therapeutic potential of GM-CSF and other rejuvenating factors  ......................................101 
5.5 Diseased microglia display specific gene expression alterations  ................................................102 
5.6 Conclusion ...........................................................................................................................................................103 
6. References  ..................................................................................................................................................................105 
Acknowledgements  .....................................................................................................................................................125 
Curriculum vitae  ...........................................................................................................................................................127 
List of Figures              
 
 
14 
 
List of Figures  
 
Graphical Abstract  ............................................................................................................................................................ 8 
Figure 1.1: Brain atrophy in advanced AD patient  ........................................................................................... 20 
Figure 1.2: Amyloid plaques and neurofibrillary tangles in the cerebral cortex of an AD patient 
 ................................................................................................................................................................................................ 21 
Figure 1.3: Glial cells surrounding amyloid plaques by Alois Alzheimer  ............................................... 21 
Figure 1.4: APP processing ......................................................................................................................................... 23 
Figure 1.5: η-Secretase processing  ......................................................................................................................... 23 
Figure 1.6: Amyloid cascade hypothesis  .............................................................................................................. 25 
Figure 1.7: Aged-related increase in amyloid plaque load in APPPS1 mice  .......................................... 29 
Figure 1.8: Astrocytes encircle amyloid plaques in APPPS1 mouse brain  ............................................. 31 
Figure 1.9: Microglial morphology changes with aging  ................................................................................. 33 
Figure 1.10: Microglial cells clustering around amyloid plaques  .............................................................. 34 
Figure 4.1: Integrity of neurons, microglia and astrocytes in brain organotypic slice culture ....... 61 
Figure 4.2: Microglial morphology is well preserved in the ex vivo model  ............................................ 62 
Figure 4.3: The ex vivo co-culture model  .............................................................................................................. 62 
Figure 4.4: Cell viability in the ex vivo model at 7 and 14 DIV  ..................................................................... 63 
Figure 4.5: Cellular marker characterization of the ex vivo model at 7 and 14 DIV  ........................... 64 
Figure 4.6: Cellular marker characterization of freshly cut brain slices  ................................................. 65 
Figure 4.7: Western blot analysis of cellular markers in the ex vivo model at 14 DIV  ...................... 65 
Figure 4.8: Amyloid plaque clearance is increased in the ex vivo co‐culture model of old and 
young brain slices  .......................................................................................................................................................... 67 
Figure 4.9: Co-deposition of mouse and human Aβ in the ex vivo co‐culture model  ......................... 68 
Figure 4.10: Amyloid plaque clearance is increased upon co-culturing of old APPPS1 and young 
WT brain slices  ................................................................................................................................................................ 68 
Figure 4.11: Aβ levels are reduced in the co‐culture of old APPPS1 and young WT brain slices .. 69 
Figure 4.12: Aβ clearance capacity in the ex vivo co-culture model is age-dependent  ..................... 70 
Figure 4.13: Recruitment and clustering of CD68‐positive cells around amyloid plaques is 
accompanied by a reduction in plaque size  ........................................................................................................ 71 
Figure 4.14: CD68-positive microglia actively take up and phagocytose Aβ  ........................................ 72 
Figure 4.15: Young microglia do not infiltrate into the old APPPS1 brain slice at 14 DIV  .............. 73 
Figure 4.16: Old CD68‐positive microglial cells cluster around amyloid plaques, and engulf 
Aβ ............................................................................................................................................................................................74 
Figure 4.17: Clodronate treatment of young and old brain slices efficiently depletes microglial 
cells ....................................................................................................................................................................................... 76 
Figure 4.18: Amyloid plaque clearance depends on both young and old microglia  .......................... 78 
Figure 4.19: Morphological characterization of microglia in the ex vivo model  .................................. 80 
                                                                                                                                                                List of Figures 
 
 
15 
 
Figure 4.20: Factors released by young microglia promote amyloid plaque clearance  ................... 82 
Figure 4.21: The pro‐inflammatory factor GM‐CSF promotes amyloid plaque clearance  ............... 84 
Figure 4.22: GM-CSF enhances amyloid plaque clearance and expands CD68-positive coverage 
 ................................................................................................................................................................................................ 85 
Figure 4.23: Amyloid plaque clearance is enhanced in the co‐culture of old APPPS1 and young 
GM‐CSF−/− brain slices  .................................................................................................................................................. 87 
Figure 4.24: Analysis of fibrillar Aβ and CD68 levels in old APPPS1 tissue upon GM-CSF 
treatment  ........................................................................................................................................................................... 88 
Figure 4.25: GM-CSF as well as co-culturing induces proliferation of old microglial cells  ............. 89 
Figure 4.26: Proliferating microglial cells can easily be detected in the co‐culture model and 
upon GM‐CSF treatment  .............................................................................................................................................. 90 
Figure 4.27: Microglial proliferation is required for amyloid plaque clearance  ................................. 91 
Figure 5.1: Model of effect of microglial immunomodulation on Aβ levels  ........................................... 99 
 
Table 1.1: Selected examples of AD transgenic mouse models  ................................................................... 28 
Table 1.2: LOAD genes involved in altered microglial function in AD  ..................................................... 36 
 
 
 
List of Abbreviations                                                                                                                                                     
 
 
16 
 
List of Abbreviations 
 
Aβ Amyloid-β peptide 
ABCA7 ATP-binding cassette, sub-family A, member 7 
ABI3 ABI family member 3 
AD Alzheimer’s disease 
ADAM10 A disintegrin and metalloproteinase domain 10 
AICD APP intracellular domain 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
APH-1 Anterior pharynx-defective-1 
API Alzheimer’s prevention initiative 
APOE Apolipoprotein E 
APP Amyloid precursor protein 
APS Ammonium persulfate 
AraC Cytosine arabinose 
BACE-1 β-site amyloid precursor protein cleaving enzyme 
BBB Blood brain barrier 
BDNF Brain-derived neurotrophic factor 
BIN1 Bridging integrator 1 
BMDM Bone marrow-derived macrophages 
BSA Bovine serum albumin 
CAA Cerebral Amyloid Angiophaty 
CCL-2 C-C motif chemokine ligand 2 
CD Cluster of differentiation 
CD33 Sialic acid-binding immunoglobulin (ig)-like lectin 
Clo Clodronate 
CLU Clusterin 
CM Conditioned media 
CNS Central nervous system 
CR1 Complement receptor type 1 
CR3 Complement receptor type 3 
CSF Cerebrospinal fluid 
CSF1R Colony-stimulating factor 1 receptor 
CTF C-terminal fragment 
CX3CL1 CX3C chemokine ligand 1 or fractalkine 
CX3CR1 Receptor for CX3C chemokine fractalkine 
CytoD Cytochalasin D 
DAPI 4’,6-Diamidin-2-phenylindol 
DAM Disease-associated microglia 
DAMP Danger-associated molecular pattern 
DIAN Dominantly inherited Alzheimer network 
DIV Days in vitro 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
dNTP Deoxynucleotide 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EOAD Early onset Alzheimer’s disease 
EPHA1 Ephrin receptor A1 
                                                                                                                                                    List of Abbreviations                                                                                                                           
 
 
17 
 
FAD Familial Alzheimer’s disease 
FERMT2 Fermitin family member 2 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
GM-CSF Granulocyte macrophage-colony stimulating factor 
GWAS Genome-wide association study 
HBSS Hank’s balanced salt solution 
HLA-DRB5/B1 Major histocompatibility complex, class II, DR beta 5/DR beta 1 
HRP Horse radish peroxidase 
Iba-1 Ionized calcium binding adapter molecule 1 
IDE Insulin degrading enzyme 
IGF-1 Insulin-like growth factor 1 
INF-γ Interferon γ 
kDa Kilodalton 
LAMP2 Lysosome-associated membrane protein 2 
LOAD Late onset Alzheimer’s disease 
LPS Lipopolysaccharide 
LRP1 Receptor-related protein 1 
LTP Long-term potentiation 
MCH Mitochondrial cascade hypothesis 
M-CSF Macrophage-colony stimulating factor 
MEM Minimum essential medium 
MG Microglia 
MGnD Microglial neurodegenerative phenotype 
MHC-II Class II major histocompatibility complex 
MRI Magnetic resonance imaging 
MS4A Membrane-spanning 4-domains, subfamily A 
NEP Neprilysin 
NLRP3 NLR family pyrin domain containing 3  
NMDA N-methyl-D-aspartate receptor 
NOS Nitric oxide synthase 
NSAID Nonsteroidal anti-inflammatory drug 
NTF Neurofibrillary tangle 
PAMP Pathogen-associated molecular pattern 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PEN-2 Presenilin enhancer-2 
PET Positron-emission tomography 
PICALM Phosphatidylinositol binding clathrin assembly protein 
PFA Paraformaldehyde 
PLCG2 Phospholipase C gamma 2 
PS1 Presenilin-1 
PS2 Presenilin-2 
PTK2B Protein tyrosine kinase 2 beta 
RAGE Advanced-glycation end-products 
ROI Region of interest 
ROS Reactive oxygen species 
RT Room temperature 
SAD Sporadic Alzheimer’s disease 
SAD-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SORL1 Sortilin-related receptor with A-type repeats 
TAE Tris-acetate EDTA 
List of Abbreviations                                                                                                                                                     
 
 
18 
 
TAU Tubulin associated unit 
TEMED Tetramethylethylendiamin 
TGF-β Transforming growth factor β 
TNF-α Tumor necrosis factor α 
TLR-2 Toll like receptor 2 
Tg Transgenic 
TREM2 Triggering receptor expressed on myeloid cells 2 
WT Wild type 
 
 
 
 
               Introduction 
 
 
19 
 
1. Introduction 
 
1.1 Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is the most common form of dementia worldwide (Andrieu et al 2015), 
estimated to contribute to about 60-80% of all dementia cases (2016 Alz Association report, 
www.alz.org/facts). The Alzheimer’s disease International Consortium reported in 2016 ~47 
million people living with dementia,  11% of which over the age of 65 and 81% over the age of 
75 (https://www.alz.co.uk/research/world-report-2016). The primary risk factor for AD is old 
age. Because of the demographic aging, the worldwide prevalence of AD is expected to 
quadruplicate in the next years with more than 130 million affected persons by 2050 
(Brookmeyer et al 2011). Thus, AD represents a major global public health problem with a huge 
economic impact. The cost AD represents for the individual, family and society also puts great 
pressure in order to better understand the disease mechanisms and to find an effective cure 
(Graham et al 2017). 
 
 
1.1.1 Pathological hallmarks of Alzheimer’s Disease 
 
The key neuropathological elements of AD were first described by Alois Alzheimer in 1906 in his 
original case report of a 51 year old patient, Auguste D., who presented a “peculiar” dementia 
(Alzheimer 1907). At the macroscopic level, a severe atrophy of the brain could be detected (Fig 
1.1). At the microscopic level, the disease manifested by amyloid plaques and neurofibrillary 
tangles (NFTs) in the medial temporal lobe and cortical areas of the brain (Fig 1.2), together 
with extensive synaptic degeneration, neuronal loss, and neuroinflammation. 
 
Amyloid plaques are abnormal extracellular accumulations of the amyloid-β (Aβ) peptide, a 37-
43 amino acid peptide in the brain parenchyma (Fig 1.2). Aβ is generated by sequential 
proteolytic cleavage of the amyloid precursor protein (APP) by the enzymes β- and γ-secretases 
(Haass 2004, Haass & Selkoe 1993, Selkoe 2001). APP processing will be described in more 
detail in section number 1.1.2. Monomers of Aβ peptide, predominantly with 42 or 40 amino 
acids (Aβ42 and Aβ40), eventually self-assemble to form intermediate oligomers as well as 
protofibrils, a heterogeneous class of soluble prefibrillar species with a characteristic secondary 
β-sheet and supersecondary structure. Protofibrils go on to form fibrils that deposit as plaques 
and disrupt normal tissue architecture (Ahmed et al 2010, Walsh et al 1999). Aβ can also deposit 
in the blood vessel walls in the form of cerebral amyloid angiopathy (CAA) (Smith & Greenberg 
2009). CAA most often accompanies the pathology of AD and can cause lobar hemorrhage and 
contribute to ischemic damage of the brain (Biffi & Greenberg 2011). 
 
In addition to the deposition of Aβ in plaques, formation of NFTs occurs in the AD brain (Fig 1.2). 
NFTs are intracellular inclusions constituted by hyperphosphorylated form of the microtubule 
binding protein, tau (Tubulin associated unit) (Grundke-Iqbal et al 1986). Tau is synthesized and 
produced in all neurons (Migheli et al 1988). The normal function of tau is to bind to tubulin and 
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stabilize microtubules, maintaining neuronal stability and homeostasis (Drechsel et al 1992). 
However, in AD, tau becomes hyperphosphorylated and this form of tau dissociates from 
microtubules and self-aggregates into paired helical filaments (PHFs), a major constituent of 
NFTs, leading to destabilization of microtubules, synaptic defects, plasma-membrane 
degeneration and neuronal damage (Iqbal et al 2005). Neuropathological studies suggest that 
the evolution of NFT distribution in the brain correlates with the clinical progression of 
cognitive deficits in AD (Perrin et al 2009).  
 
 
Figure 1.1. Brain atrophy in advanced AD patient. 
Compared to a healthy individual, a patient with Alzheimer’s disease typically presents with diffuse brain atrophy 
manifested by cortical thinning and ventricle dilatation. From the Alzheimer’s association (www.alz.org). 
 
 
Furthermore, AD is characterized by the massive loss of neurons, neuropil, and synapsis, which 
contribute to the gross cortical atrophy of the AD brain (Holtzman et al 2011) (Fig 1.1). Post-
mortem samples of AD clearly show substantial loss of cortical grey matter accompanied by 
ventricular enlargement and severe brain shrinkage (Bird 2008) (Fig 1.1). The 
neurodegenerative process involves first vulnerable neurons in the entorhinal cortex and 
hippocampus, then progresses to areas of the temporal, parietal, and frontal neocortex 
(Holtzman et al 2011). The deterioration process is manifested by early damage to synapses 
with retrograde degeneration of axons and eventual atrophy of the dendritic tree (Perlson et al 
2010). Indeed, the loss of synapses in the limbic system and neocortex is considered to be the 
best link with the cognitive impairment in patients with AD (DeKosky & Scheff 1990, Scheff et al 
2007). 
 
               Introduction 
 
 
21 
 
 
 
Figure 1.2. Amyloid plaques and neurofibrillary tangles in the cerebral cortex of an AD patient. 
Plaques are extracellular deposits of Aβ surrounded by dystrophic neurites. Tangles are intracellular inclusions consisting 
of hyperphosphorylated tau. From: Blennow et al 2006. 
 
Another major component of AD is the widespread neuroinflammatory process occurring in the 
brain, which was already recognized and described in the first case report by Alois Alzheimer  
(Alzheimer 1911) (Fig 1.3). These inflammatory responses include activation of microglia, 
astrocytes, and perivascular, meningeal and choroid plexus macrophages, resulting in the 
release of inflammatory mediators in the brain such as cytokines, chemokines, complement 
system proteins and reactive oxygen species (ROS), which contribute to AD progression (Zhang 
& Jiang 2015). This topic will be addressed in detail in section number 1.3.  
 
 
 
Figure 1.3. Glial cells surrounding amyloid plaques by Alois Alzheimer. 
First description of glial cells in relation to amyloid plaques in the brain cortex. The plate (Tafel IV) illustrates a plaque (P1) 
consisting of a small dark core and a halo (yellow) surrounded by numerous subtle ‘glial fibrils’ originating from large glial 
cells (‘fibril-forming glial cells’, glz). Neighboring ‘nerve cells’ (gaz) are also depicted. From: Alzheimer 1911. 
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1.1.2 Origin of Aβ peptide - APP processing 
 
Aβ precursor protein APP is a transmembrane, type-1, integral glycoprotein. There are three 
main isoforms of APP as a result of alternative splicing. The 695 amino acid form of APP is 
predominantly expressed in the central nervous system (CNS), particularly by neurons, whereas 
the 751 and 770 amino acid forms are more broadly expressed (Bayer et al 1999, Tanzi et al 
1988). Although the physiological function of APP itself has not been fully determined, it has 
been associated with neuro- and synaptotrophic properties, and implicated in neuronal 
development and synaptic plasticity (Dawkins & Small 2014, Muller et al 2017).  
The ~4kDa Aβ peptide was first isolated as the principal component of amyloid deposits in the 
brain and cerebrovasculature of AD and Down’s Syndrome patients (Masters et al 1985). Aβ 
peptides are generated from two consecutive proteolytic cleavages of APP by the proteases 
BACE1 (protease β-site APP cleaving enzyme), which is the main β-secretase in the brain (Vassar 
et al 1999), and the tetrameric complex γ-secretase, composed of PS (presenilin), nicastrin, APH-
1 (anterior pharynx-defective-1) and PEN-2 (presenilin enhancer-2) (Edbauer et al 2003, 
Kimberly et al 2003) (Fig 1.4). A third enzyme involved in the APP processing is ADAM10 (a 
disintegrin and metalloproteinase 10), the major neuronal α-secretase (Kuhn et al 2010), whose 
activity precludes Aβ generation (Fig 1.4).  
APP is cleaved in its extracellular region (at the amino terminus of Aβ domain) by β-secretase, 
releasing a secreted N-terminal fragment (sAPP-β) and a transmembrane C-terminal fragment 
C99 (CTF-β) (Fig 1.4). C99 is subsequently cleaved by γ-secretase to generate soluble Aβ 
peptides of different lengths, including Aβ37, Aβ38, Aβ40, Aβ42, Aβ43 and even longer species 
like Aβ45, Aβ46, Aβ48, as well as an APP intracellular fragment (AICD) (Takami et al 2009, 
Vassar et al 2014). This pathway is referred to as amyloidogenic pathway (Fig 1.4). Although 
numerous Aβ species exist, the most abundant one produced in the brain and found in the 
cerebrospinal fluid (CSF) is Aβ40 (~80-90%), followed by Aβ42 (~5-10%) (Iwatsubo et al 1994, 
Selkoe 2001, Shoji et al 1992). The slightly longer forms of Aβ, particularly Aβ42, are more 
hydrophobic, fibrillogenic, and are the principal species deposited in the brain (Vandersteen et 
al 2012). 
A rather small part of the total cellular APP is processed by β-Secretase and its activity is 
considered to be the rate-limiting step in the amyloidogenic pathway. The remaining APP is 
cleaved by α-secretase (within the Aβ sequence) generating a secreted N-terminal fragment 
(sAPP-α) and a C-terminal fragment C83 (CTF-α) (De Strooper et al 1993, Sisodia 1992) (Fig 
1.4). The subsequent γ-secretase cleavage of CTF-α produces a smaller C-terminal fragment of 3 
kDa (p3) (Haass et al 1993). In this alternative pathway, generation of Aβ peptides is prevented, 
thus the pathway also is known as anti-amyloidogenic pathway. γ-Secretase cleavage within the 
membrane-bound CTF-α also generates an AICD that may have a transcriptional function (Cao & 
Sudhof 2001) (Fig 1.4). In our lab it was recently discovered that APP processing is even more 
complex and a novel processing pathway has been identified (Willem et al 2015). η-Secretase 
processing generates a soluble N-terminal product (sAPP-η) of ~80kDa and membrane bound 
APP-C-terminal fragments (CTF-η), which were found to accumulate in dystrophic neurites 
surrounding amyloid plaque cores in both mouse model of AD and human AD patients. CTF-η 
fragments are further cleaved into longer and shorter soluble Aη peptides by α- or β-secretases 
(Aη-α, Aη-β respectively) (Fig 1.5). Notably, Aη-α was found to specifically lower neuronal 
activity and long term-potentiation (LTP) (Willem et al 2015). 
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Figure 1.4. APP processing. 
Schematic representation of the APP proteolytic processes, illustrating the non-amyloidogenic and the amyloidogenic 
pathway. Abbreviations: α, α-secretase; β, β-secretase; γ, γ-secretase; sAPP-α and sAPP-β, soluble APP N-terminal fragments 
derived from α- and β-secretase cleavage, respectively; APP-FL, APP full length; AICD, APP intracellular domain. 
 
 
 
 
 
Figure 1.5. η-Secretase processing. 
Schematic representation of the η-secretase proteolytic process. Abbreviations: α, α-secretase; β, β-secretase; η, η-secretase; 
γ, γ-secretase; CTF, APP C-terminal fragment; Aη-α and Aη-β, Aη peptides derived from α- and β-secretase cleavage 
respectively; APP-FL, APP full length. Abbreviations: CTF-η, CTF-β and CTF-α, APP C-terminal fragments derived from η-, β- 
and α -secretase cleavages, respectively; APP-FL, APP full length.  
 
 
1.1.3 Genetic and sporadic AD 
 
There are two types of AD: “familial”, also known as early onset AD (FAD or EOAD) or autosomal 
dominant AD (ADAD), and “sporadic” also known as late onset AD (SAD or LOAD). 
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FAD is inherited in a Mendelian autosomal dominant fashion and it is relatively rare, accounting 
for 1-6% of all AD cases with clinical symptom onset between 30 and 65 years of age (Bird 
2008). FAD is caused by mutations in genes encoding for APP and presenilin-1 and -2 (PS1 and 
PS2), which are catalytic subunits of the γ-secretase complex. 
Some APP mutations locate at or near the Aβ peptide and affect type or amount of Aβ peptide 
produced by altering proteolytic activity of β- and γ-secretases, resulting in increased Aβ 
aggregation and deposition. Examples of APP mutations are the “London” mutation (APP V717I) 
that increases the Aβ42/Aβ40 ratio by modifying the γ-secretase cleavage of APP (Alison Goate 
1991), or the “Swedish” mutation (APP K670N/M671L) enhancing β-secretase cleavage and Aβ 
production (Mullan Mike 1992). Besides the pathogenic mutations, a rare protective variant, the 
“Icelandic” variant (APP A673T), was reported to reduce formation of amyloidogenic peptides 
by decreasing β-secretase processing of APP (Jonsson et al 2012). Triplication of the APP gene 
located on chromosome 21 as occurring in Down’s syndrome (Trisomy 21) (Tokuda et al 1997), 
or  rare familial cases of AD with duplication of the APP gene (Rovelet-Lecrux et al 2006) also 
lead to AD pathology. Some mutations in PS1 and PS2 genes increase cleavage of APP by γ-
secretase, causing elevated Aβ42/Aβ40 ratio (Chavez-Gutierrez et al 2012, Scheuner et al 1996) 
while others have been described to result in the generation of fewer but longer and more 
amyloidogenic Aβ peptides, i.e. Aβ43 (Kretner et al 2016, Saito et al 2011).   
  
The vast majority of AD patients are late onset, with risk increasing after 65 years of age. 
Although LOAD is largely sporadic and considered multifactorial (Van Cauwenberghe et al 
2016), there are multiple susceptibility genes that confer risk for developing AD (Naj et al 2017). 
One of the major genetic risk factors that lowers the age of disease onset is the apolipoprotein E-
ε4 allele (APOE-ε4). Individuals with one copy of ε4 allele have 3-fold increased risk for AD and 
carriers of two copies have 12-fold higher risk (Slooter et al 1998). Of note, ApoE4 has been 
linked to various aspects of Aβ metabolism, such as promoting Aβ aggregation (Castano et al 
1995) but also causing a defective Aβ clearance (Verghese et al 2013).  
 
In addition to APOE, genome-wide association studies (GWAS) and next-generation sequencing 
techniques have allowed identification of more than 20 novel genetic loci associated with AD 
risk. Interestingly, most of these genes cluster in immune response and inflammation pathway 
(e.g. CLU, CR1, ABCA7, CD33, TREM2, PLCG2, ABI3), supporting the relevance of immune system 
for AD etiology (Karch et al 2014, Sims et al 2017, Tosto & Reitz 2016). Additional pathways 
regulated by AD susceptibility loci are cell migration (e.g. PTK2B), APP and tau pathology (e.g. 
SORL1 and FERMT2 respectively), synaptic function, endocytosis (e.g. BIN1, PICALM), axonal 
transport and lipid metabolism (e.g. CLU, ABCA7, SORL1) (Karch et al 2014, Tosto & Reitz 2016). 
These genes provide insights into the molecular pathways that are altered in AD pathogenesis, 
and understanding of their mechanism of action will help to elucidate the physiopathology of the 
disease and to identify novel therapeutic targets. 
 
 
1.1.4 The amyloid cascade hypothesis 
 
The amyloid cascade hypothesis is the principal hypothesis that combines a sequence of events 
that are causative for AD (Fig 1.6). According to this hypothesis, an excessive production of Aβ in 
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the brain leads to its aggregation and deposition into plaques. This initiates a cascade of events 
that harm synapses and neurons, including aggregation of tau protein in NFTs and widespread 
neuroinflammation in the brain (described in detail in section number 1.3) ultimately leading to 
neuronal degeneration and dementia (Haass & Selkoe 2007, Hardy & Higgins 1992, Selkoe & 
Hardy 2016).  
 
 
 
Figure 1.6. Amyloid cascade hypothesis. 
Simplified schematic representation of the amyloid cascade hypothesis. Abbreviations: APP, amyloid precursor protein; PS1, 
presenilin1; PS2, presenilin2; ApoE, apolipoprotein E; NFT, neurofibrillary tangles. 
 
  
The central role of Aβ in the pathogenesis of AD is strongly supported by evidences from genetic 
studies where the mutations implicated in familial forms of the disease occur in the genes for the 
substrate (APP) and the key enzyme (presenilin) for Aβ generation. Moreover, people with 
Down’s syndrome develop AD early in life (Zigman et al 2008), supporting the notion that life-
long overproduction of Aβ causes AD. Additional more recent genetic evidence comes from the 
APP-Icelandic mutation that decreases life-long production and aggregation properties of Aβ 
and protects against AD (Jonsson et al 2012). Moreover, introduction of human disease-
associated mutations into mice recapitulates some aspects of the human disease (Games et al 
1995, Radde et al 2006), further supporting the link between aberrant Aβ production and the AD 
phenotype.  
Along these lines, Aβ42 oligomers isolated from cortex of AD patients were found to decrease 
synapse density and inhibit LTP in rodent hippocampus, and their injection disrupts memory 
and learning in normal rats (Shankar et al 2008). Further studies showed that isolated human 
Aβ42 oligomers induce tau hyperphosphorylation and cause neuritic dystrophy in cultured rat 
neurons, whereas co-treatment with Aβ antibodies mitigates this effect (Jin et al 2011). 
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Moreover, Aβ oligomers can be found at the halo surrounding amyloid plaques, this correlating 
with low synaptic density (Koffie et al 2009). 
   
There is also some criticism regarding the amyloid cascade hypothesis. For example, the fact that 
amyloid plaque load in the brain does not correlate well with severity of dementia, but does 
correlate with NFT burden (Knopman et al 2003). Furthermore, amyloid plaques were found in 
post-mortem brains of non-demented aged subjects (Bennett et al 2006), indicating that Aβ and 
plaques do not necessarily trigger the neurodegeneration cascade but may associate with 
normal aging. However, these individuals could have as well been in a very early phase of AD 
where cognitive alterations were not yet manifested or were able to compensate with higher 
cognitive reserves or possible protective mechanisms.  
Criticism of the amyloid cascade hypothesis often refers to the fact that Aβ-targeted therapies so 
far were not successful in producing a significant functional recovery in patients with AD or 
slowing the disease’s course. For example, a major phase 3 clinical trial of the γ-secretase 
inhibitor, semagestat, was terminated early due to increased decline in patients treated with the 
higher dose of semagestat compared to patients treated with placebo (Doody et al 2013). The 
failure may be explained by the other functions of γ-secretase on different substrates, such as its 
function in notch processing, (Karran & Hardy 2014) and could have been anticipated from 
mouse studies. Another large phase 3 trial of the humanized monoclonal anti-Aβ antibody, 
solanezumab, failed to improve cognition in mild and moderate AD patients (Doody et al 2014). 
However, the cognitive decline was slower in patients with mild AD (Doody et al 2014), 
suggesting that the anti-Aβ therapy should have been started earlier. Indeed, in a recent phase 1 
clinical study, either prodromal or mild AD patients treated with the human monoclonal anti-Aβ 
antibody aducanumab showed pronounced reduction in brain Aβ plaques and slower clinical 
decline compared to patients receiving placebo (Sevigny et al 2016). These results highlight the 
possibility that starting the treatment at the beginning of AD development might have higher 
chances to be successfully beneficial than starting at stages where the disease is already 
consolidated and irreversible neuronal damaged has occurred. Therefore, the early detection of 
the diseased condition becomes extremely important and, in this respect, great effort is made in 
developing CSF biomarkers and neuroimaging approaches (e.g. magnetic resonance imaging, 
MRI and brain positron emission tomography, PET) (Frisoni et al 2017).  
Based on these assumptions, the DIAN (Dominantly Inherited Alzheimer Network) (Morris et al 
2012) and the API (Alzheimer's Prevention Initiative) Colombia (Reiman et al 2011) studies use 
anti-Aβ antibody treatments in pre-symptomatic individuals at risk for FAD with the hope of 
preventing or altering development of AD. Besides anti-Aβ antibodies, DIAN clinical trials are 
also using β-secretase inhibitors (Yan & Vassar 2014). If these or other amyloid-targeting 
treatments succeed in producing benefit to AD patients, this would validate the amyloid cascade 
hypothesis. 
 
It is worthy to mention that alternative hypothesis have been posited for AD process. Among 
others, the mitochondrial cascade hypothesis (MCH) states that age-associated dysfunction of 
mitochondria might contribute to the progressive oxidative and free radical damage in the brain, 
leading to increased Aβ production and AD pathology (Sonnen et al 2008, Swerdlow & Khan 
2004). Other alternative models for AD pathogenesis have proposed age-related increased DNA 
damage in neurons due to aberrant cell-cycling (Chow & Herrup 2015, Kruman et al 2004) or 
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cerebral glucose hypometabolism due to altered insulin signaling in the brain (Cholerton et al 
2013, Ferreira et al 2014, Steen et al 2005) as possible disease-causing drivers. However, these 
theories lack of human genetic evidence from GWAS studies so far supporting a valid link with 
the AD process (Karran & De Strooper 2016, Lambert et al 2013).  
 
Thus, the amyloid hypothesis is the dominant model of AD pathogenesis so far that is guiding the 
development of potential treatments against AD. 
 
 
1.2 Mouse models of Alzheimer’s Disease 
 
There is no efficient naturally occurring animal model for AD. Very old apes, monkeys, and some 
other mammals such as bears, cats and dogs may exhibit some Aβ accumulations and slight CAA, 
but without presenting the complete AD pathology (Cummings et al 1996, Heuer et al 2012). 
Thus, transgenic rodents, especially mice have become important and the most used to model 
and study AD. Transgenic modeling in mice is relatively cheap, mice have a reasonably short life 
span, and the techniques for generating transgenic (tg) mouse lines are well developed. Current 
animal models are mainly based on naturally occurring human AD mutations. Indeed, mouse 
Aβ1–42 sequence differs from human Aβ by 3 amino acids, causing a reduction in both the 
propensity of mouse Aβ to self-aggregate and its degree of neurotoxicity (Boyd-Kimball et al 
2004). A number of different tg mouse models have been generated in the last years, and an 
overview of them is available at the Alzforum website (http://www.alzforum.org/research-
models/alzheimers-disease). Table 1.1 contains selected examples of the more widely studied 
mouse models. 
 
Numerous tg mouse lines overexpress one or more of the FAD mutations, such as the Indiana 
(V717F), London (V717I), and Swedish (K670N/M671L) (Chishti et al 2001, Games et al 1995). 
In general, those mice develop extracellular Aβ deposits rather late during their life (starting at 
6-11 months of age), as well as gliosis and dystrophic neurites. Moreover, animals display 
cognitive and behavioral deficits when compared to wild-type (WT) animals. 
Mice overexpressing PS FAD mutations, such as human PS1 (M146L or M146V) or PS2 alone 
(Elder et al 2010), have also been generated but failed to develop plaque pathology. Only 
combination of both mutated human APP and PS resulted in an earlier and more extensive 
plaque formation and cognitive decline (Holcomb et al 1998). 
However, above mentioned mouse models recapitulate only amyloid pathology, but completely 
lack neurofibrillary tangles. Indeed, to reproduce both Aβ plaques and NFT pathology, mice 
expressing mutated human APP and PS were crossed with a mouse expressing tau with the 
P301L mutation (Oddo et al 2003). Despite difficulties in reproducing both amyloid and tau 
pathology, the substantial neuronal loss associated with AD is completely missing in most of tg 
mouse models (Elder et al 2010). However, an apparent reduction in neurons, limited to cortical 
layer 5, was induced in the 5X FAD line including three APP and two PS1 FAD mutations that 
individually are sufficient to cause disease in humans (Oakley et al 2006). 
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Model FAD Mutation Promoter Amyloid pathology Reference 
     
PDAPP APP-Indiana (V717F) PDGF Parenchymal plaques at 6-9 
months of age 
(Games et al 1995) 
 
 
Tg2576 APP-Swedish (K670N, 
M671L) 
PrP Parenchymal plaques by 11-13 
months of age with some 
vascular amyloid 
(Hsiao et al 1996) 
 
 
 
APP23 APP-Swedish (K670N, 
M671L) 
Thy1 Parenchymal plaques by 6-9 
months of age and prominent 
vascular deposition of amyloid 
(Calhoun et al 
1999) 
 
 
TgCRND8 APP-Swedish (K670N, 
M671L) + Indiana (V717F) 
  
PrP More aggressive parenchymal 
plaque pathology present by 3 
months of age 
(Chishti et al 2001) 
 
 
 
PSAPP PS1 (M146V); APP-Swedish PS1M146V 
× Tg2576 
Earlier and more extensive 
plaque pathology than Tg2576 
alone 
(Holcomb et al 
1998) 
 
 
APPPS1 APP-Swedish (K670N, 
M671L); PS1 (L166P) 
 
Thy1 Parenchymal plaques by 6-8 
weeks of age accompanied by 
gliosis 
 
(Radde et al 2006) 
5x FAD APP-Swedish (K670N, 
M671L) + Florida (I716V) + 
London (V717I); 
PS1(M146L, L286V) 
Thy1 Parenchymal plaque pathology 
by 2 months of age and loss in 
synapsis and cortical layer 5 
neurons by 9 months of age 
 
(Oakley et al 2006) 
3x Tg-AD APP-Swedish (K670N, 
M671L); PS1 (M146V); tau 
(P301L) 
Thy1.2 
(APP, Tau)  
Parenchymal plaques by 6 
months of age combined with tau 
pathology by 12 months of age 
(Oddo et al 2003) 
 
 
 
 
Table 1.1. Selected examples of AD transgenic mouse models. 
Abbreviations: APP, amyloid precursor protein; FAD, familial Alzheimer´s disease; PDAPP, platelet-derived growth factor 
promoter driving amyloid precursor protein; PDGF, platelet-derived growth factor β; PrP, prion protein; PS1, presenilin 1; 
PSAPP, presenilin/amyloid precursor protein; Tg, transgenic. Adapted from: Elder et al 2010. 
 
 
Besides the widely used overexpression models, a knock-in mouse with a humanized Aβ region 
containing two or three APP mutations (APP NL-F or APP NL-G-F, respectively) have been 
recently generated (Saito et al 2014). These mice produce APP under endogenous murine 
promoter leading to the preservation of the endogenous expression levels of APP and its 
physiological spatiotemporal expression pattern. The combination of NL, F and G mutations 
results in enhanced APP processing and elevated Aβ levels, and mice develop amyloid plaques 
and gliosis starting at the age of 2 months and cognitive impairment by 6 months of age. APP 
knock-in mice thus offer an improved mouse model of FAD. 
   
Overall, although none of the existing mouse models fully reproduces human AD pathology, AD 
mouse models have been and continue to be valuable tools for investigating individual aspects of 
AD pathogenesis. 
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1.2.1 The APPPS1 mouse model 
 
This thesis uses an APPPS1 tg mouse model of cerebral amyloidosis observed in AD patients. The 
APPPS1 (line 21) mouse model of AD (Radde et al 2006) co-expresses the human transgenes 
APP bearing the Swedish mutation (K670N/M671L) and PS1 mutation (L166P), both under the 
control of the neuron-specific Thy1 promoter (Radde et al 2006). The Swedish APP mutation 
causes a 2 to 3 fold increased production of Aβ (Hsiao et al 1996, Mullan Mike 1992) by 
facilitating efficiency of β-secretase cleavage, which in contrast to WT cleavage occurs already in 
Golgi-derived vesicles (Haass et al 1995). The L166P PS1 mutation is a very aggressive mutation 
that causes onset of AD as early as 24 years of age (Moehlmann et al 2002). This PS mutation 
lowers Aβ40 levels resulting in increased Aβ42/Aβ40 ratio (Li et al 2016). 
APPPS1 mice have been extensively explored as AD models and are pathologically very well 
characterized (Radde et al 2006). Amyloid deposition occurs relatively early, with the 
appearance of first plaques in the neocortex at approximately 6-8 weeks of age (Fig 1.7). 
Deposits in the hippocampus appear later (3-4 months of age) and increase in size and number 
with aging. By 8 months of age these mice exhibit a substantial plaque load with the majority of 
plaques consisting of a dense core surrounded by diffuse amyloid, resembling those in the 
human AD brain (Fig 1.7). Eight months old APPPS1 mice display increased numbers of 
microglia as well as dystrophic neurites in proximity to amyloid plaques. Moreover they have 
deficits in spatial learning and memorizing a maze task (Radde et al 2006). 
 
Therefore, the APPPS1 mouse model is a suitable system to study amyloidosis-related 
pathomechanisms allowing relatively rapid experimental readouts. 
 
 
 
Figure 1.7. Aged-related increase in amyloid plaque load in APPPS1 mice. 
Immunostaining of cortical sections from 1-, 2-, 4- and 8-month old APPPS1 mouse brains immunostained with anti-Aβ 
antibody NT12 to visualize amyloid plaques. Amyloid plaques, not yet detectable at 1 month of age, increase progressively 
in number and size and reveal substantial plaque pathology at 8-months of age in APPPS1 mice. Scale bar: 200 µm. From: 
Radde et al 2006. 
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1.3 Neuroinflammation and AD 
 
Neuroinflammation is defined as activation of the innate immune system in the brain. Its main 
function is to protect the CNS against infectious insults, injury, or disease, such as AD. 
The AD brain pathology is, besides presence of amyloid plaques and neurofibrillary tangles, also 
characterized by glial cell activation. Indeed, astrocytes and microglia are the major cell types 
that respond to disease stimuli by innate immune responses involving production and release of 
inflammatory mediators in the CNS (Zhang & Jiang 2015). In addition, perivascular macrophages 
and peripheral myeloid cells that can enter the diseased brain may also participate in 
neuroinflammatory reactions (Zhang & Jiang 2015).  
 
 
1.3.1 Astrocytes  
 
Astrocytes are the most abundant cells in the CNS, they provide trophic and metabolic support 
to neurons and are involved in neurotransmission, synaptic formation and plasticity (Kimelberg 
& Nedergaard 2010). Astrocytes are also active players in the neuroinflammatory response in 
AD.  
It is known that amyloid plaques induce development of reactive astrocytes, which cluster 
around Aβ deposits (Serrano-Pozo et al 2013) (Fig 1.8). Cytokines and chemokines, such as CCL2 
and CXCL10, are involved in the activation of astrocytes, chemotaxis and Aβ phagocytosis (Wyss-
Coray et al 2003). Moreover, in response to increased levels of Aβ, astrocytes, like microglia, can 
contribute to maintain a pro-inflammatory condition by releasing IL-1β, IL-6, TNF, nitric oxide 
synthase (NOS), CCL2, CXCL10 and TGF-β (Garwood et al 2011, White et al 2005). These 
molecules can affect neurons either directly or indirectly through microglial activation. As an 
example, exposure to Aβ activates astrocytic NFκB and production of complement protein C3, 
which can bind neuronal C3aR and induce neuronal damage (Lian et al 2015). The increased 
cytokine production by activated astrocytes attracts microglia, which further express pro-
inflammatory products and increase neuronal damage. Another astrocytic molecule, the Ca2+-
binding protein S100β, has been found to be highly expressed in proximity to Aβ deposits. 
Overexpression of human S100β in Tg2576 mice resulted in increased amyloidogenic processing 
of APP in addition to reactive astrogliosis and microgliosis. This was accompanied by increased 
expression of some pro-inflammatory cytokines, thus exacerbating AD-like pathology (Mori et al 
2010). 
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Figure 1.8. Astrocytes encircle amyloid plaques in APPPS1 mouse brain. 
Confocal image of a cortical brain section from 5 month old APPPS1 mouse immunostained with anti-GFAP antibody (red) 
for visualizing astrocytes  and anti-Aβ antibody 6E10 (green) for detecting amyloid plaques. Nuclei are counterstained with 
DAPI (blue). Activated astrocytes surround amyloid plaques and participate to the neuroinflammatory process. Image: 
courtesy of Laura Sebastian Monasor, German Center for Neurodegenerative Diseases (DZNE) Munich. 
 
 
Astrocytes have been shown to internalize and phagocytose Aβ in a receptor-mediated fashion, 
for example through advanced-glycation end-products (RAGE) receptors and Fc receptor (Jones 
et al 2013, Okun et al 2010). Moreover, astrocytes can uptake Aβ via lipoprotein receptor-
related protein 1 (LRP1) in the presence of ApoE, and perivascular astrocytes in AD brains were 
found to contain both Aβ and ApoE (Utter et al 2008). Astrocytic clearance of Aβ was also 
assessed in an ex vivo system. In this study exogenous astrocytes plated onto unfixed brain 
sections from AD mice were able to associate with Aβ deposits and induce Aβ removal (Wyss-
Coray et al 2003). 
 
 
1.3.2 Microglia 
 
Microglia are the primary immune cells in the brain. They are considered the resident brain 
macrophages due to their myeloid origin, ability to migrate within different brain regions and to 
phagocytose, process and present antigens. Microglia derive from primitive hematopoietic cells 
in the embryonic yolk sac and invade the brain during fetal development (embryonic day 9.5), 
expand in numbers after birth, and are self-renewing throughout adult life (Ginhoux et al 2010). 
They represent around 10% of the CNS population (Lawson et al 1990). 
Microglial cells are commonly visualized by cellular markers including ionized calcium binding 
adapter molecule 1 (Iba-1), which may take part in cell cytoskeletal reorganization (Sasaki et al 
2001), CD68, which localizes to the lysosomal membrane and is indicative of phagocytosis, and 
CD11b, which is part of the type 3 complement receptor (CR3). Other microglial markers are, for 
example, the class II major histocompatibility complex (MHC II) proteins, such as HLA-DR 
subgroup, which increase upon inflammatory conditions (Korzhevskii & Kirik 2016) and 
fractalkine receptor CX3CR1, whose interaction with the neuronal fractalkine ligand CX3CL1 
establishes a microglia-neuron communication (Harrison et al 1998).  
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Both in early and postnatal phases as well as in the adult brain, microglia secrete soluble factors, 
like insulin-like growth factor 1 (IGF-1) and brain-derived neurotrophic factor (BDNF), which 
regulate neurogenesis, neuronal migration and survival (Parkhurst et al 2013, Ueno et al 2013). 
Under physiological conditions, “resting” microglia act as sentinels and play a crucial role in the 
immune surveillance of the brain (Nimmerjahn et al 2005). Such microglia are highly ramified 
and that enables continuous scanning of their microenvironment for detection of any 
endogenous danger- or exogenous pathogen-associated molecular patterns (respectively, 
DAMPs and PAMPs) (Kettenmann et al 2011). It is estimated that microglial cells survey the 
entire brain parenchyma every few hours (Nimmerjahn et al 2005). Moreover, microglia fulfill 
other very important physiological functions. They participate in the removal of debris resulting 
from apoptotic cells or myelin (Mosley & Cuzner 1996, Sierra et al 2010). In addition, microglia 
monitor and remodel impaired synapses and thus can module circuit function, which is crucial 
for maintaining brain homeostasis and tissue integrity (Schafer & Stevens 2015, Wake et al 
2009). 
 
Microglia secrete anti- or pro-inflammatory mediators that act as paracrine modulators of 
neuronal plasticity and survival but that may also stimulate the autocrine polarization into 
diverse states of microglial activation in response to a danger (Cameron & Landreth 2010, 
Kettenmann et al 2011). For example, production of the growth factor M-CSF (macrophage-
colony stimulating factor) itself can induce microglial chemotaxis, proliferation, increased 
macrophage scavenger receptor expression, and enhanced cell survival (Lue et al 2001). 
Similarly, the pro-inflammatory cytokine GM-CSF (granulocyte macrophage-CSF) is involved in 
the regulation of cell survival, differentiation, proliferation, inflammation and functional 
activities of microglia (Francisco-Cruz et al 2013). 
The classical activation cytokines, including INF-γ, IL-1β, IL-6 and TNF-α, induce the polarization 
of microglia into a pro-inflammatory phenotype (often referred to as M1 phenotype). 
Conversely, the alternative activation pathway, induced by increased levels of anti-inflammatory 
cytokines, like IL-4, IL-10, IL-13 and TGF-β, promote an anti-inflammatory state of microglia 
(often referred to as M2 phenotype) (Boche et al 2013, Cameron & Landreth 2010). These 
microglial phenotypes are highly dynamic, dependent on the brain environment and may vary 
according to the type of stimulation, the progression of the inflammatory response and also with 
aging (Boche et al 2013, Lucin & Wyss-Coray 2009). It has been proposed that microglia adopt 
an activated phenotype, which is part of a “continuum” of heterogeneous phenotypes in constant 
evolution and highly dependent on their spatiotemporal context (Weitz & Town 2012). Thus, 
there is a common consensus of considering the M1/M2 classification not appropriate for 
defining microglial phenotypes. In such regard, attempts on improving microglial classification 
have started. For example, in order to identify microglial phenotypes following a specific 
stimulus, inflammatory markers and transcriptomic profile of microglia were defined and 
referred to as MLPS or MIL-4 according to the lipopolysaccharide (LPS) or IL-4 stimulation, 
respectively (Beins et al 2016). 
 
Recently, transcriptomic studies revealed the existence of distinctive gene expression profiles of 
microglia compared to peripheral immune cells (Sousa et al 2017). Those microglial genes 
encode integrins, purinergic receptors, clusters of differentiation (CD) markers, and some 
secreted proteins and include CSF1R, CX3CR1, OLFML3, P2RY12, CD33, SIGLECH, TMEM119, 
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TREM2 (Butovsky et al 2014, Hickman et al 2013, Zhang et al 2014). Transcriptomic studies are 
helpful in elucidating gene signatures of microglia as well as their transcriptional changes 
occurring in disease conditions, such as AD (Crotti & Ransohoff 2016, Wes et al 2016).   
 
 
1.3.2.1 Microglia in the aging brain 
 
Healthy aging is accompanied by enhanced glial activation, high levels of complement proteins 
and inflammatory factors, as well as atrophy of the brain (Lu et al 2004, Streit et al 2008). 
Microarray analyses of brains from aged individuals and mice revealed upregulation of genes 
linked to cell stress and inflammation, whereas genes linked to synaptic function, trophic 
support and growth factors are downregulated (Lu et al 2004). Although it is not clear yet, these 
studies propose that DNA damage induced by ROS may be involved in causing aging-related 
increase in inflammation (Lu et al 2004). It has been proposed that microglia may become 
dysfunctional and enter a senescent state with aging. These “dystrophic” (or “senescent”) 
microglia are characterized by structural deterioration, including  shortening and twisting of 
processes, cytoplasmic fragmentation and spheroid swellings’ formation, as well as reduced 
migration and increased apoptosis (Streit et al 2008) (Fig 1.9). Such a state may cause reduced 
secretion of neurotrophic factors as well as downregulation of microglial phagocytic function. 
This loss of microglial neuroprotection and phagocytic efficiency, accompanied by increased 
secretion of inflammatory mediators, may lead to chronic neuroinflammation and contribute to 
progress of neurodegenerative diseases (Lu et al 2004, Streit et al 2008) (Fig 1.9). Furthermore, 
supporting these evidences, recent RNA-sequencing studies indicate that microglia express a 
unique set of transcripts, including a sensing cluster or “sensome” of transcripts that are 
differentially regulated during aging (Hickman et al 2013). These transcriptomic analyses 
demonstrated age-dependent differences in the expression of receptors for environmental 
sensing, where aged microglia enhance expression of genes for sensing microbial ligands, while 
reducing genes for sensing endogenous ligands compared with young microglia (Hickman et al 
2013). 
 
 
Figure 1.9. Microglial morphology changes with aging. 
Immunostaining of hippocampal sections from 1-, 7-8- and 18-month old WT mice immunostained with Iba1 for microglia 
and hematoxylin for counterstaining. Microglia from young mice display small cell bodies and long, ramified processes. 
While aging, microglia gradually exhibit larger cell bodies and shorter, thicker processes. From: (Von Bernhardi et al 2015).  
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1.3.2.2 Microglia in the AD brain 
 
Microglia are tightly associated to Aβ plaques in the brain of both AD patients (Perlmutter et al 
1990) and animal models of AD (Frautschy et al 1998) (Fig 1.10). More recently, advanced 
imaging techniques, such as the two-photon intravital imaging in live AD animals, showed that 
resident microglia rapidly act in response to Aβ plaque formation by prolonging their processes 
and subsequently moving towards  plaques (Bolmont et al 2008). Moreover, the interaction 
between microglia and Aβ plaques is regulated in a way that the number and size of microglia 
augment proportionally to the size of plaques, with the number of microglia surrounding 
plaques increasing at the pace of circa three cells per plaque per month (Bolmont et al 2008, 
Meyer-Luehmann et al 2008). Other studies in APPPS1 and 3x Tg-AD mouse models also showed 
that amyloid plaque formation in AD mouse brains is accompanied by the appearance of 
microglia that become significantly activated and associated with Aβ plaques (Rodriguez et al 
2010, Yan et al 2009). Moreover, some microglial cells displayed amyloid material 
intracellularly, indicating active phagocytosis (Bolmont et al 2008, Rodriguez et al 2010). 
Notably, a significant expansion in the population of resting microglial cells has been reported to 
anticipate plaque formation and large microglial activation (Rodriguez et al 2010). 
 
Despite these and many other studies supporting the involvement of microglia in the AD brain, 
the precise role of microglia in AD pathogenesis remains to be elucidated and characterized. 
 
 
 
Figure 1.10. Microglial cells clustering around amyloid plaques. 
Confocal image of brain section from 5 month old APPPS1 mouse immunostained with anti-Iba1 antibody (green) for 
visualizing microglia and anti-Aβ antibody 6E10 (red) for detecting amyloid plaques. Nuclei are counterstained with 
hoechst (blue). Microglial cells are recruited at the plaque sites where they form clusters around the plaques. Image: 
courtesy of Dr. Alessio Colombo, German Center for Neurodegenerative Diseases (DZNE) Munich. 
 
 
1.3.2.3 Aβ-induced microglial activation 
 
Microglial cells in the AD brain are constantly exposed to Aβ, which causes activation of their 
main functions, including phagocytosis and release of inflammatory mediators, both necessary 
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and potentially beneficial aspects in a diseased context. Additionally, “activated” microglial cells 
typically change their morphology into a less ramified and more amoeboid phenotype with 
shorter and thicker processes and enlarged soma (Fig 1.9).  
 
In general, the proposed detrimental role of activated microglia in AD was based on the 
increased production of neurotoxic pro-inflammatory cytokines, including IL-1β and TNF-α, 
following Aβ stimulation (Meda et al 1995, Parajuli et al 2013). As an example, it has been 
described that oligomeric Aβ enhances maturation of pro-IL-1β into IL-1β in microglia via 
activation of the nucleotide-binding oligomerization domain (nod)-like receptor (NLR) pyrin 
domain containing-3 (NLRP3) inflammasome (Parajuli et al 2013). Other studies revealed that 
Aβ can even act synergistically with pro-inflammatory cytokines like INF-γ, driving the 
production of TNF-α and reactive nitrogen radicals that are neurotoxic (Meda et al 1995). 
Microglia emerged as harmful players also in studies focused on CD40, a member of the TNFRs 
family, whose expression by microglia is enhanced in AD (Togo et al 2000). It has been shown 
that co-activation of microglia with Aβ and CD40 ligand (CD40L), thus stimulating the 
interaction CD40-CD40L, potentiates the release of TNF-α and promotes neuronal injury (Tan et 
al 1999). Moreover, microglia from Tg2576 (APPswe) mice deficient for CD40L showed 
attenuated activation, suggesting a link between CD40 and microglial activation in AD (Tan et al 
1999). In line with that, APPswe/PS1 mice depleted of CD40L display reduced Aβ plaque load as 
well as microgliosis (Tan et al 2002). 
The detrimental effect of microglial activation on neuronal survival has also been linked to the 
complement receptor 1 (CR1) on microglia. It has been reported that upon LPS or Aβ42 
stimulation microglia increase CR1 expression, resulting in neuronal death due to enhanced 
microglial superoxide production, as well as TNF-α and IL-1β secretion. Moreover, the blockage 
of microglial CR1 had positive effects on neuronal survival (Crehan et al 2013). 
Additional investigations revealed the deleterious consequences of microglial activation 
reflected by exacerbation of the neuronal injury and associated to Aβ accumulation. 
Correspondingly, studies on the microglial specific receptor CX3CR1 have shown that CX3CR1 
deficiency resulted in a dose-dependent reduction in Aβ deposition in two different AD mouse 
models (Lee et al 2010). This effect was accompanied by reduced CD68 immunoreactivity as 
well as reduced numbers of Aβ plaque-associated microglia, decreased expression of TNF-α and 
chemokine (C-C motif) ligand-2 (CCL-2) and increased expression of IL-1β (Lee et al 2010). 
Moreover, in vivo and in vitro analyses demonstrated that CX3CR1-deficient microglia had 
enhanced capability to phagocytose Aβ, resulting in enhanced Aβ clearance (Lee et al 2010). 
A similar approach was performed in another study targeted the NLRP3 inflammasome, whose 
specific activation by microglia may be implicated in AD pathogenesis. This study found that 
NLRP3 knockout reduced IL-1β levels and Aβ deposition in APPswe/PS1 mice, and this was 
associated with enhanced phagocytic capacity of microglia cells (Heneka et al 2013). Indeed, 
APPswe/PS1-NLRP3 knockout mice showed increased Aβ observed within CD11b-positive 
microglia, which co-localized with lysosome-associated membrane protein-2 (LAMP2) (Heneka 
et al 2013). 
 
Above discussed studies suggest that microglial activity needs to be maintained at a level that is 
not harmful for neurons as inflammatory responses influence the activation state of microglia 
and may impair microglial capacity to phagocytose Aβ and trigger cascade of events leading to 
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neuronal degeneration. This continuous activation of microglia turns detrimental and may act as 
trigger for the progression of AD (Lucin & Wyss-Coray 2009, Wyss-Coray 2006). 
 
 
1.3.3 AD risk genes cluster in innate immune response pathway 
 
Recent GWASs confirmed the importance of microglia in AD by identifying variants in several 
microglial genes as risk factors for LOAD. Main LOAD genes implicated in innate immune 
response are listed in Table 1.2.  
 
Gene Function Potential effect 
on APP 
Pathways 
    
TREM2 Immune response, production of inflammatory 
cytokines  
 
Aβ clearance Immune response 
CLU  Chaperone; impact on microglial activation via 
complement regulation 
Aβ clearance Immune response and 
lipid metabolism 
 
ABCA7  Substrate transport across cell membranes; 
phagocytosis of apoptotic cells and substrates (eg. 
Aβ) 
Aβ clearance Immune response 
 
 
 
CR1  Complement cascade response Aβ clearance Immune response 
 
CD33  Sialic acid-dependent binding to cells 
 
Aβ clearance Immune response 
MS4A 
cluster 
Poorly characterized; potential involvement in 
calcium signaling or regulation of T-cell -microglia 
interactions 
 
- Immune response 
EPHA1 Neuronal development; angiogenesis, cell 
proliferation and apoptosis 
 
- Immune response and 
neuronal development 
 
HLA-
DRB5/B1 
Component of MHCII - Immune response 
 
 
 
Table 1.2. LOAD genes involved in altered microglial function in AD. 
Abbreviations: TREM2, triggering receptor expressed on myeloid cells 2 protein; CLU, clusterin; ABCA7, ATP-binding 
cassette transporter A7; CR1, complement receptor 1; CD33, sialic acid-binding immunoglobulin (Ig)-like lectin; MS4A, 
membrane-spanning 4A cluster; EPHA1, ephrin receptor A1; HLA-DRB5/B1, Major Histocompatibility Complex, Class II, DR 
Beta 1/DR Beta 5. “–“ indicates that the effect in the context of AD is still unclear. Adapted from: (Karch et al 2014); 
(Villegas-Llerena et al 2016); http://www.alzforum.org/genetics.  
 
 
For example, a rare missense mutation in the gene encoding the triggering receptor expressed 
on myeloid cells 2 (TREM2), which is expressed on microglia, causes increased risk of 
developing AD (Jonsson et al 2013). It has been shown that TREM2 mutations result in reduced 
capacity of microglia to migrate to amyloid plaques and reduced clearance of Aβ (Kleinberger et 
al 2014, Mazaheri et al 2017, Ulrich et al 2014, Xiang et al 2016). Indeed, TREM2 depletion in the 
5XFAD mouse model increased cerebral Aβ load due to a dysfunctional response of microglia, 
which became apoptotic (Wang et al 2015).  Furthermore, the TREM2 protein can be measured 
as a soluble variant (sTREM2) in the CSF and there are recent data demonstrating that CSF 
sTREM2 levels are enhanced in the early symptomatic phase of AD, possibly correlating with an 
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early activation state of microglia in response to degenerating neurons (Suarez-Calvet et al 
2016a, Suarez-Calvet et al 2016b).   
Another example is the transmembrane protein CD33, which expression is increased in AD 
microglia compared to aged-matched controls. CD33 is involved in innate immunity modulation, 
with the risk allele inducing higher expression of CD33 in microglia and monocytes (Griciuc et al 
2013). The depletion of CD33 in APPswe/PS1 mice decreased levels of insoluble Aβ42 and Aβ 
plaque deposition, suggesting a role for CD33 in inhibiting microglial uptake of Aβ, thus 
promoting Aβ accumulation (Griciuc et al 2013). 
In addition, the ATP-binding cassette transporter A7 (ABCA7) is also highly expressed in 
microglia and loss of function variants of ABCA7 can affect AD pathogenesis (Steinberg et al 
2015). ABCA7 depletion in PDGF-APPswe/ind mice impaired cerebral Aβ clearance by mainly 
reducing the capacity of bone marrow-derived macrophages (BMDMs) eliminating oligomeric 
Aβ, thus causing Aβ accumulation (Kim et al 2013). 
 
These findings further support the link between the immune system/neuroinflammation and AD 
pathogenesis.  
 
 
1.3.4 Aβ clearance by microglia 
 
There is a body of evidence suggesting a role for microglia in Aβ clearance. Microglia express 
numerous surface receptors that promote the clearance and phagocytosis of Aβ, such as 
receptors for Fc, cytokines and chemokines (e.g. CCR2), scavenger receptors (e.g. CD36 and 
RAGE), complement receptors (e.g. CR3/CD11b), TLRs and the co-receptor CD14 (Cameron & 
Landreth 2010). Indeed, microglia in the vicinity of Aβ plaques internalized systemically 
injected-Aβ binding methoxy-X04 dye, suggesting their engagement in phagocytosis (Bolmont et 
al 2008).  
It has also been shown that TLR4 and TLR2 and the co-receptor CD14 bind to fibrillar forms of 
Aβ and mediate their internalization and trafficking to the lysosome (Liu et al 2005, Reed-
Geaghan et al 2009). This can initiate the activation of intracellular signaling pathways eliciting 
microglial production and secretion of reactive oxygen and nitrogen species, IL-6, and other 
neurotoxic factors (Reed-Geaghan et al 2009). Studies in AD mouse models (APPswe/PS1dE9) 
with mutant TLR2 suggested that deficiency in TLR signaling causes cognitive impairments with 
concomitant increase in Aβ deposition (Richard et al 2008).  
Moreover, studies on complement receptors proposed a synergistic action of CR3/CD11b with 
the scavenger receptor A (SR-A) in mediating Aβ uptake and showed that murine microglia 
treated with SR-A ligands were less capable of taking up Aβ (Fu et al 2012).  
Additional studies demonstrated that microglia can internalize soluble forms of Aβ through 
constitutive, fluid-phase micropinocytosis, which involves both actin and microtubules, and the 
internalized Aβ is then delivered to the late endosomes and lysosomes for degradation 
(Mandrekar et al 2009). 
 
However, several studies suggest that Aβ clearance seems to be slow and ineffective over the 
course of disease, thus contributing to Aβ accumulation. For example, it has been reported that 
the APPswe/PS1dE9 mouse has decreased expression of various Aβ-binding receptors and Aβ-
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degrading enzymes at 8 months of age that accompanies an increase in pro-inflammatory gene 
expression (Hickman et al 2008). Furthermore, microglia isolated from AD mouse 
(APPswe/PS1dE9) brains showed significant changes in lysosomal genes, such as CD68, Gusb 
and Cts1 (Orre et al 2014). Additionally, ex vivo studies, where either acute brain slices or 
primary microglial cells from APPPS1 and APP23 mice were incubated with bead microspheres, 
identified impaired microglial phagocytosis compared with age-matched healthy controls 
(Krabbe et al 2013).  
 
Moreover, it is important to note that AD is a disease of an aging brain and this fact is also 
relevant for understanding AD pathology. Two-photon studies of AD mouse models revealed 
that microglia in the aged brain are less motile and possess fewer processes (Meyer-Luehmann 
et al 2008). In another study, young microglia from AD mice were able to clear exogenously 
added Aβ in organotypic slice cultures while microglia from adult AD mice displayed a 
significant loss of their Aβ phagocytic function (Hellwig et al 2015). This supports the concept 
that aging is accompanied by impaired microglial function (Streit et al 2008). 
 
On the other side, microglial depletion studies do not support a direct role for microglia on Aβ 
plaque deposition and clearance. In one study, they used the CD11b-thymidine 
kinase/ganciclovir suicide gene approach to induce selective ablation of microglia in 
APPswe/PS1 and APP23 mouse models of AD (Grathwohl et al 2009). Surprisingly, the absence 
of microglia did not change Aβ plaque load as well as morphology, size and cerebral distribution 
of amyloid deposits (Grathwohl et al 2009). Likewise, a more recent study using a similar 
approach showed that the conditional ablation of resident microglia did not change Aβ burden in 
APPswe/PS1 mice (Prokop et al 2015). However, those effects were observed after two to four 
weeks of microglial ablation and it is feasible that larger periods of ablation are needed to detect 
significant changes in Aβ dynamics. 
 
 
1.3.4.1 Other mechanisms of Aβ clearance 
 
In addition to phagocytic clearance of Aβ, microglia can directly secrete proteolytic enzymes that 
degrade Aβ, such as insulin degrading-enzyme (IDE), neprilysin (NEP), matrix metalloproteinase 
9 (MMP9), and plasminogen (Hickman et al 2008). NEP and MMPs can in addition to microglia 
also be secreted by astrocytes (Eckman et al 2003). For example, deletion of the NEP gene 
increased Aβ levels and amyloid plaque burden in mouse models of AD (Farris et al 2007). 
Conversely, transgenic mice with NEP overexpression resulted in reduced levels of soluble Aβ 
and plaque burden (Leissring et al 2003). Similarly, genetic inactivation of IDE gene in mice 
resulted in elevated levels of Aβ in the brain (Farris et al 2003). 
Another important clearance mechanism for Aβ is transcytosis across the blood-brain barrier 
(BBB), which is mediated mainly by the cell surface LRP1 (Shibata et al 2000) and RAGE 
receptors (Deane et al 2003) expressed on vascular brain endothelial cells. Aβ accumulation 
causes increased RAGE expression, resulting in cellular dysfunction due to RAGE-Aβ interaction 
and inflammatory responses in the cerebral endothelium (Deane et al 2003).  
Other studies have also suggested that Aβ can be cleared via lymphatic drainage along 
perivascular channels and deposition of Aβ in the periarterial pathways, along which interstitial 
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fluid drains from the cerebral cortex, contributes significantly to CAA in AD (Carare et al 2008, 
Weller et al 1998). 
 
These other mechanisms of Aβ clearance need to be taken into consideration since they may be 
alternative targets of potential therapeutic approaches aimed to reduce Aβ levels and AD 
progression.  
 
 
1.4 In vitro and in vivo models of Aβ phagocytosis by microglia 
 
Microglial Aβ phagocytosis is a crucial aspect of the AD research that requires to be investigated. 
To this end, several approaches have been explored that I will describe here in more detail. 
Microglial phagocytosis of Aβ has largely been studied in cultured primary microglial cells 
obtained from neonatal mice (Floden & Combs 2006) and incubated with recombinant Aβ 
peptides. For example, in cultured primary microglia incubated with monomeric or oligomeric 
Aβ42, lysosomal internalization of immuno-labeled Aβ was detected (D'Andrea et al 2004, 
Mandrekar et al 2009). In addition to primary microglial cells, immortalized microglial cell lines 
of mouse, rat or human origin are also commonly utilized as in vitro models (Malm et al 2012). 
One of the most used rodent microglial cell line in Aβ phagocytosis studies is the BV-2 (Henn et 
al 2009). 
Of note, it has to be taken into account that the appropriate models for studying microglial 
phagocytosis in AD would need to consider aging as a crucial parameter. However, although 
primary microglial cells can be isolated from aged mice (Floden & Combs 2006) or postmortem 
brains (Walker & Lue 2005), such cells cannot be maintained in culture for prolonged period of 
time without addition of growth factors (Moussaud & Draheim 2010) that are known to affect 
microglial homeostasis. Moreover, it has been reported that microglia obtained from aged 
animals show altered responses to inflammation and decreased Aβ uptake and phagocytosis 
compared to microglia from young animals (Njie et al 2012). Furthermore, the function of 
isolated primary microglia could be disturbed by the isolation procedure per se. Recent RNA 
signature analyses demonstrated that changes in microglial gene expression profile occur due to 
the isolation and culturing conditions (Butovsky et al 2014, Gosselin et al 2017). More 
specifically, a unique molecular signature of adult microglia has been identified. While freshly 
isolated newborn and cultured primary microglia revealed to be partially similar to freshly 
isolated adult microglia, the specific microglia signature was completely missing in microglial 
cell lines, such as N9 and BV2 lines (Butovsky et al 2014). 
 
In general, the in vitro conditions do not reflect the complexity of the microenvironment in 
which microglia are present in vivo, where production of bioactive molecules by other cells as 
well as direct cell-to-cell interactions may have an impact on microglial phenotypes (Lampron et 
al 2013). Also, collecting sufficient numbers of microglial cells from either neonatal or adult 
mouse CNS may be challenging. 
Another difficulty in examining Aβ phagocytosis in vitro is caused by the propensity of Aβ 
peptides to self-aggregate. The way Aβ is prepared and solubilized may account for differences 
in the Aβ species/form that is finally applied onto the cells and the one occurring in disease 
pathology. Different Aβ forms, which are often poorly characterized in terms of biophysical 
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properties, may also explain diverse responses to Aβ reported in different cell culture studies 
(Malm et al 2012). It has been reported that fibrillar Aβ42 (fAβ) but not oligomeric Aβ42 (oAβ) 
enhanced microglial phagocytic function in a dose-dependent manner (Pan et al 2011). 
Moreover, pretreatment of microglia with oAβ decreased microglial capacity of phagocytosing 
fAβ (Pan et al 2011). 
 
Alternatively, brain microglia and their responses to Aβ have been monitored in transgenic 
mouse models of AD by in vivo long-term imaging utilizing 2-photon microscopy (Malm et al 
2012). As an example, it has been showed that GFP-labeled microglia migrate towards Aβ 
plaques and exhibited Aβ-containing lysosomes, suggesting their phagocytosis of Aβ (Bolmont et 
al 2008).  
However, 2-photon microscopy is limited in the depth of tissue that can be imaged and is indeed 
restricted to superficial cortical areas. Since the imaging is executed in mouse cortical areas in 
which the skull has been removed or thinned, microglial activation caused by surgical 
manipulation  cannot be circumvented (Nimmerjahn et al 2005). Moreover, for technical/ethical 
reasons such in vivo approach does only allow a certain number of repeated imaging sessions to 
be performed on the same animal. Furthermore, microglial responses to a specific modulator or 
drug responses are rather difficult to achieve and monitor in vivo.  
 
All the above described tools represent efforts invested so far in the direction of examining 
microglial phagocytosis in AD. However, there are still limitations and the restricted availability 
of suitable model systems highlights our needs of developing novel methods for studying Aβ 
phagocytic functions of microglia. This is important not only for better understanding the AD-
related pathological mechanisms but also for gaining knowledge on possible ways to interfere 
with them as modulating microglial phagocytic function is indeed one of the therapeutically 
relevant approaches against AD (Sevigny et al 2016). 
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2. Aim of the study 
 
Neuroinflammation plays an important role in AD progression and microglial 
activation is one of the hallmarks of the disease pathology. However, a potential 
microglial function in amyloid plaque clearance is still controversial. Despite 
microglial recruitment and clustering around amyloid plaques, accumulation of Aβ 
occurs in AD patients as well as in AD mouse models , suggesting a possible reduction 
in phagocytic function of microglia over the course of AD. The major aim of my thesis 
was to investigate microglial amyloid plaques clearance and to understand better the 
failure of AD microglia to clear amyloid. 
  
Due to the lack of suitable tissue culture system, the first aim was to establish and 
characterize a model that allows investigating microglial phagocytosis of amyloid 
plaques. Primary microglial cultures are often used for phagocytic analysis upon 
incubation with Aβ peptides. However, microglial identity, dynamics, as well as their 
responses are determined by their cellular context. Consequently, primary microglia 
isolated from their natural environment and cultured alone display altered microglial 
homeostasis and reactivity. Therefore, for this study, I cultured organotypic brain 
slices that resemble a “close-to-in vivo”-like situation, where microglia are 
maintained in their physiological cellular environment, but at the same time easy to 
manipulate. Moreover, in order to have a system containing amyloid plaques I 
directly cultured brain slices from a transgenic mouse model for AD pathology.  
 
The second aim was to study microglia-mediated amyloid plaque clearance in the ex 
vivo co-culture model. To this end, I examined microglial cell numbers, morphology 
and activity as well as their phagocytic capacity. T he goal was to identify factors that 
are able to restore phagocytic activity of aged AD microglia and elucidate molecular 
mechanism involved in amyloid plaque clearance.  
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3. Materials and Methods 
 
3.1 Materials 
 
3.1.1 Equipment and tools 
 
3.1.1.1 General equipment and consumables 
 
Product Company 
Analytical balance (0.0001-200g) Denver Instrument 
Balance (0.01-2000g) Sartorius 
Centrifuge (5810R) Eppendorf 
Centrifuge (Heraeus Fresco 17) Thermo Scientific 
Freezer (-20°C) Liebherr 
Freezer (-80°C) Thermo Scientific 
Fridge Liebherr 
Glassware VWR 
Gloves (Nitrile) Meditrade 
Heating and stirring plate IKA RH 
MilliQ plus filtration system Merck Millipore 
N2 tank Messer Griesheim 
Oven Memmert 
Parafilm “M” Bemis 
pH indicator strips Millipore 
pH meter (Seven easy) Mettler Toledo 
Pipettes Gilson, Eppendorf 
Pipette controller accu-jet pro BrandTech 
Pipette tips (10 μl, 200 μl, 1000 μl) Sarstedt 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt 
Thermomixer compact Eppendorf 
Tubes (1.5 ml, 2 ml) Sarstedt 
Tubes (15 ml, 50 ml) Sarstedt 
Vortexer (Vortex-2 genie) Scientific industries 
 
 
3.1.1.2 Microscope and immunofluorescence equipment 
 
Product Company 
Confocal laser scanning microscope (LSM 710) Zeiss 
Dissection microscope (SZ61) Olympus 
Epifluorescence microscope (AxioImager A2) Zeiss 
Gel fluoromont acqueous mounting media Sigma Aldrich 
Immersol 518 F Zeiss 
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Microscope cover glasses 24 x 50 mm Marienfeld 
Microscope slides Thermo Scientific 
Objective (Plan Apochromat, 10x/0.45 dry DIC) – LSM 710 Zeiss 
Objective (Plan Apochromat, 20x/1 dry DIC) – LSM 710 Zeiss 
Objective (Plan Apochromat, 40x/1.4 oil DIC) – LSM 710 Zeiss 
Objective (Plan Apochromat, 63x/1.4 oil DIC) – LSM 710 Zeiss 
Objective (Plan Apochromat 10x/0.3) – AxioImager A2 Zeiss 
Relief Paste Weiss (070) Marabu 
Scalpel Braun 
 
 
3.1.1.3 Microsurgical instruments 
  
Name Company 
Dumont #2, laminectomy forceps straight 
(11223-20) 
Fine Science Tolls, FST 
Dumont #3, straight forceps (11231-30) Fine Science Tolls, FST 
Dumont #5, straight fine forceps (11252-20) Fine Science Tolls, FST 
Dumont #7, curved forceps (11271-30) Fine Science Tolls, FST 
Hardened fine scissors straight (14090-11) Fine Science Tolls, FST 
Spring scissors-angled to side sharp (15006-
09) 
Fine Science Tolls, FST 
Surgical scissor straight (91400-14) Fine Science Tolls, FST 
Large spatula, double, one round end Heathrow Scientific 
Thin spatula, double, one round end Heathrow Scientific 
 
 
3.1.1.4 Cell culture equipment and consumables 
 
Product Company 
Bunsen burner  Fuego 
CD11b MicroBeads Miltenyi Biotec 
Cell culture laminar flow hood Herasafe KS 
Cell culture hood Thermo Scientific 
Cell culture dish (3.5 cm, 6 cm, 10 cm) Nunc  Thermo Scientific 
Cell culture plate (6 well) Thermo Scientific 
Cell culture flask (75 cm2) Thermo Scientific 
Cell strainer (40 μm) NeoLab 
Centrifuge tubes corning (15 ml) Sigma Aldrich 
CO2-incubator Binder, Thermo Scientific 
LS MACS columns Miltenyi Biotec 
Magnetic Activated Cell Sorting-MACS kit Miltenyi Biotec 
Membrane inserts (PICM ORG 050) Millipore 
Neuronal tissue dissociation kit (P) Miltenyi Biotec 
PES sterile membrane filter (0.20 μm, 0.45 μm) VWR International 
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quadroMACS separator Miltenyi Biotec 
Stericup and Steritop filter bottles (250 ml, 
500 ml) 
Millipore 
Tissue chopper (TC752)  Mickle Laboratory Engineering Company 
Tissue chopper blades Gilette 
Waterbath GFL 
 
 
3.1.1.5 Biochemistry equipment and consumables 
 
Product Company 
Developer Cawo 
Glass plates for electrophoresis gels Bio-Rad 
Nitrocellulose membrane, 0.1 μm GE Healthcare 
Power supply Bio-Rad 
Protein electrophoresis gel system Bio-Rad 
PVDF membrane, Immobilon-P Millipore 
Sonifier Branson/Heinemann 
Shaker Thermo Scientific 
Tris-Tricine gels 10-20% Thermo Scientific 
X-ray films Fuji 
 
 
3.1.1.6 Molecular biology equipment and consumables 
 
Product Company 
DNA electrophoresis gel system Bio-Rad 
Imager for agarose gels INTAS Science imaging 
Microwave Sharp 
Power supplier Bio-Rad 
PCR tubes NeoLab 
Thermocycler (Analytikjena) Biometra 
 
 
3.1.2 Chemicals, reagents, enzymes, antibodies 
 
3.1.2.1 General chemicals 
 
Name Company 
Acetic acid Merck 
Agarose Ultrapure Life Technologies 
Ammonium persulfate (APS) Sigma Aldrich 
Acrylamide/Bis solution 37.5:1 Serva 
Bovine serum albumin (BSA) Sigma Aldrich 
Materials and Methods 
 
 
46 
 
Bromophenol blue Fluka 
Dimethylsolfoxide (DMSO) Roth 
ECL Thermo Scientific 
Ethanol Merck 
Ethylenediaminetetraacetic acid (EDTA) 
TRITLRIPLEX III 
Merck 
Formic acid Merck 
Glycerol Merck 
Glycine Biomol 
Goat serum Sigma Aldrich 
I-Block Thermo Scientific 
Isopropanol Roth 
KCl Merck 
KH2PO4 Merck 
NaCl Roth 
Na2HPO4 Merck 
NaOH Millipore 
NP40 USB 
Paraformaldehyde (PFA) Merck 
Sodium deoxycholate Sigma Aldrich 
Sodium dodecyl sulfate (SDS) Calbiochem 
Sucrose Sigma Aldrich 
Tetramethylethylendiamin (TEMED) Roth 
Tricine Biomol 
Tris base AppliChem 
Triton X-100 Merck 
Tween 20 Merck 
β-Mercaptoethanol Roth 
 
 
3.1.2.2 Cell culture reagents 
 
Name Company 
1x Dulbecco’s modified eagle medium, 
DMEM/F12 (1:1) (11320-033) 
Gibco 
Fetal calf serum (FCS) Sigma Aldrich 
1x  Hanks’s buffered salt solution, HBSS 
(14025-050) 
Gibco 
HEPES Gibco 
Horse serum  Stem Cell Technologies 
L-Glutamine Gibco 
1x Minimum essential medium, MEM (32360-
026) 
Gibco 
Penicillin-Streptomycin Invitrogen 
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3.1.2.3 Reagents, enzymes, DNA/protein markers and dyes 
 
Name Company 
DAPI Invitrogen 
Deoxyribonucleotides (dNTPs) Roche 
DNA Ladder 1kb Plus Invitrogen 
DNA Polymerase (GoTaq G2) Promega 
GelRed Nucleic Acid Stain  Biotium 
GoTaq buffer Promega 
Phalloidin (Alexa Fluor 555-labeled) Life Technologies 
Propidium iodide Sigma Aldrich 
Protease inhibitor cocktail (P8340) Sigma Aldrich 
SeaBlue Protein Ladder Plus 2 Thermo Scientific 
Thiazine red Sigma Aldrich 
Tryphan blue Life Technologies 
 
 
3.1.2.4 Antibodies 
 
Primary antibodies 
Antibody  Clone Species Dilution Company 
β3-Tubulin  MM-435-P mouse WB:  1:1000 Covance 
CD68  MCA1957GA rat IF:  1:1000 
WB:  1:600 
Serotec 
GFAP  Z 0334 rabbit IF:  1:200 
WB:  1:1500 
Dako Cytomation 
GFP  20R-GR011 mouse IF:  1:200 Fitzgerald 
GFP 75-132 rabbit IF:  1:200 NeuroMab 
M3.2  SIG-39155 mouse IF:  1:500 Covance 
NeuN  MAB377 rabbit IF:  1:200 Millipore 
Ki67  12202 rabbit IF:  1:100 Cell Signaling 
Technology 
6E10 (β-amyloid 
1-16) 
SIG-39320 mouse IF:  1:500 Covance 
2D8   rat IF:  0.011 µg/µl 
WB:  2 µg/ml 
(Shirotani et al 2007) 
 
Secondary antibodies 
Antigen  Labeled Species Dilution Company 
mouse IgG (H+L) Alexa Fluor 488, 647 goat IF:  1:200 Life Technologies 
rabbit IgG (H+L)  Alexa Fluor 488, 555 goat IF:  1:200 Life Technologies 
rat IgG (H+L) Alexa Fluor 488, 555, 
647 
goat IF:  1:200 Life Technologies 
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rat IgG (H+L) Alexa Fluor 555 goat IF:  1:350 Immunological 
Sciences 
mouse IgG (H+L) Horse radish 
peroxidase (HRP) 
goat WB:  1:10000 Promega 
rabbit IgG (H+L)  HRP goat WB:  1:10000 Promega 
rat IgG (H+L) HRP goat WB:  1:10000 Santa Cruz 
Biotechnology 
 
 
3.1.3 Drugs and cytokines 
 
Drug Stock 
concentration 
Solvent Used 
concentration 
Company 
Cytochalasin D (CytoD) 1 mM DMSO 1 µM Sigma Aldrich 
Clodronate (Clo) 50 mg/ml H2O 100 µg/ml Millipore 
Recombinant mouse IL-10 100 µg/ml PBS 100 ng/ml R&D systems 
Recombinant mouse TGF-β1 50 µg/ml PBS 100 ng/ml R&D systems 
Recombinant mouse IL-6 100 µg/ml PBS 100 ng/ml R&D systems 
Recombinant mouse IL-12/p40 100 µg/ml PBS 100 ng/ml R&D systems 
Recombinant mouse GM-CSF 1 µg/ml PBS 1 ng/ml R&D systems 
Cytosine arabinose (AraC) 1 mM H2O 5 µM Merck 
Millipore 
 
 
3.1.4 Buffers and media 
 
If not differently specified, all buffers were prepared in MilliQ water.  
 
3.1.4.1 Cell culture 
 
Name Composition 
Slice culture dissection media 1% Penicillin-Streptomycin  
10 mM Tris pH 7.2 
in HEPES buffered-MEM  
HBSS buffer 0.6% HEPES 
in 1x HBSS 
MACS buffer 0.5% BSA 
0.08 mM EDTA 
in 1x PBS 
Microglia media 10% heat inactivated FCS 
1% Penicillin-Streptomycin 
in DMEM/F12 
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1x Phosphate-buffered saline (PBS)  137 mM NaCl 
2.7 mM KCl 
2 mM KH2PO4 
8.1 mM Na2HPO4 
Slice culture media 50% HEPES buffered-MEM  
25% heat inactivated horse serum  
25% HBSS  
1 mM L-Glutamine  
pH 7.4 
 
 
3.1.4.2 Immunofluorescence 
 
Name Composition 
Immunofluorescence blocking solution 0.5% Triton X-100 
5% Goat serum 
in 1x PBS 
Permeabilization buffer  0.5% Triton X-100 
in 1x PBS 
4% PFA - Fixing solution 4% PFA 
4% Sucrose 
0.15 mM NaOH 
in 1x PBS 
pH 7.4 
 
 
3.1.4.3 Biochemistry 
 
Name Composition 
I-Block – blocking solution 0.2% I-Block 
0.1% Tween 20 
in 1x PBS 
4x Laemmli buffer  125 mM Tris pH 6.8 
8% SDS 
40% Glycerol  
0.025% Bromophenol blue  
10% β-Mercaptoethanol 
5x RIPA stock buffer  100 mM Tris pH 7,4 
750 mM NaCl 
5% Igepal (NP40) 
1.25% Triton X-100 
5% Sodium-deoxycholate 
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1x RIPA lysis buffer (10 ml) 5x RIPA stock buffer (2ml) 
0.5 M EDTA (50 µl) 
1x Protease inhibitor cocktail  
0.1% SDS  
4x Separating gel buffer  1.5 M Tris 
0.4% (w/v) SDS 
adjust to pH 8.8 
4x Stacking gel buffer  0.5 M Tris 
0.4% (w/v) SDS 
adjust to pH 6.8 
1x Transfer buffer  25 mM Tris 
80 mM Glycine 
1x Tris-Glycine running buffer with SDS 25 mM Tris 
80 mM Glycine 
0.1% SDS 
1x Tris-Tricine running buffer with SDS 100 mM Tris 
100 mM Tricine 
0.1% SDS 
 
 
3.1.4.4 Molecular biology 
 
Name Composition 
1% Agarose gel buffer 1% Agarose 
in 1x TAE buffer 
6x DNA loading buffer 30% Glycerol 
0.25% Bromophenol blue 
0.25% Xylene cyanol FF 
Neutralization buffer 1.5 M Tris 
pH 8.8 
1x TAE buffer 40 mM Tris 
20 mM Acetic acid 
1mM EDTA pH 8.0 
 
 
3.1.5 DNA oligonucleotides 
 
3.1.5.1 Primers for genotyping 
 
For APPPS1 mouse line 
Name Sequence 
APP_forward GAATTCCGACATGACTCAGG 
APP_reverse GTTCTGCTGCATCTTGGACA 
PS1_forward CAGGTGCTATAAGGTCATCC 
PS1_reverse ATCACAGCCAAGATGAGCCA 
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For CX3CR1+/GFP mouse line 
Name Sequence (5` 3`) 
CX3CR1_WT  GTCTTCACGTTCGGTCTGGT 
EGFP_mutant  CTCCCCCTGAACCTGAAAC 
Upstream primer CCCAGACACTCGTTGTCCTT 
 
For GM-CSF-/- mouse line 
Name Sequence (5` 3`) 
Common primer AGGTCTTCAGGGATTGATGG 
Mutant primer CTCAGCTACCACAGCCATGT 
WT primer CTCCAGACTGCCTTGGGAAAA 
 
 
3.1.6 Services 
 
Service Company 
Transfers Eurokurier München 
Oligonucleotide synthesis Sigma Aldrich 
 
 
3.1.7 Software and online tools 
 
Name Company 
Adobe Illustrator Adobe Systems 
Adobe Photoshop CS5 Adobe Systems 
AxioVision Zeiss 
ImageJ/Fiji National Institute of Health 
Imaris x64 Bitplane 
MS Office Microsoft 
NCBI (https://www.ncbi.nlm.nih.gov/) National Institute of Health 
ZEN, LSM  Zeiss 
 
 
3.2 Methods 
 
3.2.1 Animals 
 
The APPPS1 mice (line 21) overexpressing human APPKM670/671NL and PS1L166P under the control 
of the Thy-1 promoter (Radde et al 2006) and bred in a C57BL/6J background were used. The 
CX3CR1GFP/GFP reporter line (Jung et al 2000) was purchased from the Jackson Laboratory and 
bred with C57BL/6J WT and APPPS1 line to obtain CX3CR1+/GFP and CX3CR1+/GFP/APPPS1 mice, 
respectively. The GM-CSF knockout mice (GM-CSF-/-) were also purchased from the Jackson 
Laboratory (Dranoff et al 1994). For all analyses in this study both male and female mice were 
used. Mice were group housed in specific pathogen-free conditions. Mice had access to standard 
mouse food and water ad libitum and were kept in a 12/12 h light-dark cycle in IVC System Typ 
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II L-cages (528 cm2) equipped with solid floors and a layer of bedding. All animal experiments 
were executed in accordance with the German animal welfare law and have been approved by 
the government of Upper Bavaria. 
 
 
3.2.2 Genotyping 
 
Genomic DNA was extracted from a small piece of mouse tails or from ear biopsies by alkaline 
lysis of the tissue. First, the tissue was incubated with 100 µl of 50 mM NaOH and heated at 95°C 
for approximately 45 min. During the incubation, samples were vortexed every 15 min for about 
10 sec at medium intensity to facilitate tissue lysis. Afterwards, samples were put on ice for 1-2 
min to cool down and the alkaline reaction was neutralized by addition of 10 µl of neutralization 
buffer (1.5 M Tris, pH 8.8) and vortexed at medium intensity. Samples were then centrifuged at 
4°C at maximum speed in a table top centrifuge for 5 min and stored at 4°C. The extracted DNA 
was used as template for a polymerase chain reaction (PCR). A typical PCR reaction-mix was 
prepared as follows (for reaction a volume of 20 µl): 
  
Component Amount  
5x Buffer GoTaq 4 µl 
dNTPs (10 mM each) 0.5 µl 
Fw-Primer (10 pmol/µl) 1 µl 
Rev-Primer (10 pmol/µl) 1 µl 
Taq-Polymerase (5 U/µl) 0.2 µl 
DNA  1 µl 
MilliQ H2O  12.3 µl 
  
 
For the APPPS1 line, to test for the presence of the human mutated APP and PS1 genes, two 
different PCR reaction-mix solutions were prepared (APP_forward + PS1_forward; APP_reverse 
+ PS1_reverse). Also for the CX3CR1+/GFP line two different PCR reaction-mix solutions were 
prepared (upstream primer + CX3CR1_WT primer; upstream primer + EGFP_mutant primer). 
For the GM-CSF-/- line only one PCR reaction-mix solution was prepared (common + mutant + 
WT primers). The PCR reaction-mix was placed in a thermocycler and the following PCR cycling 
programs were applied, respectively: 
 
For APPPS1 mouse line 
Step Temperature Time Cycles 
Initial denaturation 95°C 10 min 1 x 
Denaturation 95°C 30 sec  
30 x Annealing 63°C 30 sec 
Extension 72°C 30 sec 
Final extension 72°C 5 min 1 x 
Storage 4°C hold  
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For CX3CR1+/GFP mouse line 
Step Temperature Time Cycles 
Initial denaturation 95°C 10 min 1 x 
Denaturation 95°C 30 sec  
30 x Annealing 60°C 30 sec 
Extension 72°C 45 sec 
Final extension 72°C 5 min 1 x 
Storage 4°C hold  
 
For GM-CSF-/- mouse line 
Step Temperature Time Note Cycles 
1. 94°C 2 min  1 x 
2. 94°C 20 sec   
3. 65°C 15 sec -0.5°C 
per cycle 
decrease 
 
10 x 
4. 68°C 10 sec   
5. 94°C 15 sec   
6. 60°C 15 sec  28 x 
7. 72°C 10 sec   
8. 72°C 2 min  1 x 
9. 4°C hold   
 
 
Separation of the PCR products was performed via gel electrophoresis. Samples (5 or 10 µl each) 
were loaded on a 1% agarose TAE gel containing 1:20000 intercalating agent gelred and TAE as 
the running buffer. For the GM-CSF-/- line a 2% agarose TAE gel was used. Voltage was set to 95 
V and run for approximately 30 minutes. The gel was then imaged with a UV light source and a 
picture was taken as documentation. The expected amplification products were as follows. For 
APPPS1 line: APP band ~250 bp; PS1 band ~250 bp; for CX3CR1+/GFP line: CX3CR1_WT band 
~410 bp; EGFP_mutant band ~500 bp; for GM-CSF-/- line: mutant band ~300 bp, WT band ~317 
bp. 
 
 
3.2.3 Organotypic slice cultures  
 
Organotypic slice cultures were prepared according to the membrane interface method 
described by Stoppini et al with some modifications (Stoppini et al 1991). Brains were isolated 
from either young neonatal (postnatal day 5 to 7) or old (10- to 20-month of age) mice. Young 
pups were decapitated and old mice were sacrificed by CO2 inhalation according to animal 
handling laws. After opening the skull, the brain was removed and collected in a 6 cm dish 
containing 3 ml of pre-cooled slice culture dissection media. The two hemispheres were gently 
separated using a wide spatula and olfactory bulb, cerebellum, and midbrain were cut off under 
a dissection microscope. Neocortices together with hippocampi were dissected from the 
neonatal mouse brains and cut to obtain cortico-hippocampal slices, whereas from the old 
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mouse brains neocortices and hippocampi were dissected and cut separately obtaining 
hippocampal and cortical slices. Sagittal sections, 350 µm thick, were sliced using a Mcllwain 
tissue chopper. The sliced tissue was collected using a thin spatula into a 15 ml tube containing 6 
ml of pre-cooled slice culture dissection media and transferred to a pre-cooled empty 6 cm dish. 
Only intact slices were carefully selected under a dissection microscope. Selected slices were 
moved into a 6 cm dish containing 5 ml of pre-cooled slice culture dissection media using a fire-
polished glass pipette with wide tip diameter and incubated for at least 30 min at 4°C. 
Afterwards, four slices were plated onto 0.4 µm porous polytetrafluoroethylene (PTFE) 
membrane inserts placed into a previously prepared 3.5 cm dish containing 1 ml of slice culture 
media. Slice culture samples were kept in a cell-culture incubator at 37°C, 5% CO2. 
Slice culture media were exchanged the day after the preparation and then every 3-4 days. In the 
co-culture paradigm, two slices of young WT tissue (cortico-hippocampal) were plated together 
with two slices of old APPPS1 tissue (cortical and hippocampal) in the same culture dish.  
 
 
3.2.4 Drug and cytokine treatments of slice cultures 
 
Treatments were performed by directly adding drugs to the slice culture media. Slice cultures 
were usually treated starting from day 1 in vitro (DIV) and retreated at every media exchange 
(each 3-4 days). The drugs/cytokines used for all experiments are listed in the table above. 
For the clodronate treatment, either old APPPS1 or young WT tissue was treated till 7 DIV. 
Afterwards, the treatment was stopped by placing the inserts with the slices in new dishes 
containing fresh pre-equilibrated slice culture media then and either young WT or old APPPS1 
tissue was added to the culture to re-establish the co-culture condition. 
 
 
3.2.5 Slice culture conditioned media: collection and incubation 
 
Collection of conditioned media (CM) from young WT and old APPPS1 tissue (4 slices/dish) was 
performed starting from 4-5 DIV and every 3-4 DIV for a total of six times. CM were collected in 
1.5 ml tubes, centrifuged at 0.9xg for 5 min at 4°C and supernatants stored at -20°C. CM from 
different tubes were thawed, pooled and distributed into new 3.5 cm dishes (1 ml/dish) and pre-
equilibrated at 37°C, 5% CO2 for at least 2 hours before incubating the old APPPS1 tissue.  
For collection of CM from microglia-depleted young WT tissue, slices (4 slices/dish) were 
treated with 100 µg/ml of bisphosphonate clodronate (Clo) from 1 DIV until 7 DIV. After 
stopping the treatment, CM were collected (starting from 10-11 DIV) every 3-4 days for a total of 
five times. CM were filtered through a 0.2 µm pore size sterile filter (VWR International) and 
stored at -20°C until usage. As a control, media were collected from vehicle (H2O)-treated young 
WT tissue and subjected to the same experimental procedure. Slice cultures were incubated in 
CM, starting from 1 DIV, and re-incubated every 3-4 days with freshly thawed and pre-
equilibrated CM. Samples were fixed at 7, 11 and 14 DIV and immunostained. 
For analysis of cell proliferation, old APPPS1 slices were incubated in CM from young WT tissue 
in combination with 5 µM AraC or H2O as a vehicle control, starting from 1 DIV and re-incubated 
every 3-4 days with freshly thawed and pre-equilibrated CM and retreated. Samples were fixed 
at 14 DIV and immunostained. 
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3.2.6 Primary microglial cultures, conditioned media: collection and incubation 
 
Isolation of primary microglia was executed from postnatal day 5 WT mouse brains utilizing 
Magnetic Activated Cell Sorting (MACS) Technology and according to manufacturer’s 
instructions. After decapitation, brains were removed and collected in a 6 cm dish containing 3 
ml of HBSS buffer. Cortices were dissected under a dissection microscope, cleaned from 
meninges and cut in small pieces. Cortical pieces were transferred into a clear 15 ml tube, pieces 
were left to sink in the tube and the supernatant containing only HBSS buffer was carefully 
aspirated. Tissue was dissociated by enzymatic digestion using a Neural Tissue Dissociation Kit 
(P). First, 1950 µl of pre-warmed (37°C) enzyme mix1 (part of the Kit) was added, gently mixed 
and incubated for 15 minutes at 37°C in the waterbath. Then 30 µl of enzyme mix2 (part of the 
Kit) were added to the sample, mixed and a mechanical dissociation was carried out using a fire-
polished Pasteur pipette with wide diameter and pipetting up and down 10 times followed by 
incubation for 10 minutes at 37°C. Tissue was mechanically dissociated using two fire-polished 
Pasteur pipettes in decreasing diameter and again incubated for 10 minutes at 37°C. Cell 
suspension was applied onto a 40 µm cell strainer placed on a 50 ml tube prior conditioning of 
the cell strainer with 5 ml of HBSS buffer. Then additional 5 ml of HBSS buffer were added 
through the cell strainer. Cell suspension was centrifuged at 300xg for 10 minutes at RT, the 
supernatant was completely aspirated and cells were resuspended in 10 ml of HBSS buffer and 
counted by diluting 1:2 with tryphan blue using a cell counter chamber. Cell suspension was 
again centrifuged at 300xg for 10 minutes at RT and cell pellet was resuspended in 90 µl of 
MACS buffer and 10 µl of CD11b MicroBeads were added per 107 cells and incubated for 15 
minutes at 4°C with occasional shaking. Cells were washed by addition of 2 ml of MACS buffer 
and centrifuged at 300xg for 10 minutes. The supernatant was discarded and the pellet plus 
CD11b-magnetic beads was resuspended in 1 ml of MACS buffer. LS MACS columns were placed 
in the quadroMACS separator on top of a collecting tube and conditioned with 3 ml of MACS 
buffer. Then cell suspension was loaded onto the column and subjected to magnetic separation. 
After three washing steps with 1ml MACS buffer, the column was removed from the separator 
and placed on a new 15 ml collection tube. 2 ml of MACS buffer was applied onto the column and 
cells were flushed out by firmly pressing the plunger into the column. Cd11b-positive microglial 
cells were counted, diluting 1:2 with tryphan blue and centrifuged at 300xg for 2 minutes at RT. 
The cell pellet was resuspended in 1 ml of pre-warmed microglia media consisting of 
DMEM/F12 with 10% heat inactivated FCS and 1% penicillin-streptomycin. Microglia were 
plated onto 6 cm tissue culture dish at density of 1x106cells/dish and cultured for 24 hours in 
microglia media in a cell-culture incubator at 36.5°C, 5% CO2. After 24 hours, microglia media 
were replaced with fresh slice culture media described above. 
CM were collected after additional 48 hours and filtered through a 0.45 µm pore size sterile filter 
and stored at -20°C. Old APPPS1 slices were incubated in CM from young primary microglia or in 
slice culture media as a control, starting from 1 DIV and re-incubated every 3-4 days with freshly 
thawed and pre-equilibrated CM. Samples were fixed at 14 DIV and immunostained. 
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3.2.7 Immunoblotting 
 
For biochemical characterization of slice cultures, samples were prepared as follows. For each 
sample, 8 brain slices were pooled (from 4 independent slice culture dishes with 2 slices/dish) 
and this was performed in triplicates and in three independent experiments. Brain slices were 
collected from the inserts using a thin spatula and transferred into a tube containing ice-cold 
PBS, centrifuged at 600xg for 5 minutes at 4°C pellets frozen in liquid nitrogen (after removal of 
the supernatant) and stored at -80°C until usage. 
The slices were homogenized with 200 µl 1x RIPA buffer mechanically with a little pestle in 1.5 
ml tubes. After centrifugation at 14.000xg for 60 minutes at 4°C RIPA soluble proteins were 
obtained. The remaining pellet was further homogenized in 100 μl 70% formic acid by 
sonication for 7 min. The formic acid fraction was neutralized with 20x 1 M Tris-HCl buffer at pH 
9.5 and used for Aβ analysis. For Aβ detection, samples were heated at 95°C in 4x Laemmli 
buffer for 5 minutes and proteins were loaded on precasted Tris-Tricine gels (10-20%). Gels 
were run at 60 V in Tris Tricine running buffer with SDS for the first 10 min and afterwards at 
120 V until the dye front reached the very end of the gel. Proteins were transferred to 
nitrocellulose membranes at 400 mA for 60 minutes in Tris-Glycine transfer buffer. Membranes 
were boiled for 5 min in PBS and subsequently incubated with the blocking solution consisting 
of 0.2% I-Block and 0.1% Tween 20 in PBS for 1 hour, followed by overnight incubation with 2 
µg/ml 2D8 antibody diluted in the blocking solution.  
RIPA lysates (10 to 20 µg of protein) were separated under denaturating conditions on 8% Tris-
Glycine gels (complete composition is described below) in Tris-Glycine running buffer with SDS. 
Proteins were blotted on isopropanol activated PVDF membranes in Tris-Glycine transfer buffer 
for the detection of CD68, GFAP and β3-Tubulin. After primary antibody incubation, 
nitrocellulose membranes were washed in PBS with 0.1% Tween 20 and PVDF membranes in 
PBS containing 0.2% Triton X-100 three times for 10 minutes. Next, the corresponding anti-
horseradish peroxidase (HRP) conjugated secondary antibodies (listed in table above) diluted in 
blocking solution were added and the membranes were incubated for 1 hour at RT, followed by 
appropriate washing steps as before. Antibody detection was performed using 
chemiluminescence detection reagent ECL and films were developed and used for 
quantifications with ImageJ. 
 
Gel type Composition of a 8% Tris-Glycine gel 
Stacking gel (5 ml) 40% Bisacrylamide (0.5 ml) 
4x stacking gel Tris buffer (1.25 ml) 
TEMED (5 µl) 
10% APS (5 µl) 
H2O dest (3.2 ml) 
Separating gel (20 ml) 40% Bisacrylamide (4.0 ml) 
4x separating gel Tris buffer (5 ml) 
TEMED (20 µl) 
10% APS (20 µl) 
H2O dest (11.0 ml) 
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3.2.8 Immunohistochemistry  
 
Slice culture samples were fixed in 4% paraformaldehyde (PFA)/sucrose, pH 7.4 for 15 min at 
room temperature (RT). 1 ml of PFA/sucrose was pipetted below the insert and 1 ml was 
directly added onto the slices placed on the insert. Slices were washed three times in PBS and 
permeabilized for 30 min in permeabilization buffer (0.5% Triton X-100 in PBS). Afterwards, 
slices were cut from the membrane insert using a scalpel and transferred with a forceps in a wet 
chamber, where they were incubated for 1 hour in a blocking solution consisting of PBS 
containing 0.5% Triton X-100 and 5% goat serum. Slices were incubated overnight at RT in 
blocking solution containing primary antibodies (listed in table above). Slices were washed 
three times for 10 min with PBS containing 0.5% Triton X-100 and incubated for 3 to 5 hours at 
RT in blocking solution containing nuclear marker DAPI (1:20000) and appropriate secondary 
antibodies conjugated to Alexa Fluor (listed in table above). For actin-cytoskeleton staining 
Phalloidin-Alexa Fluor 555 was used (1:50) in solution together with the secondary antibodies. 
Subsequently, slices were washed three times for 10 min with PBS containing 0.5% Triton X-
100. Fibrillar dense core plaques were stained with the dye Thiazine red (2 µM solution in 1x 
PBS) for 20 min in the dark at RT followed by three washing steps with PBS, 10 minutes each. 
Slices were mounted onto glass slides, covered with Gel Mount media and with a glass coverslip. 
Stained slices were then imaged by confocal and fluorescent microscopy. 
 
 
3.2.9 Image acquisition, analysis and quantification 
 
Confocal images were taken on a LSM 710 confocal microscope (Zeiss) utilizing ZEN 2011 
software package. The acquisition was performed using a Plan-Apochromat 10x/0.45 M27 and 
40x/1.4 oil differential interference contrast (DIC) objectives at 0.6 and 1.5-fold magnifications. 
3D reconstruction image was done utilizing Imaris x64 software (version 7.6.0). 3D images were 
analyzed utilizing the “surpass volume” mode. Representative images were taken using the 
“snapshot” tool. To quantify numbers of amyloid plaques, slice culture samples were 
immunolabeled with M3.2 or 6E10 anti-Aβ antibodies for visualizing plaques. Stained slices 
were imaged on a fluorescence microscope (Zeiss AxioImager A2) equipped with AxioCam MRm 
utilizing AxioVision software package. The objective used was a Plan-Apochromat 10x/0.45. The 
counting of the total number of amyloid plaques and number of core-only plaques was 
performed manually from acquired images and normalized to the tissue surface (in square 
micrometers). The imaged tissue surface was determined utilizing the ZEN lite 2011 software 
package. Quantified values are expressed as percentages of core-only plaques from the total 
number of amyloid plaques. All quantification analyses were based on a minimum of 18 images 
per experiment, from at least 3 independent experiments. As an exception, data showed in Fig 
4.20B and Fig 4.27B were based on quantification analyses from 12 images per experiment, from 
3 independent experiments. Core-only plaques were categorized as plaques consisting of 
fibrillar, TR positive amyloid core without detectable halo positive for 6E10 (as illustrated in Fig 
4.8 and Fig 4.9). To quantify the number of plaque associated CD68 positive cells and plaque 
size, slice culture samples were immunolabeled with CD68 and 6E10 antibodies and confocal 
images were taken using a 40x/1.4 oil DICIII objective at 1.5-fold magnification. The counting of 
the plaque associated CD68 positive cells was performed manually considering signal of CD68 
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and nuclear-DAPI staining. Quantified values were expressed as numbers of CD68 positive cells 
per plaque. The plaque area was calculated by drawing manually its outline and the plaque 
surface was determined utilizing the ZEN lite 2011 software package and expressed in square 
micrometers. Quantification analyses were based on a minimum of 50 plaques, from at least 3 
independent experiments. To quantify the area occupied by CD68 positive cells (CD68 
coverage), slice culture samples were immunolabeled with CD68 antibody and confocal images 
were taken using a Plan-Apochromat 10x/0.45 objective at 1.5-fold magnification. Images were 
taken from cortical areas and each image was defined as a region of interest (ROI). A total of 12 
ROI per analyzed condition were imaged. Thus, 12 images per experiment, from 3 independent 
experiments were utilized for the analysis. CD68 coverage was determined from the acquired 
images by the thresholding technique available on ImageJ software. Measured values were then 
normalized to CD68 coverage values of the Ctr. To quantify the area occupied by CX3CR1-GFP 
positive cells (CX3CR1-GFP coverage), samples were immunolabeled with GFP antibody and 
same experimental procedure as described above was performed. To quantify the number of 
proliferating CD68 positive microglial cells, slice culture samples were immunolabeled with 
CD68 and Ki67 antibodies and cortical areas imaged using Plan-Apochromat 10x/0.45 objective 
at 1.5-fold magnification. Both the number of CD68 positive and CD68-Ki67 double positive 
microglial cells were calculated based on the thresholding technique and the “analyze particle” 
command available on ImageJ software. The size limit for CD68 positive cells was set to 0.01-
Infinity, and for CD68-Ki67 double positive cells was set to 0.0015-Infinity. To define the 
number of CD68 positive cells, images were subjected to a thresholding step before a 
“watershed” command was run. Quantification analyses were based on a minimum of 8 images 
per experiment, from 3 independent experiments for results in Fig 4.25B. Whereas, data showed 
in Fig 4.25D were based on quantification analyses from 12 images per experiment, from 2 
independent experiments. Quantified values are expressed as percentages of Ki67-CD68 double 
positive cells from the total number of CD68 positive cells.    
 
 
3.2.10 Cell viability assay  
 
Cell viability was evaluated by incubating brain slices (at 7 and 14 DIV) with 5 µg/ml propidium 
iodide (PI) directly added to the media for 15 min at 37°C, 5% CO2. Subsequently, slice culture 
samples were fixed in 4% PFA/sucrose, pH 7.4 for 15 min at RT, washed three times with PBS 
and stained with rabbit anti-GFAP, rabbit anti-NeuN antibodies (astrocytic and neuronal 
markers respectively) and DAPI as described before. Confocal microscopy, using a 20x dry 
objective, was performed to acquire representative pictures. PI positive cells were quantified 
and normalized to the total cell number (DAPI positive cells) using an automated counting of 
single color images available in the ImageJ software (NIH). For the quantification at least 3 
pictures per sample from 3 independent experiments were used. 
 
 
3.2.11 Morphological analysis of microglia 
 
To analyze microglial morphology ex vivo, slice cultures from young CX3CR1+/GFP and old 
APPPS1/CX3CR1+/GFP mice were prepared. The microglial specific expression of GFP in these 
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mice allowed a clear visualization of cell body, processes and ramifications. Only cells not 
directly in contact with amyloid plaques were considered for the analysis in old 
APPPS1/CX3CR1+/GFP mice. Brain slices at 0 DIV (young and old) and 10 DIV (young and old 
cultured alone and in co-culture) were fixed in 4% PFA/sucrose and stained using rabbit anti-
GFP, mouse anti-Aβ antibody M3.2 and DAPI as described before. Representative images were 
acquired with a confocal microscope using a 20x dry objective at 1.7-fold magnification. At least 
5 images from each sample, from 3 independent experiments, were used for the analysis. A 
minimum of 250 cells per condition in each experiment was analyzed. Microglial cells were 
classified into 2 distinct groups, ramified versus amoeboid, according to cell body volume with a 
cut off of 523 μm3 (radius = 5 µm). Data are expressed as percentages of amoeboid cells versus 
total number of microglial cells that were analyzed. 
 
 
3.2.12 Data analysis and statistics 
 
Data were collected and analyzed in Microsoft Excel, which was used to generate all graphics. All 
data are presented as ± standard error of the mean (± SEM), depicted by the error bars, from at 
least 3 independent experiments. The statistical significance (P value) of the data was calculated 
using the unpaired two-tailed Studentʼs t-test. P value of <0.05 was considered to be statistically 
significant (*P < 0.05, **P <0.01 and ***P< 0.001; n.s. = not significant).  
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4. Results 
 
4.1 Development of the ex vivo model of AD  
4.1.1 Organotypic brain slice culture model (ex vivo model)  
 The thesis uses organotypic slice cultures of mouse brain tissue to investigate microglial phagocytosis of Aβ. This method was chosen as it provides a good compromise between in vitro and in vivo methods as described in more detail in section 4 of the introduction. The three dimensional tissue architecture is resembling the in vivo-like situation (Carson et al 2008) with the well preserved integrity of neurons, microglia and astrocytes (Fig 4.1A, B). Importantly, microglia present ex vivo with ramified morphology (Fig 4.2) and can be studied in the vicinity of their CNS counterparts, but in a system where recruitment of immune cells coming from the periphery is excluded (Carson et al 2008). Despite glial activation induced by cutting and preparation procedure, this inflammatory reaction is settling down after one week in culture, a period sometimes referred to as consolidation phase (Humpel 2015a). This is reflected by the ramified morphology of microglia after 7-10 days in vitro (DIV) (Fig 4.2). Organotypic brain slices can indeed be maintained in culture over long time periods (in our laboratory up to 6 months) and thus may to a certain extent mimic aging. In addition, they can be relatively easily manipulated and exposed to compounds/drugs, offering the opportunity to monitor and study cell responses over long periods of time (Humpel 2015a). In such respect, the absence of the blood brain barrier makes the system particularly suitable for manipulation.  
 
Figure 4.1. Integrity of neurons, microglia and astrocytes in brain organotypic slice cultures. 
(A, B) Representative confocal images of brain slices from postnatal day 6-old CX3CR1+/GFP mice, which exhibit GFP-expressing microglia, at 10 days in vitro (DIV) immunolabeled with neuronal NeuN (A) and astrocytic GFAP (B) markers (red). The signal of the GFP-expressing microglial cells was amplified using a GFP-specific antibody (green). Both hippocampal (hc) and cortical (ctx) areas are shown. Scale bar: 100 µm. 
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Figure 4.2. Microglial morphology is well preserved in the ex vivo model. Confocal images of microglial cells in brain slices of a young CX3CR1+/GFP reporter mouse at 10 DIV immunostained with GFP (green) to amplify the signal of the GFP-expressing microglial cells. Boxed region in the left panel is shown at higher magnification in the right panel and displays microglial cells homogeneously distributed and mainly resembling their typical ramified morphology. Scale bars: 50 μm (left panel) and 25 μm (right panel). 
 To investigate the capacity of microglial cells in phagocytosing amyloid plaques, I developed an 
ex vivo co-culture system. Amyloid plaques were provided by culturing organotypic brain slices from 14 up to 20-month-old APPPS1 mice (Radde et al 2006). This mouse model of amyloidosis overexpresses human APP bearing the Swedish mutation (K670N/M671L) and PS1 carrying the L166P mutation under control of Thy1 promoter and shows robust plaque pathology, with Aβ deposition starting already at 6 weeks of age in the cortex (Radde et al 2006). To explore the role of microglia in amyloid plaque clearance, I added to the same culture dish slices from young, neonatal (5-7 days old) WT mice (Fig 4.3A). I used cortico-hippocampal young slices and cortical and hippocampal old slices, since those are the brain regions mainly affected by the amyloid pathology in AD. One example of such co-culture dish is illustrated in Fig 4.3B. Note that the young tissue is transparent compared to the old tissue, which exhibits a more white-yellow color (Fig 4.3B). As healthy slices thin in culture over time, tissue transparency is a good indicator of cell viability (Humpel 2015a).  
 
 
Figure 4.3. The ex vivo co-culture model. 
(A) Representative image of a characteristic young WT cortico-hippocampal slice (350 μm) from a co-culture sample at 14 DIV. A nuclear staining was performed using DAPI (grey). Tags indicate respectively, dentate gyrus (DG), cornus ammonis 1 (CA1), and cortical (CTX) brain regions. (B) Example of a typical co-culture dish consisting of two young WT (*, young co-culture) and two old APPPS1 (+, old co-culture) brain slices.
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4.1.2 Characterization of the ex vivo co-culture model: cell viability  To characterize cell viability in the ex vivo co-culture model, I used propidium iodide (PI), a red-fluorescent intercalating dye which stains nuclei of cells with a compromised plasma membrane. I compared numbers of PI-positive cells from the total number of DAPI-positive cells in young and old brain slices maintained in culture alone, or co-cultured, at 7 and 14 DIV. I observed high cell viability in the young slices either alone or in co-culture with the old at both 7 and 14 DIV. In contrast, the number of PI-positive cells was much higher in the old slices, reflecting approximately 70% reduction in cell viability already at 7 DIV and more than 80% reduced viability at 14 DIV (Fig 4.4A, B). Cell viability was comparable in co-culture and respective tissues cultured alone, indicating that the higher degree of cellular death in the old tissue was not influencing survival of the young tissue, and vice versa (Fig 4.4A, B).    
 
Figure 4.4. Cell viability in the ex vivo model at 7 and 14 DIV.
(A) Representative confocal images of young WT and old APPPS1 brain slices alone in culture (young alone, old alone) or in co-culture (young co-culture, old co-culture) at 7 DIV stained with propidium iodide (PI, red). Drawings above the images schematically represent analyzed conditions. The increased PI signal in old brain slices reveals the lower cell viability compared to young brain slices. (B) Quantifications of the % of PI-positive cells from the total number of DAPI-positive cells in young WT and old APPPS1 slices alone in culture (grey and black bars, respectively) or in co-culture (white and squared bars, respectively) at 7 and 14 DIV. Data are presented as mean ± SEM from three independent experiments, each experiment including two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. n.s. = not significant; ***P < 0.001. Scale bar: 75 μm.
 
 
4.1.3 Characterization of the ex vivo co-culture model: cellular markers  To identify different cell populations in the ex vivo co-culture model, I performed immunostaining using cellular markers to visualize neurons, astrocytes and microglia in the 
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young and old slices cultured alone or in co-culture at 7 and 14 DIV. Correspondingly to cell viability data, in the young slices I observed good viability of neurons (positive for NeuN) and astrocytes (positive for GFAP) at both 7 (Fig 4.5A, B) and 14 DIV (Fig 4.5D, E). In the old brain slices, the reduced immunopositivity for NeuN and GFAP already at 7 DIV mirrored the prominent loss of neuronal and astrocytic cells (Fig 4.5A, B and Fig 4.5D, E). To identify microglia, I used the microglial marker CD68, which labels lysosomes of microglial/macrophages and is indicative of phagocytic microglia (Boche et al 2013, Zotova et al 2011). Remarkably, I detected an elevated CD68 signal in the old tissue cultured alone at 7 DIV, which increased further at 14 DIV, indicating that despite the death of neurons and astrocytes microglia were able to survive and got activated. Of note, CD68 immunopositivity was even further elevated upon co-culturing of old and young brain slices (Fig 4.5C, Fig 4.5F). In contrast, I did not observe microglial activation in the young tissue at 7 DIV. Low CD68 signal could only be detected in the young tissue in co-culture with old at 14 DIV.  
 
 
Figure 4.5. Cellular marker characterization of the ex vivo model at 7 and 14 DIV. 
(A–F) Confocal images of young WT and old APPPS1 brain slices alone in culture or in co-culture at 7 (A-C) and 14 (D-F) DIV and immunostained for neuronal NeuN, astrocytic GFAP, and microglial CD68 markers (green). Drawings schematically illustrate conditions analyzed. Immunofluorescence analysis shows a robust decrease in NeuN and GFAP immunosignals in old brain slices already at 7 and also at 14 DIV, while CD68 signal increases, compared to young brain slices. Scale bar: 75 μm.   As additional control for tissue preservation after the cut, I fixed both young and old brain slices without culturing them (0 DIV), and performed immunostaining for NeuN, GFAP, and CD68 cellular markers. Immunofluorescence analyses confirmed that integrity of neurons and astrocytes in both young and old tissue was not compromised by the cut (Fig 4.6A-B). As expected, in the old tissue CD68-positive microglial cells were mostly detected at amyloid plaques, while in the young tissue I barely detected CD68 positive microglia (Fig 4.6C).    
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Figure 4.6. Cellular marker characterization of freshly cut brain slices. 
(A-C) Confocal images of young WT and old APPPS1 brain slices immediately after the cut at 0 DIV immunostained for neuronal NeuN, astrocytic GFAP, and microglial CD68 markers (green). Immunofluorescence analysis shows the presence of reactive GFAP and CD68 positive cells in the old APPPS1 slices, which are characteristic signs of gliosis and typically occurring in aged AD brains.  Scale bar: 75 μm.  Immunofluorescence data were confirmed by western blot analyses that showed reduced protein levels of neuronal β3-tubulin and astrocytic GFAP and increased protein levels of the microglial marker CD68 in the old tissue at 14 DIV, in contrary to what is observed in the young tissue (Fig 4.7). Importantly, the elevation of CD68 levels in the old tissue co-cultured with the young was clearly evident, suggesting further induction of microglial activation mediated by the young tissue (Fig 4.7).   
 
Figure 4.7. Western blot analysis of cellular markers in the ex vivo model at 14 DIV. Immunoblot of microglial CD68, astrocytic GFAP, and neuronal β3-Tubulin protein levels in old APPPS1 and young WT tissue cultured alone or in co-culture at 14 DIV. Drawings schematically illustrate analyzed conditions. For each condition 
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samples were loaded in triplicates and β-actin was used as a loading control.  Altogether, these observations indicate that viability of neurons and astrocytes in aged brain slices is very poor, as also reported by others (Mewes et al 2012, Staal et al 2011). However it is remarkable that microglia can be maintained in such environment and more importantly can acquire a phagocytically active phenotype.   
4.2 Clearance of amyloid plaque halo is enhanced in the ex vivo co-culture 
model 
 To study microglial phagocytosis of amyloid plaques, I first analyzed amyloid plaque morphology in the ex vivo co-culture model. I was still able to detect a typical amyloid plaque morphology in the old APPPS1 tissue until 7 DIV. Amyloid plaques are composed of a fibrillar core visible from co-staining of the human anti-Aβ antibody 6E10 and thiazine red (TR), a dye which labels β-sheet structures of amyloid fibrils, and of a plaque halo of diffuse Aβ detected only by 6E10, surrounding the core (Fig 4.8A). Intriguingly, morphology of amyloid plaques changed over 14 DIV in the co-culture model, resulting in plaques consisting mainly of amyloid cores (Fig 4.8A, B). Upon co-culturing of old APPPS1 with young WT brain slices at 7 DIV, the majority of amyloid plaques still contain 6E10- and TR-positive core surrounded by 6E10-positive halo. In contrast, at 14 DIV, amyloid plaques are mainly 6E10- and TR-positive core-only plaques without 6E10- detectable halo (Fig 4.8B). 
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Figure 4.8. Amyloid plaque clearance is increased in the ex vivo co-culture model of old and young brain slices. 
(A) Confocal images of the old APPPS1 brain slice in co-culture with the young WT immunolabeled with 6E10 antibody for amyloid plaque detection (green) and thiazine red (TR, red) for detection of fibrillar amyloid cores. At 7 DIV, most of the amyloid plaques consist of 6E10- and TR-positive dense core (encircled in B) surrounded by 6E10-positive halo of diffuse Aβ (arrowheads in B). Conversely, at 14 DIV, most of the amyloid plaques are 6E10- and TR-positive core-only plaques without 6E10-positive detectable halo. (B) Higher magnification confocal images of boxed regions in (A) showing the different morphology of two representative amyloid plaques at 7DIV (upper panels) and at 14 DIV (lower panels). Scale bars: 50 μm.   In addition, core-only plaques were also positive for the mouse anti-Aβ antibody M3.2. Indeed, as previously described, this is due to the co-aggregation of the endogenously produced mouse Aβ and the human Aβ produced by the transgene (van Groen et al 2006) (Fig 4.9).   
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Figure 4.9.  Co-deposition of mouse and human Aβ in the ex vivo co-culture model. Confocal images of core-only plaques in the old APPPS1 brain slice in co-culture at 14 DIV immunolabeled with mouse-specific M3.2 (green) and human-specific 2D8 (red) Aβ antibodies.  The full co-localization of M3.2 and 2D8 antibodies reveals co-deposition of mouse endogenous and transgenic human Aβ. Scale bar: 50 μm.  Since I observed clearance of the plaque halo in a system where the old APPPS1 tissue is cultured together with the young tissue, I next also examined amyloid plaque morphology in the old slices cultured alone. The analysis revealed that numbers of core-only plaques were significantly higher in the old tissue upon co-culturing with the young already at 7 DIV and further increased at 14 DIV in comparison with the old tissue cultured alone (Fig 4.10A-C). Thus, clearance of the plaque halo is enhanced upon co-culturing of old APPPS1 and young WT slices.  
 
Figure 4.10. Amyloid plaque clearance is increased upon co-culturing of old APPPS1 and young WT brain slices. 
(A-B) Confocal images of old APPPS1 slices alone in culture or in co-culture at 7 (A) and 14 (B) DIV and immunolabeled with M3.2 antibody. Amyloid plaque clearance is enhanced in the old brain slices upon co-culturing with the young slices. Scale bar: 100 μm. (B) Quantifications of the % of core-only plaques from the total number of amyloid plaques in old APPPS1 slices alone in culture (white bars) or in co-culture (squared bars) at 7 and 14 DIV. Analysis shows progressive increase in the % of core-only plaques upon co-culturing of old APPPS1 and young WT brain slices together compared to old cultured alone. Data are presented as mean ± SEM from three independent experiments, each experiment including three independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001. 
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Furthermore, in line with immunohistochemical analyses of amyloid plaques, also biochemical analyses revealed almost 60% reduced Aβ levels in the old tissue upon co-culturing with the young at 14 DIV compared to old tissue alone (Fig 4.11A, B). Notably, due to our culturing conditions that include frequent media exchange (every 3-4 days), it is not possible to detect accumulation of soluble Aβ (Humpel 2015b). Therefore, soluble Aβ forms in brain slice extracts, protein analyses of brain slices was conducted on the formic acid extractable aggregated Aβ material, whereas the immunofluorescence analyses focused on clearance of the plaque halo of diffuse Aβ. Taken together, co-culturing of old and young brain slices induced, in addition to the clearance of the plaque halo, also removal of fibrillar Aβ.  
 
 
Figure 4.11. Aβ levels are reduced in the co-culture of old APPPS1 and young WT brain slices. 
(A) Immunoblot of Aβ levels detected with 2D8 antibody in the old APPPS1 brain slices alone in culture or in co-culture with the young WT at 14 DIV. For both conditions analyzed samples were loaded in triplicates. (B) Quantification of immunoblot signals shows reduced Aβ levels when old brain slices are co-cultured together with young slices compared to the old tissue cultured alone. Data are normalized to the Aβ levels in the old tissue cultured alone and are presented as mean ± SEM from two independent experiments, and each experiment was performed in triplicates. P values are derived from unpaired two-tailed Student's t-test. **P < 0.01.     In summary, the old APPPS1 brain tissue exhibits evident amyloid plaque pathology and the presence of the young tissue stimulates clearance of Aβ plaques in the old APPPS1 tissue. The reduction of Aβ levels upon co-culturing of old and young brain slices suggests an increased plaque phagocytosis that goes in parallel with the increased levels of microglial marker CD68.   
4.3 Age-dependent reduction of amyloid clearance in old APPPS1 brain 
slices in the ex vivo model   I wondered whether increased amyloid clearance detected in the in the co-culture model was triggered by the different age (young vs old) or different genotype (WT vs APPPS1) of the co-cultured tissue. Therefore, I extended the amyloid plaque analysis to additional groups, comparing co-cultures of old APPPS1 and young WT brain slices  with co-cultures of old APPPS1 and either young APPPS1 or old WT brain slices. Regardless of whether I used young WT or young APPPS1 slices, core-only plaque numbers increased similarly in the APPPS1 old, indicating that the young age of the co-cultured tissue was promoting clearance of Aβ plaque halos independently on its genotype (Fig 4.12). In contrast, presence of old WT brain slices together with old APPPS1 brain slices did not show a profound effect on clearance of Aβ plaque 
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halos, even though counts of core-only plaques were slightly higher compared to old APPPS1 alone in culture (Fig 4.12).    
 
Figure 4.12. Aβ clearance capacity in the ex vivo co-culture model is age-dependent. Quantifications of the % of core-only plaques from the total number of amyloid plaques in old APPPS1 brain slices cultured alone (old APPPS1 alone) or co-cultured with young WT (old APPPS1 + young WT), young APPPS1 (old APPPS1 + young APPPS1), or old WT brain slices (old APPPS1 + old WT) at 14 DIV. Drawings schematically illustrate analyzed conditions. Amyloid plaque clearance increases significantly only upon co-culturing of old APPPS1 brain slices with young slices, both WT and APPPS1, but not upon co-culturing with old slices. Data are presented as mean ± SEM from three independent experiments, each experiment including three independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. n.s. = not significant, ***P < 0.001.  Altogether, these results indicate that different effects observed on plaque phagocytosis in the ex 
vivo model depend on the age of the mouse, where the brain slices have been isolated from, rather than its AD-related genotype.     
 
 
4.4 Microglial recruitment and clustering at amyloid plaques in the co-
culture model 
 The fact that co-culturing of old and young brain slices triggers clearance of the plaque halo suggested involvement of microglial cells in amyloid removal in the ex vivo co-culture model. To study microglia in the co-culture model, I used CD68 marker. Immunofluorescence analyses revealed strong upregulation of CD68 in the old APPPS1 brain slices in co-culture with the young WT slices (Fig 4.13A). More closely, I observed that CD68-positive cells were organized in clusters decorating amyloid plaques (Fig 4.13B). I quantified numbers of CD68-positive cells clustering around single amyloid plaques and measured amyloid plaque size at 7 and 14 DIV upon co-culturing. Quantifications showed that numbers of plaque-associated CD68-positive cells had the tendency towards increase between 7 and 14 DIV (Fig 4.13C). This effect was accompanied by a dramatic decrease in plaque size, mostly due to the loss of the plaque halo (Fig 4.13D). Furthermore, I quantified numbers of amyloid plaques, which I defined as clustered 
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plaques when they were surrounded by at least four CD68-positive cells. I observed increase in the number of clustered plaques by two fold from 7 to 14 DIV (Fig 4.13E). This was consistent with the decrease in plaque size.     
 
 
Figure 4.13. Recruitment and clustering of CD68-positive cells around amyloid plaques is accompanied by a 
reduction in plaque size. 
(A, B) Confocal images of the old APPPS1 brain slice in co-culture at 14 DIV and immunostained with 6E10 (green) for amyloid plaques and CD68 (red) for microglial cells. DAPI (blue) was used to counterstain nuclei. Boxed region in (A) is shown at higher magnification in (B) and displays several CD68-positive cells forming clusters around amyloid plaques. Scale bars: 100 μm (A) and 10 μm (B). (C) Quantifications of the number of plaque-associated CD68-positive cells in co-culture samples at 7 and 14 DIV show a tendency towards increased number of CD68-positive cells. Data are presented as mean ± SEM from three independent experiments, including total of at least six independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. n.s. = not significant. (D) Quantifications of the size of amyloid plaques in co-culture samples at 7 and 14 DIV show a decrease in plaque size. Data are presented as mean ± SEM from at least three independent experiments, including total of at least six replicates. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001. (E) Quantifications of % of plaques encircled by CD68-positive cells (clustered plaques) from the total number of amyloid plaques in co-culture samples at 7 and 14 DIV. Values show increased % of clustered plaques over time. Data are presented as mean ± SEM from three independent experiments, including total of at least six independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001.  
 
 Taken together, presented data suggest that CD68-positive cells may be actively recruited to amyloid plaques in the ex vivo co-culture model to initiate phagocytosis. To verify this hypothesis, I used cytochalasin D (CytoD), a drug that binds to cytoskeletal protein actin and 
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inhibits its polymerization (Schliwa 1982). Interfering with actin cytoskeleton dynamics impaired migration and phagocytosis, abolished microglial clustering at amyloid plaques and caused an almost complete inhibition of the plaque halo clearance (Fig 4.14A, B). Disturbed cytoskeletal disorganization induced by CytoD was confirmed by staining with the actin specific-dye phalloidin. In contrast, ring-like staining pattern was observed upon vehicle- treatment and attributable to actin cytoskeletal structure of CD68-positive cells encircling Aβ plaques (Fig 4.14A). Therefore, CD68-positive microglial cells that cluster around amyloid plaques may be actively engaged in phagocytosing amyloid plaques in the ex vivo co-culture model.    
  
Figure 4.14. CD68-positive microglia actively take up and phagocytose Aβ.   
(A) Confocal images of the old APPPS1 brain slice in co-culture at 14 DIV treated with cytochalasin D (CytoD) and vehicle control (Ctr) and immunolabeled with M3.2 (green) and CD68 (red). Phalloidin (blue) was used to stain actin. In the Ctr condition Phalloidin staining shows ring-like structures likely attributable to actin cytoskeleton of microglial cells tightly clustered around amyloid plaques (arrows). In contrast, upon CytoD treatment tissue cytoskeletal organization is clearly disrupted (arrowheads) and microglial clustering is not taking place. Amyloid plaque clearance is also prevented when phagocytosis is inhibited by CytoD. Scale bar: 50 μm. (B) Quantifications of the % of core-only plaques from the total number of amyloid plaques in the old APPPS1 brain slice in co-culture at 14 DIV and treated with CytoD and Ctr. Analysis shows very low % of core-only plaques upon CytoD treatment compared to Ctr. Data are presented as mean ± SEM from three independent experiments, including total of six independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001.  
 
 
4.5 Young microglia do not infiltrate into the old APPPS1 slice 
 Since the ex vivo co-culture model contains both young and old brain slices, I could not distinguish whether plaque-associated CD68-positive cells derive from young or old brain tissue. To this end, brain slices were prepared from CX3CR1+/GFP microglia/macrophage mouse reporter line (Jung et al 2000), in which the fraktalkine receptor-encoding gene CX3CR1 that is specifically expressed by microglia/macrophages has been replaced by the GFP-encoding gene, thus these mice exhibit green microglia. To investigate possible infiltration of young microglial cells into old tissue, I prepared co-cultures of young brain slices from CX3CR1+/GFP mice with the old APPPS1 brain slices. Immunofluorescence analyses showed young GFP-expressing microglial cells migrating towards 
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the old tissue at 14 DIV, however only few reached the border of the old slice and almost none were detectable inside of the old tissue (Fig 4.15A, B). This showed that young microglia do not infiltrate the old APPPS1 tissue, at least at the time points when clearance of the plaque halo is evident (14 DIV). Thus, young microglia are not directly participating in amyloid plaque phagocytosis.   
  
Figure 4.15. Young microglia do not infiltrate into the old APPPS1 brain slice at 14 DIV. 
(A, B) Confocal images of young CX3CR1+/GFP co-cultured with old APPPS1 brain slices at 14 DIV and immunostained with GFP (green), CD68 (red), and 6E10 (blue). Drawing schematically illustrates the analyzed condition with GFP-expressing microglia depicted by green dots in the young slice. GFP-positive young microglial cells are moving towards the old tissue, but only few GFP-positive cells are visible within the old slice at 14DIV (arrowhead) and mainly confined to the border of the old tissue. Young and old brain slices are delineated by dotted lines. Boxed regions in (A) are shown at higher magnification in (B) and display that GFP-positive microglial cells are indeed detected in the young slice (upper panels), whereas they are not present in the old slice (lower panels). The signal of the GFP-expressing microglial cells was amplified using a GFP-specific antibody. Scale bars: 100 μm (A) and 10 μm (B). 
 
 
4.6 Old microglia engulf Aβ  
 The observation that CD68-positive cells surrounding amyloid plaques were negative for GFP (Fig 4.15A, B) suggested that plaque-associated microglial cells do not derive from the young tissue but rather belong to the old tissue. To verify this hypothesis, I first crossed the CX3CR1+/GFP mouse reporter line with the APPPS1 mouse line and aged those animals to allow development of plaque pathology. Next, I prepared co-cultures of old APPPS1/CX3CR1+/GFP brain slices with young WT brain slices and analyzed localization of microglial cells (Fig 4.16A). 
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Immunofluorescence analyses revealed that M3.2-labeled amyloid plaques were indeed surrounded by GFP and CD68 double positive microglial cells, confirming their origin from the old tissue (Fig 4.16A). To further validate involvement of old microglial cells in amyloid plaque phagocytosis, 3-dimensional reconstruction analyses of old GFP-expressing cells were performed in co-cultures of old APPPS1/CX3CR1+/GFP and young WT brain slices using Imaris software. I detected M3.2-positive amyloid material intracellularly within old GFP-positive microglial cells, proving the identity of old AD microglia as Aβ engulfing cells (Fig 4.16B). However, intracellular amyloid material was only occasionally detected, suggesting rapid intracellular degradation of Aβ. 
 
  
Figure 4.16. Old CD68-positive microglial cells cluster around amyloid plaques, and engulf Aβ. 
(A) Confocal images of the old APPPS1/CX3CR1+/GFP brain slice co-cultured with the young WT slice at 14 DIV and immunolabeled with GFP (green), CD68 (red), and M3.2 (blue). Drawing schematically illustrates the analyzed condition with GFP-expressing microglia depicted by green dots in the old slice. GFP-positive old microglial cells co-localize with CD68-positive cells surrounding amyloid plaques (arrows). The signal of the GFP-expressing microglial cells was amplified using a GFP-specific antibody. Scale bar: 10 μm.  (B) 3D reconstruction of the old APPPS1/CX3CR1+/GFP brain slice in co-culture with the young WT slice at 10 DIV and immunolabeled with GFP (green) and M3.2 (red). GFP-positive old microglial cells clustering around amyloid plaques display M3.2-positive amyloid material intracellularly suggestive of Aβ uptake. Overview at lower magnification of a representative area is shown in the left panel. Scale bar: 15 μm. A representative amyloid plaque image at higher magnification is shown in the right panels. Scale bar: 10 μm.
 
 
4.7 Amyloid plaque clearance depends on both young and old microglia 
 Clearance of the plaque halo is enhanced in the co-culture model where old microglia are directly involved in phagocytosis of Aβ while young microglia trigger this effect but do not get in direct contact with Aβ plaques. This statement is additionally supported by experimental evidence obtained by pharmacological depletion of young or old microglia using bisphosphonate 
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clodronate as described below. This toxin is commonly utilized to specifically deplete cells derived from the monocytic cell lineage like osteoclasts, macrophages or microglia and well established protocols are available (Hellwig et al 2015, Ji et al 2013, Kohl et al 2003, Kreutz et al 2009, Vinet et al 2012).   
4.7.1 Clodronate efficiently depletes microglial cells 
 First, I tested the efficiency and specificity of clodronate treatment in young and old brain slices by measuring the tissue area covered by microglial CX3CR1-GFP positive immunosignal, referred to as microglial coverage and by analyzing other non-target cell types such as astrocytes and neurons. For this examinations, brain slices were prepared from the young CX3CR1+/GFP microglia/macrophage mouse reporter line (Jung et al 2000) and treated with clodronate or vehicle-control from 1 until 7 DIV, followed by immunofluorescence analysis. Clodronate treatment of young CX3CR1+/GFP slices resulted in almost complete microglial depletion, as shown by coverage analyses of young GFP-expressing microglial cells (Fig 4.17A-C), without affecting GFAP-positive astrocytic and NeuN-positive neuronal cell numbers (Fig 4.17A, B).  
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Figure 4.17. Clodronate treatment of young and old brain slices efficiently depletes microglial cells.  
(A, B) Confocal images of the young CX3CR1+/GFP brain slice treated with Clo and Ctr from 1 until 7 DIV and immunolabeled with GFP (green) and astrocytic-GFAP marker (red) in (A), and with GFP (green) and neuronal-NeuN marker (red) in (B). Nuclei were counterstained with DAPI (blue). Drawings on the left schematically illustrate conditions analyzed with GFP-expressing microglia depicted by green dots in the young slice. The signal of the GFP-expressing microglial cells was amplified using a GFP-specific antibody. Scale bars: 50 μm. (C) Area covered by CX3CR1-GFP-positive cells in the young CX3CR1+/GFP slice (CX3CR1-GFP coverage young) treated with Clo and Ctr. CX3CR1-GFP coverage indicates complete elimination of young microglial cells upon Clo treatment. Values are normalized to CX3CR1-GFP coverage of the Ctr and are presented as mean ± SEM from three independent experiments, including total of six independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001.   
(D, E) Confocal images of the old APPPS1/CX3CR1+/GFP brain slice treated with Clo and Ctr from 1 until 7 DIV and 
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immunolabeled with GFP (green) and astrocytic-GFAP marker (red) in (D), and with GFP (green) and neuronal-NeuNmarker (red) in (E). Nuclei were counterstained with DAPI (blue). Drawings schematically illustrate conditions analyzed with GFP-expressing microglia depicted by green dots in the old slice. The signal of the GFP-expressing microglial cells was amplified using a GFP-specific antibody. Scale bars: 50 μm. (F) Area covered by CX3CR1-GFP-positive cells in the old APPPS1/CX3CR1+/GFP slice (CX3CR1-GFP coverage old) treated with Clo and Ctr. Reduced CX3CR1-GFP coverage indicates removal of old microglial cells upon Clo treatment. Values are normalized to CX3CR1-GFP coverage of the Ctr and are presented as mean ± SEM from three independent experiments, including total of six independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. *P < 0.05. (G) Area covered by CD68-positive cells in the old APPPS1/CX3CR1+/GFP slice (CD68 coverage old) treated with Clo and Ctr and immunolabeled with CD68.  Reduced CD68 coverage indicates also removal of old microglial cells upon Clo treatment, consistent with CX3CR1-GFP coverage in (F). Values are normalized to CX3CR1-GFP coverage of the Ctr and are presented as mean ± SEM from three independent experiments, including total of six independent slice culture dishes. P values are derived from unpaired two-tailed Student's 
t-test. ***P < 0.001.      In parallel, I analyzed clodronate treatment of brain slices from old APPPS1/CX3CR1+/GFP mice and found that microglial removal was approximately 65 % efficient, as revealed by coverage analyses of old GFP-expressing microglial cells (Fig 4.17D-F). Consistent with this, tissue area covered by CD68 immunosignal was also reduced upon clodronate treatment of old slices (Fig 4.17G). As already described, I showed that old astrocytes and neurons survive poorly in the ex 
vivo model (Fig 4.5A, B, Fig 4.5D, E). In line with that, both control and clodronate treated old slices presented no GFAP immunopositivity and only sparse NeuN immunosignal (Fig 4.17D, E).   
4.7.2 Both young and old microglia contribute to amyloid plaque clearance  Next, to discriminate a specific contribution of young or old microglia in the ex vivo co-culture model, young slices were pre-treated with clodronate from 1 until 7 DIV to remove microglia. Treatment was then stopped by exchanging media and subsequently old APPPS1 slices were added to restore the co-culture condition, as schematically indicated in Fig 4.19A. 14 days after, samples were fixed and the old APPPS1 tissue analyzed by immunofluorescence. Removal of young microglia caused a significant reduction in numbers of core-only plaques, reflecting a decreased amyloid plaque clearance and therefore supporting the involvement of young microglia in the Aβ clearing process (Fig 4.18B, C). In the parallel experiment, I pre-treated old slices with clodronate, stopped the treatment and subsequently added young WT slices (Fig 4.18D). The substantial depletion of old microglial cells, as showed by CD68 coverage analyses (Fig 4.18F), caused an even more pronounced reduction of amyloid plaque clearance with almost no core-only plaques detected (Fig 4.18E-G). Those additional quantitative analyses are in agreement with previous immunofluorescence analyses that identified microglial cells in the old APPPS1 tissue as cells that are responsible for amyloid clearance in the ex vivo co-culture model (see Fig 4.15 and Fig 4.16). Altogether, the findings presented here indicate that both young and old microglia are required for amyloid plaque clearance, supporting a synergistic effect of both microglial populations.  
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Figure 4.18. Amyloid plaque clearance depends on both young and old microglia. 
(A) Schematic representation of the experimental procedure. (B) Confocal images of the old APPPS1 tissue co-cultured with the young WT tissue pre-treated with Clo and Ctr as presented in (A), and immunolabeled using CD68 (red) and M3.2 (green). Scale bar: 50 μm. (C) Quantifications of the % of core-only plaques from the total number of amyloid plaques in the old APPPS1 slice co-cultured with the young WT slice pre-treated with Clo and Ctr as presented in (A). Values show a reduced number of core-only plaques upon Clo treatment. Data are presented as mean ± SEM from three independent experiments, including total of six independent slice culture dishes. P values are derived from unpaired two-tailed Student's 
t-test. ***P < 0.001. (D) Schematic representation of the experimental procedure. (E) Confocal images of the old APPPS1 tissue treated with Clo and Ctr and afterwards co-cultured with the young WT tissue as presented in (D), and immunolabeled using CD68 (red) and M3.2 (green). Scale bar: 50 μm. (F) Area covered by CD68-positive cells (CD68 
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coverage) in the old APPPS1 brain slice treated with Clo and Ctr and afterwards co-cultured with the young WT tissue as presented in (D). CD68 coverage is decreased upon Clo treatment. Values are normalized to CD68 coverage of the Ctr and are presented as mean ± SEM from three independent experiments, including total of six independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001. (G) Quantifications of the % of core-only plaques from the total number of amyloid plaques in the old APPPS1 brain slice treated with Clo and Ctr and afterwards co-cultured with the young WT slice as presented in (D). Values show a reduced number of core-only plaques upon Clo treatment. Data are presented as mean ± SEM from three independent experiments, including total of six independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. **P < 0.01.   
 
 
4.8 Morphological characterization of microglia in the ex vivo model 
 Since it is known that microglial activation is accompanied by morphological transformation from a ramified morphology into cells with enlarged bodies and amoeboid morphology, I performed detailed morphological analyses. Brain slices were isolated from CX3CR1+/GFP microglia/macrophage reporter mice, allowing better visualization of the whole microglial cell body and ramifications compared to CD68 used elsewhere. Microglial morphology was examined in young CX3CR1+/GFP and old APPPS1/CX3CR1+/GFP brain slices in the following conditions: freshly cut slices (0 DIV), young and old slices cultured alone at 10 DIV and co-cultures at 10 DIV (Fig 4.19A, B). Numbers of ramified versus amoeboid microglia were quantified using as a cut-off a cell body volume of 523 µm3 (with radius equal to 5 µm) and expressed as percentages of amoeboid microglia from the total number of microglial cells analyzed. The results showed that immediately after cutting both young and old microglia appeared as ramified cells reflecting their in vivo morphology. After 10 DIV young microglia still exhibited mainly ramified morphology, whereas almost 70% of old microglial cells showed amoeboid morphology in the old APPPS1 slices cultured alone (Fig 4.19A, B). This might likely be attributed to the increased cell death occurring in cultured old slices (see Fig 4.4, Fig 4.5 and Fig 4.7). Importantly, numbers of old microglia with amoeboid shape were further augmented, to almost 90 %, upon co-culturing with the young slices (Fig 4.19A, B), well in accordance with the increased phagocytosis detected in co-cultures of old and young brain slices (see Fig 4.10 and Fig 4.11). Thus, morphological changes in old microglial cells ex vivo precisely reflect their activation state and phagocytic capacity. Taken together, these results indicate that old APPPS1 microglia upon co-culturing present with amoeboid morphology, cluster around plaques, and become competent for the uptake of Aβ. 
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Figure 4.19. Morphological characterization of microglia in the ex vivo model. 
(A) Confocal images of young CX3CR1+/GFP and old APPPS1/CX3CR1+/GFP brain slices immediately after the cut at 0 DIV, cultured alone or in co-culture at 10 DIV, and immunolabeled with GFP (green) to amplify the signal of the GFP-expressing microglial cells. Drawings schematically illustrate analyzed conditions with the GFP-expressing microglia depicted by dots in both young and old slices. Immunofluorescence analysis reveals altered microglial morphology of old cells upon culturing. Boxed regions are shown in enlargement in the upper left panels. Scale bars: 50 μm. (B) Quantifications of the numbers of amoeboid microglial cells in young CX3CR1+/GFP (white bars) and old APPPS1/CX3CR1+/GFP (grey bars) tissues immediately after the cut at 0 DIV, and cultured alone or in co-culture at 10 DIV. Values are reported as % of amoeboid microglia from the total number of microglial cells and are presented as mean ± SEM from three independent experiments, each experiment including at least 250 cells per condition. P values are derived from unpaired two-tailed Student's t-test. *P < 0.05, ***P < 0.001.  
 
 
4.9 Soluble factors released by young microglia promote Aβ uptake of old 
microglia 
 The results described so far confirmed by using independent experimental approaches that both young and old microglia actively contribute to amyloid plaque clearance. In particular, old microglia are directly responsible for phagocytosing amyloid plaque halos, while young microglia may contribute by releasing soluble factor(s) that promote Aβ uptake of old microglia. To test this hypothesis, I first examined whether soluble factors produced by young slices contribute to amyloid clearance. For this purpose I incubated old APPPS1 tissue in conditioned media collected from young WT brain slices. Histological analyses showed that young conditioned media triggered clearance of Aβ halos, as reflected by increased numbers of core-only plaques compared to old tissue cultured in unconditioned slice culture media (Fig 4.20A).  Remarkably, core-only plaque numbers raised to a very similar extent to that detected upon co-culturing of old and young brain slices at 7, 11, and 14 DIV (Fig 4.20A). As additional negative control, I included old APPPS1 brain slices cultured in conditioned media collected from old APPPS1 slices. As expected, numbers of core-only plaques were not significantly different compared to old tissue cultured in unconditioned culturing media (Fig 4.20A). To determine the cellular population in the young tissue that is secreting phagocytosis-promoting factors, I first treated young WT brain slices with clodronate to induce microglial 
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depletion and subsequently started with the collection of the conditioned media. Upon incubation of old APPPS1 slices in conditioned media from microglia-depleted young slices I did not detect alteration in core-only plaque numbers. On the contrary, conditioned media collected from vehicle -treated young slices induced a progressive raise in core-only plaques at 7, 11 and 14 DIV, reproducing above presented results (Fig 4.20B). This suggests that young microglial cells in the young tissue secrete soluble factors that act in trans on old APPPS1 microglial cells and enables them to re-gain or at least enhance their phagocytic function.  To further corroborate whether the observed effect on plaque clearance was mediated by the young microglial cells, I collected conditioned media from young primary microglial cultures, which I used for culturing of the old APPPS1 brain slices. As expected, numbers of core-only plaques increased again significantly compared to old brain slices cultured in unconditioned media (Fig 4.20C), supporting the conclusion that soluble factors secreted by the young microglia are directly responsible for restoring Aβ phagocytic capacity of old microglia.  
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Figure 4.20. Factors secreted by young microglia promote amyloid plaque clearance. 
(A) Old APPPS1 brain slices were cultured alone (old alone, white bars) or exposed to conditioned media (CM) derived from young WT tissue (old alone + young CM, grey bars). The analysis included co-culture of old APPPS1 and young WT brain slices (old co-culture, squared bars) as a positive control and old APPPS1 slices exposed to conditioned media derived from old APPPS1 tissue (old alone + old CM, black bars) as a negative control. Drawings schematically illustrate analyzed conditions. Quantifications of the % of core-only plaques from the total number of amyloid plaques in the old APPPS1 brain slices as described above at 7, 11, and 14 DIV. Data show higher numbers of core-only plaques upon addition of conditioned media collected from young WT tissue to the old APPPS1 slices, fully mimicking core-only plaque numbers detected upon co-culturing conditions. Values are presented as mean ± SEM from three independent experiments, each experiment including at least two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. n.s. = not significant, **P < 0.01, ***P < 0.001. (B) Old APPPS1 brain slices were exposed to conditioned media derived from young WT tissue pre-treated with clodronate (old alone + young CM + Clo, grey bars) and vehicle control (old alone + young CM + Ctr, white bars). Quantifications of the % of core-only plaques from the total number of amyloid plaques at 7, 11, and 14 DIV show reduced numbers of core-only plaques upon exposure of the old APPPS1 brain slices to the conditioned media derived from microglia-depleted young WT tissue. Values are presented as mean ± SEM from three independent experiments, each experiment including at least two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. n.s. = not significant, ***P < 0.001. (C) Old APPPS1 brain slices were exposed to conditioned media derived from cultured WT primary microglial cells (old alone + MG CM, grey bar) or to unconditioned slice culture media as a control (old alone + Ctr, white bar). Quantifications of the % of core-only plaques from the total number of 
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amyloid plaques at 14 DIV show increased numbers of core-only plaques upon exposure of the old APPPS1 slices toconditioned media derived from cultured WT primary microglia. Values are presented as mean ± SEM from three independent experiments, each experiment including two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. *P < 0.05. 
 
 
4.10 GM-CSF stimulates Aβ uptake of old microglia 
 As the previous results pointed towards the involvement of secreted factors in inducing Aβ phagocytosis, I next aimed at identifying factors that enhance Aβ uptake and phagocytic capacity of old microglial cells. It has been described that several pro- and anti-inflammatory cytokines may impact microglial Aβ phagocytosis (Chakrabarty et al 2015, Guillot-Sestier et al 2015, Lai & McLaurin 2012, Wilcock 2012). Therefore, to directly evaluate stimulatory effects of soluble factors on Aβ phagocytosis in the ex vivo model, I started with testing several selected pro- and anti-inflammatory cytokines by adding them directly to the old APPPS1 tissue. I analyzed whether addition of a single factor was enough to increase Aβ uptake and thus would reproduce the effect observed upon co-culturing of old and young brain slices. As can be seen in Fig 4.21A-E, immunofluorescence analyses revealed that treatment with the anti-inflammatory cytokines interleukin-10 (IL-10) and transforming growth factor β (TGF-β), as well as the pro-inflammatory cytokines IL-6 and IL-12/p40 resulted in preservation of the M3.2-positive plaque halo surrounding the plaque core in the ex vivo model (Fig 4.21A-E). In contrast, treatment of old APPPS1 brain slices with granulocyte-macrophage colony-stimulating factor (GM-CSF) promoted clearance of the Aβ plaque halo by the old CD68-positive microglial cells as evident by the increased appearance of core-only plaques (Fig 4.21F and Fig 4.22A, C). This effect was as potent as co-cultures of old and young brain slices (see Fig 4.10). 
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Figure 4.21. The pro-inflammatory factor GM-CSF promotes amyloid plaque clearance. 
(A–F) Confocal images of the old APPPS1 tissue at 14 DIV treated with vehicle Ctr in (A), anti-inflammatory cytokines IL-10 and TGF-β in (B, C) and pro-inflammatory cytokines IL-6, IL-12/p40, and GM-CSF in (D, E, and F), respectively, and immunolabeled using CD68 (red) and M3.2 (green). Immunofluorescence analysis shows appearance of core-only plaques only upon GM-CSF treatment. Other factors tested did not stimulate amyloid clearance, as the typical amyloid plaque morphology with the M3.2-positive halos of Aβ surrounding amyloid cores was fully preserved. Scale bar: 50 μm.  
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Besides involvement in inflammation, cell differentiation, survival and phagocytosis, GM-CSF is also known for its mitogen capacity of inducing proliferation of microglial cells (Lee et al 1994, Suh et al 2005). Therefore, I performed quantitative analyses of GM-CSF effect on the CD68-positive coverage area based on immunofluorescence analyses. As already indicated in Fig 4.21F, these quantitative analyses revealed significantly increased CD68 coverage upon GM-CSF treatment of the old slices (Fig 4.22A, B). This was paralleled by significantly increased numbers of core-only plaques reflecting an enhanced phagocytosis of the plaque halo compared to vehicle-treated old brain slices (Fig 4.22A-C). Of note, upon GM-CSF treatment, numbers of core-only plaques increased to a very similar extent to what I measured upon co-culturing conditions (see Fig 4.10 and Fig 4.20A).  Since I previously observed an almost identical increase in core-only plaque numbers upon co-culturing and upon addition of conditioned media from young WT slices to the old APPPS1 slices, I additionally measured CD68 coverage area in the old APPPS1 brain slices incubated in young conditioned media. I found that young conditioned media was able to increase CD68-positive microglial density compared to unconditioned slice culture media, mimicking the observed effect of GM-CSF on the old APPPS1 brain slices (Fig 4.22D).   
  
Figure 4.22. GM-CSF enhances amyloid plaque clearance and expands CD68-positive coverage. 
(A) Confocal images of the old APPPS1 brain slice at 14 DIV treated with GM-CSF and vehicle Ctr and immunolabeled with CD68 (red) and M3.2 (green). Scale bar: 50 μm. (B) Area covered by CD68-positive cells (CD68 coverage) in the old APPPS1 
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brain slice at 14 DIV treated with GM-CSF and vehicle Ctr. CD68 coverage is enhanced upon GM-CSF treatment. Values are normalized to CD68 coverage of the Ctr and are presented as mean ± SEM from three independent experiments, each experiment including two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test.  *P < 0.05. (C) Quantifications of the % of core-only plaques from the total number of amyloid plaques in the old APPPS1 tissue at 14 DIV treated with GM-CSF and Ctr. Data show higher numbers of core-only plaques upon GM-CSF treatment. Values are presented as mean ± SEM from three independent experiments, each experiment including three independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001. (D) Area covered by CD68-positive cells (CD68 coverage) in the old APPPS1 brain slice at 14 DIV exposed to conditioned media derived from young WT tissue (young CM) or to non-conditioned slice culture media (Ctr). CD68 coverage is enhanced upon exposure of the APPPS1 slice to the young CM. Values are normalized to CD68 coverage of the Ctr and are presented as mean ± SEM from three independent experiments, each experiment including two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. **P < 0.01.  Altogether observed similarities between GM-CSF and co-culturing suggest that GM-CSF might be one potential factor released by the young microglia and responsible for increasing Aβ uptake and clearance in the ex vivo co-culture model of young and old brain slices. 
 
 
4.11 Amyloid clearance can be achieved upon co-culturing of young GM-
CSF-/- and old APPPS1 brain slices 
 To investigate whether GM-CSF is the sole factor responsible for triggering proliferation of old microglial cells and Aβ phagocytosis in the ex vivo model, I analyzed amyloid plaque clearance in the absence of GM-CSF. For this purpose I prepared slice cultures from young GM-CSF knock-out (GM-CSF-/-) mice and co-cultured together with old APPPS1 brain slices (Fig 4.23A). Surprisingly, lack of GM-CSF secretion by the young brain slices did not result in a reduction of Aβ clearance, but instead, similarly to WT brain slices, still allowed amyloid clearance (Fig 4.23A, B). In line with the induced occurrence of core-only plaques, also the density of CD68-positive cells was enhanced in the old APPPS1 slices co-cultured with the young GM-CSF-/- slices in contrast to the old slices cultured alone (Fig 4.23C). Thus, these data indicate that GM-CSF is not the only factor mediating microglial proliferation and Aβ uptake in the ex vivo co-culture model.  
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Figure 4.23. Amyloid plaque clearance is enhanced in the co-culture of old APPPS1 and young GM-CSF−/− brain 
slices. 
(A) Confocal images of the old APPPS1 brain slice alone in culture (old alone) or in co-culture with young GM-CSF−/− brain slices (old co-culture) at 14 DIV and immunlabeled using CD68 (red) and M3.2 (green). Immunofluorescence analysis shows higher numbers of core-only plaques upon co-culturing with young GM-CSF−/− slices. Scale bar: 50 μm. (B) Quantifications of the % of core-only plaques from the total number of amyloid plaques in the old APPPS1 tissue alone in culture or in co-culture with young GM-CSF−/− slices at 14 DIV. Data show higher numbers of core-only plaques upon co-culturing of old APPPS1 brain slices together with young GM-CSF−/− slices. Values are presented as mean ± SEM from three independent experiments, each experiment including three independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001. (C) Area covered by CD68-positive cells (CD68 coverage) in the old APPPS1 slice at 14 DIV alone in culture or in co-culture with young GM-CSF−/− slices. CD68 coverage is enhanced upon co-culturing of old APPPS1 brain slices with young GM-CSF−/− slices. Values are normalized to CD68 coverage of the old slice cultured alone and are presented as mean ± SEM from three independent experiments, each experiment including two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test.  *P < 0.05.  
 
 
4.12 Aggregated Aβ is reduced upon co-culturing and not upon GM-CSF 
application 
 To further characterize the effect of GM-CSF on amyloid plaque clearance and microglial numbers and compare it to the ex vivo co-culture model, I performed biochemical analyses of Aβ levels. Formic acid extracts of old APPPS1 brain slices cultured and treated with GM-CSF were prepared. Western blot analyses revealed no difference in aggregated Aβ levels in old APPPS1 slices upon GM-CSF treatment compared to vehicle-treated old slices (Fig 4.24A). Although I could detect increased protein levels of microglial CD68 upon GM-CSF, this effect was less pronounced compared to co-culture samples of young and old brain slices (Fig 4.24B and Fig 4.7), suggesting a more robust stimulation of amyloid clearance in the co-culture condition with 
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respect to GM-CSF. In contrast, as previously showed, I could detect a strong reduction of aggregated Aβ upon co-culturing of old and young brain slices compared to old tissue cultured alone (see Fig 4.11A, B), fully reflecting the increased Aβ phagocytosis observed in the co-culture model. In line with that, also CD68 levels were strongly elevated in the old tissue co-cultured with the young tissue (Fig 4.7 and Fig 4.24B). Thus, these results confirm prior data obtained with GM-CSF-/- mice (Fig 4.23A-C) and are consistent with the conclusion that GM-CSF is not the only factor necessary for modulating plaque phagocytosis in the ex vivo co-culture model.     
 
 
Figure 4.24. Analysis of fibrillar Aβ and CD68 levels in old APPPS1 tissue upon GM-CSF treatment. 
(A, B) Immunoblot of Aβ using 2D8 antibody (A) and CD68 levels in (B) in the old APPPS1 tissue treated with GM-CSF and vehicle Ctr at 14 DIV. For both analyzed conditions samples were loaded in triplicates. In (B) old APPPS1 tissue co-cultured with the young WT at 14 DIV was included in the analysis for the comparison. 
 
 
4.13 GM-CSF as well as co-culturing induces proliferation of old microglial 
cells  
 Based on above results and on the observation that the CD68 coverage in the old APPPS1 tissue was increased both upon GM-CSF treatment as well as upon incubation of the old brain slices in the young WT conditioned media (Fig 4.22B, D), I next analyzed microglial proliferation and investigated its potential link to amyloid clearance in the ex vivo model. To evaluate numbers of proliferating cells, I utilized a cell proliferation marker Ki67, which detects proliferating cells in all active phases of the cell cycle (G1, S, G2, and mitosis) (Scholzen & Gerdes 2000). Quantitative analyses based on immunofluorescence data revealed higher numbers of Ki67-positive cells upon GM-CSF treatment of old APPPS1 slices compared to control-treated slices (Fig 4.25A). Specifically the number of CD68-positive microglia that were positive also for Ki67 was highly enhanced (Fig 4.25A, B), confirming the described mitogenic potential of GM-CSF on microglia (Lee et al 1994, Suh et al 2005). Next, to investigate whether cell proliferation takes place also in co-cultures of young and old brain slices, I performed the same quantitative measurements on co-cultured samples. Similarly to GM-CSF effect, also upon co-culturing conditions I could detect increased numbers of proliferating microglial cells that were positive for both Ki67 and CD68 markers, compared to old tissue cultured alone (Fig 4.25C, D). Higher magnification images in Fig 4.26A and B demonstrate that nuclei positive for Ki67 are also positive for microglial marker CD68 and can be easily detected both upon GM-CSF application and in the co-culture model. These results suggested the involvement of microglial proliferation in both GM-CSF as well as co-culture paradigm.  
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Figure 4.25. GM-CSF as well as co-culturing induces proliferation of old microglial cells. 
(A) Confocal images of the old APPPS1 tissue at 14 DIV treated with GM-CSF and vehicle Ctr and immunolabeled using CD68 (red), cell proliferation marker Ki67 (green) and M3.2 (blue). Scale bar: 50 μm. (B) Quantifications of the % of Ki67 and CD68 double-positive microglial cells from the total number of CD68-positive cells in the old APPPS1 tissue at 14 DIV treated with GM-CSF and Ctr. Data show enhanced proliferation of microglia upon GM-CSF treatment. Values are presented as mean ± SEM from two independent experiments, each experiment including four independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. ***P < 0.001.  (C) Confocal images of the old APPPS1 slice alone in culture or in co-culture with the young WT tissue at 14 DIV and immunolabeled using CD68 (red), Ki67 (green) and M3.2 (blue) Scale bar: 50 μm. (D) Quantifications of the % of Ki67 and CD68 double-positive microglial cells from the total number of CD68-positive cells in the old APPPS1 tissue alone in culture or in co-culture with the young tissue at 14 DIV. Data show enhanced proliferation of microglia upon co-culturing of old and young brain slices. Values as presented as mean ± SEM from three independent experiments, each experiment including two independent slice culture dishes. P values are derived from unpaired two-tailed Student's t-test. **P < 0.01.
 
 
 
 
 
A
C
B
D
Old alone
Old co-culture
OverlayKi67CD68 M3.2
Ctr
GM-CSF
Ki67CD68 OverlayM3.2
**
0
5
10
15
20
25
30
35
Old
alone
Old
co-culture
%
 K
i6
7+
 m
ic
ro
gl
ia
%
K
i6
7+
 m
ic
ro
gl
ia
0
5
10
15
20
25
30
35
40
***
Ctr GM-CSF
Old APPPS1
Young WT
Old APPPS1
Old APPPS1
Results 
 
 
90 
 
  
Figure 4.26. Proliferating microglial cells can easily be detected in the co-culture model and upon GM-CSF 
treatment. 
(A, B) Confocal images of proliferating microglial cells in old APPPS1 brain slice treated with GM-CSF (A) or in co-culture with young WT brain slices (B) at 14 DIV and immunolabeled using CD68 (red) and cell proliferation marker Ki67 (green). Proliferating microglial cells are detectable upon both GM-CSF treatment and co-culturing and are clearly double-positive for CD68 and Ki67. Scale bar: 10 μm.  
 
 
4.14 Proliferation of old microglial cells is required for amyloid clearance  As above results indicated that GM-CSF treatment as well as the addition of young WT conditioned media to old APPPS1 slices lead to increased CD68 coverage that is reflected by elevated numbers of proliferating microglial cells in the old APPPS1 tissue, I next investigated the potential connection between microglial proliferation and Aβ clearance in the ex vivo model. I cultured the old APPPS1 slices in young WT conditioned media with and without the addition of cytosine arabinose (AraC), a well-known inhibitor of cell proliferation (Doetsch et al 1999, Gomez-Nicola et al 2013). As can be seen in Fig 4.27A, immunofluorescence analyses revealed that microglial cells do not proliferate upon AraC treatment and at the same time amyloid plaque clearance is abolished (Fig 4.27A, B). Indeed, the number of core-only plaques measured in AraC-treated old slices was significantly reduced compared to vehicle-treated old slices (Fig 4.27A). This suggested that proliferation of old microglial cells is necessary for promoting amyloid uptake and clearance in the ex vivo model. Moreover, proliferative and phagocytic pathways might be interconnected.  Altogether, these results indicate that soluble factors released in the media by the young microglia can stimulate old microglial cells to proliferate, and this is required for increasing Aβ clearance in the ex vivo co-culture model. Such effect on old microglia is also very well recapitulated by GM-CSF treatment.     
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Figure 4.27. Microglial proliferation is required for amyloid plaque clearance. Old APPPS1 brain slices were exposed to conditioned media derived from young WT tissue and simultaneously treated with AraC (young CM + AraC), which inhibits cell proliferation, or vehicle Ctr (young CM + Ctr). (A) Confocal images of the old APPPS1 tissue as described at 14 DIV immunolabeled with CD68 (red) and M3.2 (green). Scale bar: 50 μm. (B) Quantifications of the % of core-only plaques from the total number of amyloid plaques in the old APPPS1 slice exposed to conditioned media from young WT tissue and at the same time treated with AraC or Ctr at 14 DIV. Data show a reduced number of core-only plaques upon AraC treatment. Values are presented as mean ± SEM from three independent experiments, each including two independent slice culture dishes. P values are derived from unpaired two-tailed Student's 
t-test. ***P < 0.001. 
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5. Discussion 
 
5.1 Studying amyloid plaque clearance of microglia 
 
A characteristic feature of Alzheimer’s disease is the pathological accumulation of Aβ in the form 
of amyloid plaques in the patients’ brain. One of the main beliefs currently is that Aβ deposits 
originate from a disturbed balance between production and removal of Aβ peptides (Selkoe & 
Hardy 2016). Indeed, the beneficial effect of reduced Aβ peptide production is supported by 
mutations that, decreasing β-secretase cleavage of APP, lower Aβ peptide production and 
protect against AD (Jonsson et al 2012). On the other hand, decreased Aβ clearance was detected 
in sporadic AD patients, which comprise approximately 90% of all AD patients (Mawuenyega et 
al 2010). The brain’s phagocytic effectors, microglial cells, are engaged in the removal of Aβ 
(Bolmont et al 2008, Rodriguez et al 2010). Microglia seem not to be capable of sustaining the 
increased amount of Aβ in the diseased brain, resulting in a progressive Aβ accumulation 
(Mawuenyega et al 2010, Wildsmith et al 2013). Therefore, it would be very important to better 
understand microglial-mediated mechanisms of Aβ clearance in the course of AD. Studies on 
microglial functions in the context of amyloid plaque phagocytosis have so far been restricted by 
the limitations of suitable model systems. Researchers often used in vitro cultures of microglial 
cells isolated from neonatal pups that are not suitable for investigations of age-related changes 
occurring in AD (Butovsky et al 2014). Moreover, it has been shown that microglia undergo 
changes during aging (Hickman et al 2008, Krabbe et al 2013, Orre et al 2014, Streit et al 2008).  
Thus, in my PhD work I decided to explore organotypic slice cultures from mouse brain to study 
the phagocytic capacity of microglial cells towards Aβ. 
 
 
5.1.1 Organotypic brain slice culture as a model to study microglial phagocytosis of 
amyloid plaques (ex vivo model) 
 
Among diverse applications, the organotypic brain slice culture model has been used so far as a 
model for studying Aβ toxicity. For example, it has been shown that treatment of rat 
hippocampal slices with oligomeric Aβ42 species induced cell toxicity, probably via activation of 
the ERK signaling pathway, which in turn activated caspase-3 and triggered apoptotic cell death 
(Chong et al 2006). In another study, using entorhinal-hippocampal organotypic slices, it has 
been found that oligomeric Aβ induced rise in intracellular Ca2+ and apoptotic cell death through 
a mechanism requiring NMDA and AMPA receptor activation (Alberdi et al 2010). Moreover, in 
organotypic hippocampal slice cultures it was shown that ganglioside GM1, a glycosphingolipid 
of the cellular plasma membrane, exhibited a neuroprotective activity upon Aβ-induced 
apoptosis (Kreutz et al 2011).  
Brain slice cultures have also been explored in an attempt to mimic the Aβ plaque pathology in 
AD. However, it was shown that hippocampal slice cultures from AD mice unfortunately did not 
develop Aβ plaques even after long-term culturing (Novotny et al 2016). Absence of de novo 
plaque formation in APPPS1 brain slices was indeed confirmed in the laboratory of Sabina 
Tahirovic (unpublished data). It is likely that because of the required regular exchange of the 
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media (each 3-4 days), the threshold concentration of Aβ needed to nucleate the aggregation 
process could not be achieved. However, the ex vivo cellular environment seemed to help in 
producing better seeding material upon addition of brain homogenate from different aged AD 
mouse models together with continuous treatment with synthetic Aβ (Novotny et al 2016). 
Along this line, another study described that repeated applications of synthetic Aβ42 to WT 
mouse hippocampal slices failed to induce Aβ plaque formation. This can be explained by the 
fact that microglial cells were able to phagocytose Aβ. Indeed, only after microglial depletion, Aβ 
aggregates could be detected in WT hippocampal slices (Hellwig et al 2015).  
Thus, despite some limitations, the slice culture approach represents a useful method to study 
the involvement of microglia in phagocytosis of amyloid exogenously added to cultured brain 
slices. However, what remains challenging is to study aged microglia and their capacity to clear 
amyloid ex vivo.  
 
Therefore, within my PhD, I set up an ex vivo co-culture model of old APPPS1 and young WT 
brain slices to investigate microglial contribution to amyloid plaque clearance. This co-culture 
system enabled monitoring the behavior of microglial cells in the vicinity of amyloid plaques and 
their phagocytic activity over longer culturing times. 
  
Remarkably, my work demonstrates that amyloid clearance dysfunction of AD microglia can be 
reversed in the ex vivo co-culture model, regardless of the massive neuronal and astrocytic loss, 
inevitably occurring in the old tissue in culture. According to PI analyses, I measured 
approximately 70% reduction in cell viability in the old APPPS1 brain slice already after 7 days 
in culture and more than 80% after 14 days. Such poor survival of neurons and astrocytes in 
cultured brain slices from aged mice has been reported also by others (Humpel 2015, Mewes et 
al 2012, Staal et al 2011). Actually, I believe that it is important to consider microglial response 
not only in an amyloid plaque-containing environment but also in presence of ongoing neuronal 
degeneration. Transgenic mouse models, like the APPPS1 model used in this thesis, recapitulate 
well the plaque pathology typical of AD, however they do not display evident 
neurodegeneration. On the other hand, it is very likely to expect that microglia in the human AD 
brain are influenced by the continuous neurodegeneration. Therefore, the ex vivo model may 
more closely reproduce the hostile environment of the human AD brain, even though the 
mechanisms of cell death may be different in an ex vivo model compared to human brain. 
 
 
5.2 Role of microglia in Aβ clearance 
 
In the AD brain microglia rapidly react to Aβ plaque formation by extending their processes and 
forming tight clusters around the plaques (Bolmont et al 2008, Meyer-Luehmann et al 2008). 
However, as recapitulated in mouse models of AD, despite recruitment of microglia to sites of Aβ 
deposition, Aβ levels continue to accumulate (Bittner et al 2012, Hefendehl et al 2011). It has 
been described that, along the progression of AD-like pathology, microglia become dysfunctional 
and lose their capacity to phagocytose and degrade Aβ (Hickman et al 2008, Krabbe et al 2013, 
Meyer-Luehmann et al 2008). This is in line with the human pathology, where reduced Aβ 
clearance rates have been observed in sporadic AD patients (Mawuenyega et al 2010), and an 
inefficient phagocytosis of myeloid cells from AD patients compared to non-AD control patients 
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has also been reported (Fiala et al 2005). Moreover, recent genome-wide association studies 
have identified several risk alleles for AD that belong to innate immune responses and are 
functionally linked to microglial phagocytosis (Karch et al 2014). So, specific variants that 
modify microglial efficiency of Aβ clearance might have detrimental effects in the brain. 
Additionally, microglia in the AD brain have been reported to be similar to aged microglia and to 
present impairments in phagocytosis and motility, as well as altered morphology  (Mosher & 
Wyss-Coray 2014). This may result in age-related defects of microglia in binding and digesting 
Aβ. For example, it has been found that microglia from 8 month old APPPS1 mice demonstrate 
significantly reduced expression of Aβ binding receptors as well as Aβ degrading enzymes 
compared to WT littermates, and levels decline even further by 14 months of age (Hickman et al 
2008). Other transcriptional analyses have also reported that genes implicated in phagocytosis 
were downregulated in microglia from aged AD mice (Orre et al 2014). Moreover, in vitro 
studies using microglia cultured from adult animals have shown that aged microglia internalize 
less Aβ peptide than young microglial cells (Floden & Combs 2011, Njie et al 2012). In particular, 
while aging negatively affects microglial Aβ-phagocytosing function, it does not appear to limit 
their ability to interact with amyloid plaques or Aβ fibrils (Floden & Combs 2011). Likewise, 
young microglia from AD mice were able to clear exogenously added amyloid in organotypic 
slice cultures, whereas microglia from adult AD mice displayed a significant loss of their Aβ 
phagocytic function (Hellwig et al 2015). 
In full agreement with above discussed studies, data presented in this thesis also reflect a 
defective ability of microglia from aged AD mice to phagocytose Aβ.  This is illustrated by the fact 
that the majority of amyloid plaques I observed in the ex vivo cultures of brain slices from old 
APPPS1 mice displayed typical morphology of a fibrillar Aβ core surrounded by a halo of diffuse 
Aβ. Interestingly, I observed that amyloid plaques become drastically smaller in size upon co-
culturing of APPPS1 brain slices carrying aged AD microglia together with brain slices from WT 
neonatal mice in the same culture dish, suggesting a potential for stimulation of old and diseased 
AD microglia. Remarkably, soluble factors released by the young microglia were sufficient to 
activate aged AD microglia and fully restore their Aβ phagocytic capacity of aged AD microglia.  
 
Activated microglial cells accumulating in the vicinity of amyloid plaques and decreased amyloid 
plaque size in the ex vivo co-culture model described here, have indeed been described in 
amyloidosis mouse models as well as in AD patients following Aβ immunotherapy (Bard et al 
2000, Boche & Nicoll 2008, Nicoll et al 2006, Schenk et al 1999, Wilcock et al 2004). The idea of 
using anti-Aβ antibodies as therapeutic agents to treat AD might be a useful approach, especially 
in light of the promising data obtained from an ongoing clinical trial with aducanumab (Sevigny 
et al 2016). A human recombinant monoclonal antibody developed by Biogen Inc., which 
selectively targets aggregated forms of Aβ, has been employed in this trial. Early data showed 
that intravenous infusions of aducanumab reduce Aβ plaque load in a dose- and time-dependent 
fashion. Aβ clearance is accompanied by enhanced recruitment of microglia, suggesting 
increased microglial-mediated plaque phagocytosis and clearance (Sevigny et al 2016). This also 
seems to correlate with cognitive improvement, although larger cohorts are necessary to verify 
this initial observation. 
Even though the involved mechanisms are not completely clear yet, it is well accepted that anti-
Aβ antibodies can stimulate microglia to actively clear amyloid plaques (Fu et al 2010, Moreth et 
al 2013, Wisniewski & Goni 2015). For example, upon treatment with anti-Aβ antibodies, Aβ has 
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been detected within microglia and found to co-localize with CD68, marker for 
microglial/macrophage lysosomes, which is indicative of phagocytically active microglia (Nicoll 
et al 2006, Xiang et al 2016, Zotova et al 2011). Similarly, I found that stimulation with factors 
secreted from young microglia can induce a strong CD68 immunoreactivity and Aβ uptake in 
aged microglial cells, reflecting that they also acquired a phagocytically active phenotype. 
Moreover, core-only plaques that lack the halo of diffuse Aβ, as I have observed in the ex vivo 
model, have also been described in AD patients following Aβ immunization and are often 
referred to as “naked” dense core plaques (Boche & Nicoll 2008, Nicoll et al 2006, Nicoll et al 
2003, Sevigny et al 2016). Indeed, removal of soluble forms of Aβ has been shown to occur more 
efficiently than that of compact fibrillar Aβ forming the plaque core, which is well in line with 
results of this thesis study (Mandrekar et al 2009, Nicoll et al 2006, Serrano-Pozo et al 2010). Of 
note, soluble oligomeric forms of Aβ are believed to be the toxic entity in AD (Umeda et al 2011). 
Specifically, soluble Aβ has been associated with spine loss, neuritic and synaptic degeneration 
in AD and therefore a reduction in soluble Aβ levels might positively influence memory and 
cognition (Koffie et al 2009, Selkoe 2008). 
Taken together, data presented here and obtained in immunotherapeutic studies strongly 
suggest that stimulation of microglial functions to reduce amyloid burden might be a useful 
approach for treating AD (Fig 5.1).  
 
 
5.3 Modulation of microglial activity as a tool to reduce Aβ load 
 
It is very important to keep in mind that microglia directly control various pro- and anti-
inflammatory signaling pathways, which are often affected in AD (Lucin & Wyss-Coray 2009, 
Weitz & Town 2012). Therefore, modulation of their activity requires caution. Microglia can 
acquire different phenotypes and their activation may have both beneficial and detrimental 
effects, which are strongly linked to the specific stage of the disease and brain area affected as 
well as to the level of exposure to Aβ, cytokines and other inflammatory mediators (Heneka et al 
2015, Lucin & Wyss-Coray 2009, Weitz & Town 2012). Indeed, it has been shown that in the AD 
brain microglia can mount exaggerated immune responses and release molecular mediators that 
trigger pro-inflammatory reactions, eventually causing neuronal damage as well as contributing 
to microglial dysfunction (Heneka et al 2015, Weitz & Town 2012). Thus, it would be adequate 
to activate beneficial responses of microglia and at the same time to try avoiding the damage. 
Although this will be difficult, the more we know about pathways regulating microglial 
functions, the better we may be able to keep the microglial activation status under control. This 
PhD study indeed developed a suitable model system for studying microglial phagocytic 
functions in AD and shows that upon appropriate stimulation aged AD microglia acquire an 
activated state that make them capable of clearing Aβ.    
 
One of the initial approaches targeting microglia in AD consisted in the inhibition of microglia 
using nonsteroidal anti-inflammatory drugs (NSAIDs). This idea was based on previous 
epidemiological findings reporting a lower incidence of AD in elderly patients with arthritis 
under NSAIDs compared to the general population, thus suggesting a beneficial effect of reduced 
inflammation (McGeer & Rogers 1992). Indeed, the chronic administration of oral ibuprofen in 
Tg2576 (APPswe) mice reduced Aβ plaque load and diminished IL-1β production in the brain of 
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treated mice (Lim et al 2000). Analysis of phosphotyrosin-labeled microglia showed lower 
recruitment of microglia to the Aβ plaques and reduced microglial cell activation in the 
ibuprofen-treated mice (Lim et al 2000). Similarly, another study in Tg2576 mice confirmed 
ibuprofen effects in reducing Aβ plaque burden, which was accompanied by decreased levels of 
the microglial activation markers CD45 and CD11b (Yan et al 2003). However, despite these 
evidences from animal models, a clinical trial that used NSAIDs as a therapeutic approach in AD 
patients failed to show a protective effect, and was even found to be detrimental (Martin et al 
2008). 
 
In contrast, and well consistent with results described in this thesis, boosting the inflammatory 
response of microglia has also resulted in beneficial outcome. It has been reported that a single 
intrahippocampal injection of LPS (TLR4 ligand) in the brain of APPswe/PS1 mice resulted in 
activated MHCII-positive microglia and reduced cerebral Aβ load (DiCarlo et al 2001). More 
recently, another study showed that the chronic systemic administration of a detoxified LPS-
derivative, namely monophosphoryl lipid A (MPL), reduced soluble and insoluble Aβ load in the 
brain of APPswe/PS1 mice, by stimulating microglial Aβ phagocytic capacity and triggering 
rather moderate inflammatory reaction (Michaud et al 2013). 
In line with that, it has been reported that genetic depletion of the inflammatory protein 
complement factor C3 protein, in aged AD mice lowered microgliosis and increased Aβ burden 
(Maier et al 2008). The reduced microgliosis was accompanied by increase in IL-4 and IL-10 
levels, and decrease in CD68, F4/80, inducible nitric oxide synthase (iNOS), and TNF-α levels. 
Those results propose a beneficial role for C3 in Aβ clearance via modulation of the microglial 
phenotype. A more recent study focused on the scavenger receptor Scara-1, which is expressed 
on microglia and has been reported to be involved in internalization and phagocytosis of Aβ 
(Hickman et al 2008). In this study, they showed that Scara-1 depletion in APPswe/PS1 mice 
accelerated Aβ accumulation, while the pharmacologically induced overexpression of Scara-1 
enhanced phagocytosis and clearance of Aβ (Frenkel et al 2013). 
 
This evidence together with data in my thesis suggest the possibility that microglial activation in 
AD is not detrimental and that the spatiotemporal context in which microglia are targeted and 
other factors play a determinant role (Breitner et al 2011). 
 
 
5.3.1 Pro- and anti-inflammatory modulation of microglia through cytokines 
 
Modulating the pro- or anti-inflammatory potential of microglia is far from being simple. As an 
example, it was originally thought that suppressing the inflammation by enhancing the anti-
inflammatory signaling of microglia might produce beneficial effects. However, results obtained 
over the past years do not support this hypothesis.  For example, one study enhancing the anti-
inflammatory signaling through IL-10 overexpression in brains of two different AD mouse 
models increased soluble and insoluble Aβ and this was accompanied by impaired Aβ 
phagocytosis by microglia (Chakrabarty et al 2015). Consistent with it, a parallel study reported 
that genetic depletion of IL-10 in APPswe/PS1 mice reduced soluble and insoluble Aβ load 
(Guillot-Sestier et al 2015). Moreover, IL-10 depletion increased microglial migration and 
recruitment at Aβ plaques, and increased the number of Aβ-immunoreactive microglia, implying 
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an enhanced phagocytic capacity (Guillot-Sestier et al 2015). Data obtained in these two studies 
are a good demonstration that we have to deal with larger complexity of immune system 
responses than previously anticipated.  
 
However, what has clearly been confirmed by number of studies in the literature is that 
modulation of microglial functions through inflammatory cytokines does have an impact on 
amyloid plaque pathology and can improve cognition in mouse models of AD (Zheng et al 2016).  
Some pro-inflammatory cytokines like IL-6 and TNF-α have been shown to associate with a 
reduction in amyloid plaque load by inducing microglial phagocytosis (Chakrabarty et al 2011, 
Chakrabarty et al 2010b). As an example, overexpression of INF-γ in AD mouse brains 
suppressed Aβ accumulation by activating immune system components that enhanced Aβ 
phagocytosis and clearance by microglia (Chakrabarty et al 2010a). In parallel, anti-
inflammatory cytokines like IL-4 and IL-10 have been found to not decrease Aβ deposition 
(Chakrabarty et al 2015, Chakrabarty et al 2012). However, for several cytokines, including IL-
10 and INF-γ there are studies reporting controversial results, suggesting that the same cytokine 
may have multiple and even opposite roles that may vary, most likely depending on the specific 
spatial-temporal context (Zheng et al 2016).  
 
 
5.3.2 The pro-inflammatory factor GM-CSF induces amyloid clearance and proliferation of 
microglia in the ex vivo model 
 
The increased phagocytosis in the ex vivo model described here was recapitulated by the 
application of the pro-inflammatory cytokine GM-CSF to the old APPPS1 tissue. At the same time, 
microglial Aβ uptake did not increase in the ex vivo model system upon treatment with pro-
inflammatory cytokines IL-6 and IL-12/p40 or the anti-inflammatory factors IL-10 and TGF-β. 
Notably, the increase in amyloid clearance observed upon GM-CSF treatment, was accompanied 
by augmented microglial proliferation, as shown by increased CD68 coverage levels. On the 
contrary, I did not detect any increase in microglial density upon addition of other tested 
cytokines (IL-6, IL-12/p40, IL-10 and TGF-β), which was in line with the observed absence of 
Aβ-clearance.  
It is worth to mention that upon addition of TGF-β, the density of CD68-positive cells in old 
APPPS1 slices seemed to be even diminished compared to controls, which is consistent with 
other studies showing an inhibitory effect on cell proliferation mediated by TGF-β (Datto et al 
1995, Grainger et al 1994). In contrast, the increased CD68 coverage that I detected upon GM-
CSF confirms its mitogenic-inducing potential on microglial cells (Lee et al 1994, Suh et al 2005). 
 
Taken together, the observed induction of microglial activation and proliferation, and 
consequent enhancement of amyloid clearance in the ex vivo model seemed to be more specific 
for GM-CSF compared to all the other tested cytokines (Fig 5.1). My results reveal mechanistic 
similarities between co-culturing condition and GM-CSF application as microglial proliferation 
and amyloid plaque clearance occurred in both experimental paradigms. However, the effect on 
Aβ degradation was more robust in co-cultures compared to GM-CSF application. Although my 
immunofluorescence data clearly showed that GM-CSF induced clearance of the plaque halo of 
diffuse Aβ, biochemical analyses revealed that co-culturing of young and old tissue resulted in 
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addition in a decrease of fibrillar Aβ. Thus, the co-culture condition appears to act as a more 
potent stimulus on Aβ clearance compared to the tested GM-CSF treatment paradigm.  
 
In line with these observations, co-culturing of old APPPS1 slices together with young GM-CSF-/- 
slices was still able to increase plaque phagocytosis and, in line with that, also CD68 coverage. 
This indicates that, in the ex vivo co-culture model, microglial population can expand also in 
absence of endogenous GM-CSF secretion and that other factors with a mitogenic potential may 
contribute to this effect. In addition, there are also evidences reporting that the GM-CSF-/- mice 
overproduce M-CSF, another cytokine capable of inducing microglial proliferation and I cannot 
exclude this as a possible compensatory mechanism (Bonfield et al 2008, Shibata et al 2001). 
Possibly, in addition to GM-CSF, other factors released by the young microglia may mediate 
phagocytic clearance. 
It would be very interesting to identify those secreted factor(s) and their mode of action on 
amyloid clearance. One possible approach would be to use mass spectrometry analysis and 
compare secreted proteins in conditioned media from young/old slices cultured alone versus 
young and old slices co-cultured together. However, we ascertained that this is technically 
challenging due to the high amount of serum contained in the slice culture medium. Ongoing cell 
death occurring in old slices in culture may be additional challenge to this approach.  
 
 
 
Figure 5.1. Model of effect of microglial immunomodulation on Aβ levels. 
Schematic representation of the potential effect of microglial activation on Aβ levels. Aged AD microglia are less capable of 
orchestrating a controlled inflammatory response and have dysfunctional phagocytosis (“inactive” microglia). However, 
upon stimulation with anti-Aβ antibodies, as well as GM-CSF and other immune-modulators aged AD microglia can still 
acquire an activated state, which is also reflected by their amoeboid morphology (“stimulated” microglia). Reactive 
microglia may increase their inflammatory and phagocytic functions, leading to reduced Aβ accumulation.       
 
 
5.4 Link between microglial proliferation and amyloid clearance 
 
Data in this thesis propose that GM-CSF-mediated effects on amyloid clearance are linked to 
microglial proliferation. In agreement with that, other studies support a connection between 
proliferation of microglia and Aβ clearance. For example, it has been shown that deletion of the 
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microglial specific receptor CX3CR1 in a mouse model of AD resulted in higher proliferation 
rates of microglia and decreased plaque deposition, which was well associated with the 
increased microglial uptake and phagocytic ability and reflected by the high LAMP1-positive 
phagolysosomal Aβ content (Liu et al 2010). Moreover, another more recent study also pointed 
out the connection between proliferative and phagocytic processes and showed that TNF-α-
induced proliferation of microglia stimulates phagocytosis of beads and increased phagocytosis 
of neurons in vitro (Neniskyte et al 2014). In line with these findings, it was reported that in an 
AD mouse heterozygous for the AD-associated microglial specific receptor TREM2 (Trem2+/-), 
proliferation of microglia in response to Aβ was impaired, suggesting that deficient phagocytosis 
might be linked with impaired microglial proliferation (Ulrich et al 2014). 
On the contrary, recent findings reported increased microglial proliferation in AD that was 
correlating with disease severity. In this study, inhibition of microglial proliferation in a mouse 
model of AD, by specifically targeting microglial CSF1R, prevented disease progression with 
positive outcome on behavioral and memory tasks (Olmos-Alonso et al 2016). However, Aβ 
deposition remained unaffected even in the absence of proliferating microglia (Olmos-Alonso et 
al 2016). Similarly, a complete or partial blockage of microglial CSF1R lead to improved 
cognition in AD mice with no detectable changes in Aβ levels and plaque load (Dagher et al 
2015).  
 
Although microglial proliferation in the ex vivo co-culture model seems to be required to induce 
amyloid reduction, it is reasonable to think that the increase in phagocytosis might not simply be 
the consequence of augmented microglial numbers. Indeed, often microglial activation is 
associated with enhanced proliferation, but also with augmented phagocytic activity of the 
microglial cells (Giulian & Ingeman 1988). This suggests that both proliferation and 
phagocytosis may be interconnected processes possibly governed by the same signaling 
pathways. At the same time, also microglial morphology is presumed to relate with microglial 
function and a morphological transformation from ramified into amoeboid microglia denote 
them as activated microglial cells. Data in this thesis, indeed, show that microglia in the old 
APPPS1 slice exhibit mainly amoeboid morphology especially upon co-culture with the young 
slice, reflecting their highly active phagocytic phenotype in presence of young secreted factors as 
well as of GM-CSF (Fig 5.1).  
As discussed above, similar to GM-CSF, also the cytokine M-CSF has been found to stimulate 
proliferation and phagocytosis of microglia (Mitrasinovic & Murphy 2002, Mitrasinovic et al 
2003, Smith et al 2013). In particular, it has been reported that M-CSF can increase the acidity 
and hydrolytic activity of microglial lysosomes, resulting in a more efficient degradation of Aβ 
(Majumdar et al 2007). M-CSF injection in an AD mouse increased number of microglial cells, 
with the high proportion of microglia internalizing Aβ and displaying Aβ-containing lysosomes. 
This correlated well with the reduction in amyloid plaque load and improved cognitive 
impairment (Boissonneault et al 2009). Moreover, previous studies have reported that microglia 
might be incapable of efficiently eliminating internalized Aβ (Chung et al 1999, Frackowiak et al 
1992, Paresce et al 1997), whereas,  in a later study, increased Aβ degradation was induced after 
exogenous targeting of lysosomal enzymes (Majumdar et al 2008). This suggests that low 
lysosomal activity may account for a limited ability of microglia to degrade Aβ, and therefore, 
increasing the lysosomal degradation may be a way to promote amyloid clearance. In the ex vivo 
co-culture model presented here, I detected increased levels of the lysosomal marker CD68 in 
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AD microglia, which is indicative of enhanced lysosomal activity. It would be of relevance to 
study this aspect more closely and examine whether increased acidity and hydrolytic activity 
accompany the enhanced amyloid clearance effect observed in our model. 
In light of these considerations, further analyses are required to better understand mechanisms 
of action of specific cytokines and their potential influence on microglial phagocytosis and 
amyloid removal. 
 
 
5.4.1 Therapeutic potential of GM-CSF and other rejuvenating factors 
 
Data presented here showed that administration of GM-CSF is sufficient to enhance amyloid 
clearance in the ex vivo model of AD, supporting a potential role for GM-CSF as a therapeutic 
molecule. In this regard, it has been reported that GM-CSF injection into an AD mouse model 
resulted in increased microglial density, reduced amyloid load of about 50%, and almost 
completely reversed cognitive impairment compared to saline-treated mice (Boyd et al 2010). 
These data strongly support that using the ex vivo model I was indeed able to identify a 
phagocytosis enhancing molecule that has the same properties when tested in vivo. Moreover, it 
is important to mention that GM-CSF already succeed in short-term Phase I clinical trials for 
assessing safety of a manufactured version of it (Sargramostim or Leukine®) and it is currently 
tested in Phase II clinical trials for long-term treatment of patients with AD 
(www.alzforum.org/therapeutics/sargramostim) (Lai & McLaurin 2012). Nevertheless, there 
are also opposite reports showing that neutralization of GM-CSF may be beneficial for AD. In this 
study it has been reported that anti-GM-CSF antibody-injected AD mice exhibited decreased 
amyloid burden, while levels of activated microglia were reduced (Manczak et al 2009). 
However, they argue for a potential interference of the GM-CSF antibody with Aβ production, to 
explain reduced Aβ deposits, without taking into consideration eventual effects on Aβ 
phagocytosis.  
 
Besides GM-CSF effect described here, other approaches showed a potential in reverting Aβ 
phagocytic dysfunction of microglia. It has been reported that microglia in the AD brain become 
dysfunctional and incapable of efficiently phagocytosing Aβ while undergoing age/disease-
related changes, acquiring a so-called senescent phenotype (Streit et al 2008). In this regard, 
efforts to rejuvenate old microglia in order to rescue their young beneficial functions have been 
made. These may help us to gain some knowledge about the heterogeneity of microglial 
functions in AD as well as their pathological changes and may offer an intriguing way of 
reversing microglial disease-associated alterations. So far several studies focused on 
rejuvenating the brain as idea to reverse age-related deficits and reestablish brain functions. For 
example, heterochronic parabiosis studies, where aged and young animals share the circulatory 
system, showed increased neurogenesis and improved cognitive functions in the aged mice after 
being exposed to young blood (Baruch et al 2014, Smith et al 2015, Villeda et al 2014). Similarly, 
plasma transfer from younger mice into the aged mice replicated the same findings, implying the 
involvement of blood-derived soluble factors, and not only blood cells (Villeda et al 2011). Also, 
caloric restriction and aerobic exercise have been found to promote similar healthy effects 
(Willette et al 2012, Witte et al 2009) (Barrientos et al 2011). In a recent preclinical study, aged 
AD mice (16-20 months old) were heterochronically connected with a young WT mouse (2-3 
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months old) or repeatedly injected with plasma from young mice. That was sufficient to restore 
synaptic protein levels and cognitive deficits observed in AD mice, demonstrating therapeutic 
properties of young plasma, however without reducing Aβ burden, at least at the time of their 
analysis (Middeldorp et al 2016). Of note, clinical trials involving plasma protein transfer from 
young individuals are currently ongoing for treating patients with AD, such as the Plasma for 
Alzheimer SymptoM Amelioration (PLASMA) study (clinicaltrials.gov; NCT02256306) (Niraula 
et al 2016).  
 
The ex vivo model could be of great help in identifying and verifying potential key factors capable 
of inducing Aβ clearance and lowering Aβ accumulation. 
 
 
5.5 Diseased microglia display specific gene expression alterations 
 
The fact that microglial cells in the old APPPS1 tissue - when co-cultured with the young WT 
tissue or supplemented by GM-CSF - acquired an activated state, illustrated by amoeboid cell 
morphology, increased proliferation and enhanced Aβ clearance, may suggest changes in the 
gene expression profile of those cells. This indicates that a specific condition/factor can act as 
trigger and induce a phenotypic switch of aged AD microglia from their inactive state into an 
active one. In this regard, recent studies invested big effort in characterizing gene signature 
alterations of microglia in disease. Notably, one study using single-cell gene expression profiling 
to better define subsets of immune cells in brains of 5XFAD mice identified a subpopulation of 
microglial cells, named as disease-associated microglia (DAM), characterized by a distinct profile 
of gene expression (Keren-Shaul et al 2017). During AD progression homeostatic microglia 
activate the “DAM program” and begin to express genes implicated in phagocytosis and lipid 
metabolism, like Trem2, lipoprotein lipase (Lpl) and ApoE. DAM microglia have been found to 
localize in proximity of amyloid plaques in both mouse and human AD brains and to contain Aβ 
material, and are considered to be the cells enrolled against AD pathology (Keren-Shaul et al 
2017). Very similarly, additional transcriptomic analyses, identified a disease-associated 
molecular signature in a subset of microglia (MGnD, microglial neurodegenerative phenotype), 
which was found to be present in several neurodegenerative models, including the APPPS1 
model as well as in plaque-associated microglia in brains of AD patients (Krasemann et al 2017). 
Specifically, they reported that the molecular mechanism leading to MGnD phenotype was 
triggered by upregulation of the phagocytosis regulating gene Trem2, resulting in the activation 
of APOE signaling, while microglial homeostatic genes, such as P2ry12, Tmem119, Csf1r, Cx3cr1, 
Tgfb1 among others, were downregulated (Krasemann et al 2017). Indeed, when Trem2 was 
knocked out in APPPS1 mice, inflammatory genes (e.g. Trem2 and ApoE) were suppressed and 
homeostatic genes were restored (Krasemann et al 2017), indicating that presence of Trem2 can 
reverse homeostatic signature of microglia towards a diseased-associated signature. Moreover, 
in a previous study, TREM2 deficiency has been proposed to lock microglia in a homeostatic 
state, therefore preventing them from getting activated (Mazaheri et al 2017). Altogether, it 
seems we are starting to understand molecular changes microglia undergo in neurodegenerative 
disease conditions, which are responsible for their dysfunctions. This may give space for 
potential new strategies aimed at restoring fully functional microglia to fight neurodegenerative 
conditions like AD.     
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Along these lines, it would be highly interesting to decipher alterations in the microglial 
transcriptome in the ex vivo model when switching from an old and dysfunctional state of AD 
microglia into a phagocytically active state. 
 
In addition, transcriptomic analyses could also help to explain the observed similarities as well 
as possible differences in the phagocytic state of microglia in the old APPPS1 tissue upon GM-
CSF treatment and co-culturing paradigm. Knowing the mitogenic potential of GM-CSF, it may be 
likely to expect that RNA signature would reflect stronger proliferative capacity, whereas in the 
co-culture model the combined stimulation of several factors may reflect even stronger 
phagocytic response by microglia. However, this is very speculative and further investigations 
are needed to better understand this point. 
 
Altogether, results of my PhD thesis support the view that modulating microglial activity may be 
beneficial for AD. Upon an appropriate stimulus AD microglia appear still capable of turning into 
an active state and exerting their innate capacity of phagocytosis and proliferation. Therefore, 
further investigations are definitely required to better understand microglial functional 
potential. It is very crucial to elucidate how this great potential is changing in the disease context 
in order to explore the possibility to restore those innate, young and protective functions that 
characterize microglia in a healthy context. Determining the transcriptome profile might be a 
potential initial step in that direction. However, we need to understand microglial changes not 
only on the molecular level with transcriptomic analyses but we would need also to combine 
with proteomic studies to validate those gene expression changes in microglia on a protein level. 
Once learned how to define those gene expression switches more precisely, we may be in a 
better position to specifically target and modulate microglial activity.  
 
 
5.6 Conclusion 
 
In this thesis work, I established an ex vivo model to study microglial phagocytosis of amyloid 
plaques. The findings described here suggest that phagocytic functions of old microglial cells 
that become dysfunctional and ineffective during the course of AD can be restored to lower the 
amyloid plaque load. These data support the view that enhancing microglial ability to clear Aβ 
may be a potential therapeutic strategy to fight AD. Therefore, it is of great importance to 
investigate further microglial phagocytic potential and expand ways of action to restore 
microglial function. The ex vivo model provides a valuable tissue culture system for identifying 
factors as well as testing molecules/compounds aiming at strengthening microglial phagocytosis 
and thus may help to identify novel and therapeutically relevant targets. 
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